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Abstract 
Background: Choline is an essential nutrient required for many biological functions such as 
methyl metabolism, structural integrity of cell membranes, transmembrane signaling, and 
phospholipid metabolism. A higher intake or status of choline in plasma has been related to 
higher prostate cancer risk. Choline may affect cancer development through few mechanisms; it 
can affect DNA methylation and might lead to a disruption of DNA repair; it can modify cell 
signaling that is mediated by intermediary phospholipid metabolites; and it can support the 
synthesis of cell membranes and thus support cell proliferation. Choline metabolism in prostate 
cancer might be dysregulated in order to meet the tumor requirements for phospholipid and 
methyl groups. 
Objective and methods: We hypothesized that the concentrations of choline and choline 
metabolites in plasma will be higher in men with prostate cancer than those with benign prostatic 
hyperplasia. The aim of this thesis was to investigate potential differences in choline and its 
metabolites relate to one-carbon and phospholipid metabolisms between patients with prostate 
cancer and those with benign prostatic hyperplasia. We studied differences in blood 
concentrations of choline, betaine, dimethylglycine, S-adenosyl methionine, S-adenosyl 
homocysteine, homocysteine, and phospholipid species between cases and controls. 
Quantifications were carried out by using liquid and gas chromatography, coupled with tandem 
mass spectrometry. 
Results: Concentrations of choline and other metabolites did not differ between cases and 
controls. The concentrations of sphingomyelin species 14:0 and 20:0 were significantly higher in 
the younger prostate cancer patients (age ≤65 years) compared to the young controls (median SM 
14:0 = 10.8 vs. 9.4 µmol/L, p=0.033 and SM 20:0 = 16.2 vs. 13.6 µmol/L, p=0.004). The results 
according to the pathological grade showed that the same 2 species were significantly increased 
in the young low-grade prostate cancer patients (Gleason score ≤3+4) compared to the young 
controls (mean SM 14:0 = 12.1 vs. 10.0 µmol/L, p=0.035, and SM 20:0 = 16.6 vs. 14.1 µmol/L, 
p=0.027). Sphingomyelin species (16:0, 18:0, 18:1, 20:0, 22:0, 22;1, 23:0, 23:1 24:0, 24:1, and 
24:2) were significantly lower in prostate cancer cases than controls in the elderly group (age >65 
years). Mean concentrations of sphingomyelin 16:0 and 18:0 were significantly (p<0.01) lower in 
the elderly patients with low-grade (SM 16:0 = 82.9, SM 18:0 = 18.6 µmol/L) or high-grade 
prostate cancer (Gleason score ≥4+3) (SM 16:0 = 85.6, SM 18:0 = 18.4 µmol/L) compared to the 
 X 
elderly controls (SM 16:0 = 95.0, SM 18:0 = 21.2 µmol/L). Age was associated with significantly 
higher choline, S-adenosyl methionine, S-adenosyl homocysteine, total homocysteine, 
cystathionine levels in the prostate cancer patients. Statin use was associated with lower plasma 
phospholipid species levels, especially phosphatidylcholine and sphingomyelin species in cases 
and controls. This lowering effect is synergized by the presence of prostate cancer. 
Discussion and conclusions: The current study does not confirm significant differences in 
plasma concentrations of plasma free choline or metabolites of the methionine cycle between 
patients with prostate cancer and controls with benign prostate hyperplasia. Because free choline 
pool may not be a good marker for choline nutrient, the results can not exclude a role for choline 
in prostate cancer. In line with this, sphingomyelin that originates from choline metabolism was 
divergent between young patients with prostate cancer and those with benign prostatic 
hyperplasia (SM 14:0 and 20:0). In addition, sphingomyelin species 16:0 and 18:0 distinguished 
between prostate cancer and benign prostatic hyperplasia elderly patients. Age and prostate 
cancer had a significant association with circulating phospholipid profile. These findings support 
alterations in phospholipid metabolism in prostate cancer and warrant further investigation. 
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Zusammenfassung 
Hintergrund: Cholin ist ein essentieller Mikronährstoff, der an vielen biologischen 
Funktionen beteiligt ist, wie Methylgruppen-Stoffwechsel, strukturelle Integrität von 
Zellmembranen, Neurotransmittersynthese und Phospholipidstoffwechsel. Eine erhöhte Zufuhr 
oder erhöhte Plasmaspiegel von Cholin wurden in Zusammenhang mit einem erhöhten 
Prostatakrebs-Risiko beobachtet. Unterschiedliche Wirkmechanismen werden dabei diskutiert: 
Störung der DNA-Methylierung mit daraus resultierenden gehäuft auftretenden DNA-Brüchen; 
Störung der zellulären Signaltransduktion durch zelluläre Phospholipidmetabolite sowie 
Störungen des Zellwachstums durch modifizierte Membranensynthese. Beim Prostatakarzinom 
ist der Cholin-Metabolismus möglicherweise modifiziert durch den gesteigerten Bedarf von 
Phospholipiden und Methylgruppen der Tumorzellen.    
Fragestellung und Methoden: Untersucht wurden 73 Probanden mit benigner 
Prostatahyperplasie (Kontrollgruppe) und 145 Probanden mit Prostatakarzinom. Die Probanden 
wurden in Altersgruppen (≤65 und >65 Jahre) eingeteilt.  Ausgehend von den Literaturdaten über 
den Zusammenhang zwischen Cholinstoffwechsel und Karzinommanifestation sind bei Patienten 
mit Prostatakrebs höhere Konzentration für Cholin und dessen Metaboliten zu erwarten. In der 
vorliegenden Arbeit wurde ein Panel von Parametern, die den Cholinstoffwechsel, aber auch den 
C-1- und Phospholipid-Stoffwechsel beschreiben, eingesetzt. Mit der Gas- und 
Flüssigkeitschromatographie gekoppelten Massenspektrometrie wurden folgende Parameter 
untersucht: Cholin, Betain, Dimethylglycin, S-Adenosylmethionin, S-Adenosylhomocystein, 
Homocystein, Cystathionin und Phospholipidformen (Phosphatidylcholin, Lyso-
Phosphatidylcholin, Phosphatidylethanolamin und Sphingomyelin).    
Ergebnisse: Die Konzentrationen für Cholin und die anderen Metaboliten zeigten keine 
signifikanten Unterschiede zwischen der Kontrollgruppe und Patienten mit Prostatakarzinom. In 
der Altersgruppe bis 65 Jahre waren die Konzentrationen für die Sphingomyeline (SM) 14:0 und 
20:0 signifikant höher bei Patienten mit Protatakrebs im Vergleich zur Kontrollgruppe (Median 
SM 14:0 = 10.8 vs. 9.4 µmol/L, p=0.033 und SM 20:0 = 16.2 vs. 13.6 µmol/L, p=0.004). Die 
Ergebnisse bezogen auf den Gleason-Score zeigten in der gleichen Altersgruppe, dass bei 
Tumorpatienten mit niedrigem Scorewert (≤3+4) im Vergleich zur Kontrollgruppe die 14:0 und 
20:0 Sphingomyeline ebenfalls signifikant erhöht waren (Mittelwert SM 14:0 = 12.1 vs. 10.0 
µmol/L, p=0.035, und SM 20:0 = 16.6 vs. 14.1 µmol/L, p=0.027). In der Altersgruppe über 65 
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Jahre waren die Sphingomyelinformen (16:0, 18:0, 18:1, 20:0, 22:0, 22:1, 23:0, 23:1 24:0, 24:1, 
und 24:2) signifikant erniedrigt bei Patienten mit Prostatakrebs im Vergleich zu den 
Kontollprobanden. Die Konzentrationen für Sphingomyeline 16:0 und 18:0 waren signifikant 
niedriger in der älteren Patientengruppe unabhängig vom Gleason-Score (Gleason-Score ≤3+4: 
SM 16:0 = 82.9, SM 18:0 = 18.6 µmol/L und Gleason-Score ≥4+3: SM 16:0 = 85.6, SM 18:0 = 
18.4 µmol/L) im Vergleich zur Kontrollgruppe (SM 16:0 = 95.0, SM 18:0 = 21.2 µmol/L). In der 
Gruppe der Patienten mit Prostatakarzinom war das Alter signifikant assoziiert mit höheren 
Konzentrationen für Cholin, S-Adenosylmethionin, S-Adenosylhomocystein, Homocystein und 
Cystathionin. Eine Einnahme von Statinen war assoziiert mit erniedrigten Phospholipiden, 
insbesondere Phosphatidylcholin- und Sphingomyelinformen bei Patienten und Kontrollen. Der 
Statineffekt wurde in der Gruppe mit Prostatakrebs verstärkt. 
Diskussion und Schlussfolgerungen: Die vorliegenden Ergebnisse zeigten keine 
Unterschiede für Cholin und Metaboliten des Methioninstoffwechsels zwischen den 
Tumorpatienten und Probanden mit benigner Prostatahyperplasie. Da freies Cholin im Plasma 
kein Marker mit hoher Aussagekraft für die Cholinversorgung des Tumorgewebes ist, kann eine 
Relevanz nicht sicher ausgeschlossen werden. Die Sphingomyelinformen 14:0 und 20:0, die im 
Cholin-Metabolismus entstehen, zeigten in der jüngeren Altersgruppe Unterschiede zwischen der 
Prostatakarzinom- und der Kontrollgruppe. In der älteren Altersgruppe waren die 
Sphingomyelinformen 16:0 und 18:0 unterschiedlich. Diese Ergebnisse deuten auf eine mögliche 
Relevanz von Cholin. Alter und das Vorliegen eines Prostatakarzinoms waren signifikant 
assoziiert mit dem Phospholipidprofil. Die Ergebnisse lassen interessante Veränderungen des 
Phospholipidstoffwechsels bei Patienten mit Prostatakarzinom vermuten und geben Anregung für 
weitere Untersuchungen.       
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1. Introduction 
Dietary factors have been thought to account for about 30% of cancers. Furthermore, many 
epidemiological evidences and research studies suggesting that diet plays an important role in 
cancer prevention and/or progression (1;2). Prostate cancer (PCa) is the leading cancer in males 
of many countries, with nearly a million new cases diagnosed worldwide (3). Both the substantial 
variation in the incidence of PCa worldwide (more than 25 fold incidence rate of PCa) and the 
increased risk in the migrant population (moving from low risk to high risk countries) provide a 
strong evidence that modifiable environmental factors, particularly diet, promote the 
development of PCa (3;4). 
The roles of choline in human health and disease have been rapidly evolving. Choline is an 
essential nutrient required for many biological functions such as the biosynthesis of 
acetylcholine, phosphatidylcholine and sphingomyelin or as an important source of methyl 
groups (5). Choline deficiency appears to play an important role in the pathogenesis of several 
disorders in humans including neural tube defects (6), fatty liver, muscle damage (7), and cancer 
(8). Moreover, choline deficiency associated with an increase in inflammation indexes (9) and 
apoptosis in tissues (10). Therefore, the nutrient choline may be of special interest for prevention 
and progression of PCa. 
Choline is the only nutrient for which dietary deficiency causes liver cancer without any 
known carcinogen (11;12). Interestingly, choline-deficient rats not only have a higher incidence 
of spontaneous hepatocarcinoma, but they are markedly sensitized to the effects of administered 
carcinogens. Choline deficiency is therefore considered to stimulate both cancer-initiating and 
cancer-promoting activities (12). However, abnormal choline metabolism is a metabolic hallmark 
that is associated with oncogenesis, as well as one of the characteristic features of PCa (13;14). 
Multiple roles for choline in cancer development are suggested. Choline can affect DNA 
methylation and lead to a disruption of DNA repair. It can also modify cell signaling that is 
mediated by intermediary phospholipid metabolites, and it can support the synthesis of cell 
membranes and thus support cell proliferation (15). Therefore, this study was undertaken to 
investigate blood concentrations of choline and related metabolites in men with PCa compared to 
those with benign prostatic hyperplasia (BPH). We expect differences in related metabolites 
levels between PCa patients and controls. 
Prostate cancer 
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1.1 Prostate cancer 
The prostate is a tubuloalveolar gland that surrounds the urethra and is located between the 
bladder neck and the pelvic diaphragm. It encases the ejaculatory ducts and is adjacent to the 
seminal vesicles (Figure 1a). The gland is composed of a smooth muscle stroma and acini lined 
by a bilayered epithelium composed of basal cells and mature columnar secretory cells. It is 
found only in men as a part of the reproductive system. In humans, the gland is divided into 
zones (transition, central, and peripheral) that attain their greatest distinction in disease states 
(Figure 1b) (16). 
 
 
 
Figure 1a. The prostate diagram 
Figure 1b. The prostate zone 
Prostate cancer 
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The prostate starts to develop before birth and continues to grow until man reaches adulthood. 
This growth is fueled by androgens in the body. The main androgen, testosterone, is made in the 
testicles. In the prostate, the enzyme 5alpha-reductase converts testosterone into more active form 
dihydrotestosterone (DHT). The latter strongly influences prostate function, as well as signals the 
prostate to grow (16). The weight of the prostate remains relatively constant (approximately 1-2 
g) until puberty, at which point it increases to approximately 20-25 g in men between 20 and 30 
years old. Increases in gland weight and size after the age of 30 years are largely due to the 
stromal and epithelial hyperplasia, which leads later to a non-cancerous enlargement of the 
prostate in older men called BPH (17). 
Beyond non-cancerous prostate diseases, the possibility of developing PCa increases as men 
increase in age, about 97% of all PCa occur in men over 50 years old (18). Different types of 
cancer are found in the prostate, but almost all of them develop from the secretory glandular 
cells. This type is known as adenocarcinoma and accounts for more than 95% of all PCa. 
However, there are a few other rare cancers in the prostate that can also start in the prostate 
gland, including sarcomas, small cell carcinomas, and transitional cell carcinomas (16). 
1.1.1 Epidemiology of prostate cancer 
PCa is one of the most common cancers in men. It is the second most frequently diagnosed 
cancer and the sixth leading cause of cancer death, accounting for 14% (903,500) of the total new 
cancer cases and 6% (258,400) of the total cancer deaths in males worldwide in 2008. Western 
Europe shows high incidence rate 94.1 per 100,000 compared with less developed countries 12 
per 100,000 (3). Widespread screening for prostate-specific antigen (PSA) and early detection 
procedures in the developed countries contribute partly to this pattern (19). Since PCa rates 
increase steeply with age, some part of the variability in the incidence of PCa is attributed to the 
different age structure between the populations, but large variability remains after rates' 
correction for age (18). Furthermore, the incidence is also influenced by several risk factors 
including genetic susceptibility, environmental factors, dietary factors, regional differences in the 
prevalence and distribution of the major risk factors, and differences in health care and cancer 
registration (3). 
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1.1.2 Risk factors for prostate cancer 
At present, the major established risk factors for PCa are age, family history and ethnicity. 
Other important risk factors are hormones, environmental and anthropometric factors, and diet 
(20). Epidemiological studies of PCa are complex, Since many factors appear to be involved (21). 
 Age: PCa rates increase with age faster than many other cancers. Autopsy studies show that 
histological PCa increases with age, presenting 15%-30% in men older than 50 years and 60%-
70% in men older than 80 years of age (18). 
 Family history: Several studies have shown an increased risk (odd’s ratios from 2-6) for PCa 
in men with affected relatives (18). Moreover, in a study of the risk of cancer among 44,788 
pairs of twins, 42 percent of PCa cases were attributed to inheritance (19). 
 Ethnicity: Large variations in PCa incidence were observed in different ethnic groups. For 
example, African Americans have higher incidence rates than white Americans of similar 
education and socioeconomic background (18). Furthermore, they are also more likely to 
develop PCa at an earlier age in addition to higher mortality compared to whites (22). 
 Hormones: Androgens significantly alter PCa growth rates. Elevated levels of testosterone 
and DHT may increase PCa risk, but the results are inconsistent. However, androgens’ levels 
are influenced by endogenous factors such as genetic, and exogenous factors (environmental 
influences) (19;20). 
 Environmental and anthropometric factors: Epidemiologic evidences support a major 
contribution of environmental and anthropometric factors to the development of PCa. Many 
factors are suggested such as cigarette smoking history, physical activity, body mass index 
(BMI), height, and cadmium exposure (18). For fatal PCa, higher vigorous physical activity 
level is associated with lower risk. In contrast, recent smoking history, height, and BMI are 
associated positively with PCa risk (21). Cadmium is linked to PCa risk in some, but not all, 
epidemiological studies (20). 
 Diet: A wide variety of dietary factors are implicated in the development of PCa according to 
descriptive epidemiologic studies of migrants, geographic variations, and temporal studies 
(20). For instance, a high intake of total energy were associated with a significant increased 
risk (21) In addition, a high intake of dietary fat showed a strong positive correlation with PCa 
incidence and mortality (20). Vitamin D deficiency may be a risk factor for PCa, but in 
contrast, the high intake of total calcium increases PCa risk (22). Retinoids, including vitamin 
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A had a positive association with PCa risk (20). Phyto-oestrogens, present in a soy-rich diet, 
were associated with a decreased PCa risk (18). Clinical studies linked the intake of 
antioxidants, including selenium, α-tocopherol (vitamin E), and lycopene (a carotenoid) to a 
reduced PCa risk (22). On the other hand, vitamin C intake and alcohol consumption appear to 
have no significant association with PCa risk (20). 
An association between nutrients involved in one-carbon metabolism and cancer risk have 
been reported (23;24). One-carbon metabolism provides the methyl groups for numerous 
methyl transferase reactions and plays a critical role in DNA methylation and DNA synthesis. 
Therefore, it has an impact on both genetic and epigenetic processes in the cell. Furthermore, 
the perturbation of one-carbon metabolism may lead to chromosome breaks and disruption of 
DNA repair mechanisms (25). Besides folate, choline, and methionine, other nutrients 
influence one-carbon metabolism, including vitamin B6, vitamin B12, and vitamin B2 (25). 
The Northern Sweden Health and Disease Cohort study investigated components of one-
carbon metabolism in relation to PCa risk in 561 cases of PCa and 1,034 controls (23). The 
study showed that elevated plasma concentrations of choline and vitamin B2 were associated 
with increased risk of PCa, whereas elevated concentrations of methylmalonic acid (marker of 
vitamin B12 deficiency) were associated with decreased risk (23).  
Collectively, a wide variety of dietary factors have been linked to PCa risk with different 
suggested mechanisms. Furthermore, since several genes may modify the association of 
specific nutrients with PCa risk, diet-gene interactions may have an important effect (26).  
1.1.3 Screening and diagnosis of prostate cancer 
The main screening tools for PCa are the digital rectal examination and PSA test. The digital 
rectal examination is a relatively simple test that allows checking the surface of the prostate with 
a gloved finger. The physician is able to feel any lumps, hard areas, or anything else that seems 
unusual on the prostate (27). Despite its poor reliability, sensitivity, and the inability to palpate 
the entire prostate gland, the rectal examination is still a necessary screening method (28).  
PSA is a serine protease produced primarily by epithelial cells lining the acini and ducts of 
the prostate gland. It appears in the blood via releasing from prostatic stroma. Like other serine 
proteases, serum PSA exists mostly in a complex form, in addition to a small proportion remains 
in a free form. PSA is metabolized by the liver with a 2.2- to 3.2-day serum half-life (27). Every 
prostate disease, such as cancer, inflammation, infection, hyperplasia, and others, can cause PSA 
Prostate cancer 
 6 
levels to rise. However, BPH is still the most common cause of elevated serum PSA (27). About 
30% of men with total PSA values above the currently accepted cut-off point (4.0 ng/mL) will 
have PCa based on biopsy results (29). The screening results for PCa are significantly better by 
using PSA test combined with digital rectal examination (27). 
Transrectal ultrasound and transrectal ultrasound guided needle biopsies are performed to 
confirm diagnosis following PSA or digital rectal examination testing. Transrectal ultrasound 
guided systematic prostate biopsy is the standard test for PCa diagnosis (30). The current protocol 
using extended biopsy schemes (12 cores) provides a higher sensitivity in detecting PCa 
compared to previous sextant protocol. The cores are taken from a standard set of locations (30). 
Recent studies suggested that magnetic resonance imaging (MRI) guided prostate biopsies are 
superior to transrectal ultrasound guided systematic prostate biopsy and could reduce the false-
negative results due to targeting areas considered to be suspicious for PCa (31). However, further 
studies are needed to confirm the additional benefits of MRI guided prostate biopsies. 
Non-invasive clinically imaging techniques that provide data on metabolic activity in vivo 
such as positron emission tomography (PET/CT) and magnetic resonance spectroscopic imaging 
(MRSI) were evaluated for detection and staging of PCa (32;33). These techniques detect 
primarily the abnormalities in choline metabolism that are associated with oncogenesis and tumor 
progression. PET/CT techniques use positron-emitting isotopes such as 
11
C-choline, which 
generally displays a high uptake in tumor tissues (34). However, PET/CT shows a low detection 
rate for PCa (35). One the other hand, PET/CT plays a promising role for diagnosis of recurrent 
PCa, as well as for the detection of lymph node metastases (36). MRSI techniques map the 
distribution of metabolites throughout the entire prostate gland, such as choline and citrate. 
Elevated choline can be seen in the presence of cancer (34). MRSI shows a better sensitivity than 
PET/CT for PCa detection (34). Moreover, MRSI is a valid tool for detecting cancer recurrence 
and monitoring therapy response (37). 
Due to the high prevalence of latent PCa, a considerable number of PCa cases are diagnosed 
incidentally from histopathologic examination of the prostectomy specimens. The common 
clinical scenario that leads to the diagnosis of incidental PCa is through the performance of 
prostatectomies for presumed BPH. However, the incidence of such a finding becomes lower as 
many patients undergo PSA screening test in addition to the increase use of medical therapy for 
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BPH (30). Further, screening programs have been implemented in the health care system in 
Europe (38). 
1.1.4 Staging and grading of prostate cancer 
Following histological diagnosis of PCa, staging is performed to determine the extent of the 
patient’s cancer to predict prognosis and to evaluate and select the appropriate treatment options. 
Accurate staging is helpful in assessing different treatment options and defining prognostic 
models (34). Currently, the following systems are used to accomplish this purpose. 
1.1.4.1 TNM classification system 
The TNM classification is the most widely used means for classifying the extent of cancer 
spread. It is developed by the Union for International Cancer Control (UICC) and is used as a 
global method to classify cancers. The classification is based on the extent of the primary tumor 
(T), the presence and extent of involved lymph nodes (N), and distant metastases (M) (34). The 
TNM system allows PCa classification according to two distinct systems, the clinical TNM 
(cTNM) and pathological TNM (pTNM). The first is determined from the information that is 
available without surgery, whereas pTNM is based on the surgical removal and histological 
examination of the entire prostate gland, the seminal vesicles and surrounding structures and, if 
relevant, pelvic lymph nodes. In general, cTNM is used to determine initial treatment strategy, 
while pTNM is used to determine the requirement for post surgical adjuvant therapy and follow 
up (39). The 2009 TNM classification for PCa is shown in Table 1. 
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Table 1: The 2009 Tumor Node Metastasis (TNM) classification of PCa (39). 
T - Primary tumor  
Stage Sub-stage Definition 
TX  Primary tumor cannot be assessed 
T0  No evidence of primary tumor 
T1  Clinically inapparent tumor not palpable or visible by imaging 
 T1a Tumor incidental histological finding in 5% or less of tissue resected 
 T1b Tumor incidental histological finding in more than 5% of tissue resected 
 T1c Tumor identified by needle biopsy (e.g. because of elevated PSA level) 
T2  Tumor confined within the prostate 
1
 
 T2a Tumor involves one half of one lobe or less 
 T2b Tumor involves more than half of one lobe, but not both lobes 
 T2c Tumor involves both lobes 
T3  Tumor extends through the prostatic capsule 
2
 
 T3a 
Extracapsular extension (unilateral or bilateral) including microscopic 
bladder neck involvement 
 T3b Tumor invades seminal vesicle(s) 
T4  
Tumor is fixed or invades adjacent structures other than seminal vesicles: 
external sphincter, rectum, levator muscles, and/or pelvic wall 
N - Regional lymph nodes
 3
 
Stage Sub-stage Definition 
NX  Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 
N1  Regional lymph node metastasis 
M - Distant metastasis 
4
 
Stage Sub-stage Definition 
MX  Distant metastasis cannot be assessed 
M0  No distant metastasis 
M1  Distant metastasis 
 M1a Non-regional lymph node(s) 
 M1b Bone(s) 
 M1c Other site(s) 
1
 Tumor found in one or both lobes by needle biopsy, but not palpable or visible by imaging, is classified as T1c. 
2
 Invasion into the prostatic apex, or into (but not beyond) the prostate capsule, is not classified as pT3, but as pT2. 
3
 Metastasis no larger than 0.2 cm can be designated pN1 mi. 
4
 When more than one site of metastasis is present, the most advanced category should be used. 
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1.1.4.2 Gleason grading system 
The most common method for the histological grading of prostate tissue is the Gleason 
grading system. In 2005 the Gleason system is altered by International Society of Urological 
Pathology, and is currently the standard for grading adenocarcinoma of the prostate on core 
biopsy and operative specimens (39). In this system the tissue is classified into five grades, 
numbered 1 through 5. The grade increases with increasing malignancy level and therefore 
cancer aggressiveness (Figure 2) (40).  
 
 
 
 
The Gleason score represents the sum of the most and second most predominant Gleason 
grades present in the tissue section, and the first number is often more important. All Gleason 
scores range from 2 (1+1) to 10 (5+5). Although, two scores might be the same, but the 
underlying grades might be different and therefore, the tumor characteristics might be different. 
For instance, a Gleason 7 (3+4) cancer would likely prove to be less aggressive than a Gleason 7 
(4+3) cancer, even though, both have the same Gleason score (40). In case, a small area of a third 
pattern (generally more aggressive) is observed, the pathologists should mention details of this 
"tertiary" pattern. Similarly, a Gleason score 7 (3+4) with a tertiary component of pattern 5 would 
be considered to be more aggressive than the same score without tertiary pattern 5 (40). 
Figure 2. Schematic diagram of Gleason grading system 
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1.1.4.3 Stage grouping system 
The American Joint Committee on Cancer (AJCC) in cooperation with the TNM Committee 
of the Union for International Cancer Control (UICC) develops a stage grouping schema. This 
stage grouping system is based on TNM classification, Gleason grade, and PSA. If the Gleason 
score or PSA results are not available, the stage can be based only on the TNM classification. The 
overall stage is expressed in Roman numerals from I (the least advanced) to IV (the most 
advanced), as shown in Table 2. The classification of stages of cancer is done to help determine 
the best treatment approach and as a guide for prognosis, as well as provide an outlook for 
survival (39). However, the prognosis is also affected by other factors such as age, ethnic origin, 
and socio-economic condition that are completely independent of the tumor’s stage. These factors 
should be also considered in the determination of the individual patient’s prognosis (34). 
Table 2: Stage grouping (39). 
Group T N M PSA (ng/mL) Gleason 
I 
T1a-c N0 M0 PSA <10 Gleason ≤6 
T2a N0 M0 PSA <10 Gleason ≤6 
T1-2a N0 M0 - - 
IIA 
T1a-c N0 M0 PSA <20 Gleason 7 
T1a-c N0 M0 PSA ≥10, <20 Gleason ≤6 
T2a N0 M0 PSA ≥10, <20 Gleason ≤6 
T2a N0 M0 PSA <20 Gleason 7 
T2b N0 M0 PSA <20 Gleason ≤7 
T2b N0 M0 - - 
IIB 
T2c N0 M0 Any PSA Any Gleason 
T1-2 N0 M0 PSA ≥20 Any Gleason 
T1-2 N0 M0 Any PSA Gleason ≥8 
III T3a-b N0 M0 Any PSA Any Gleason 
IV 
T4 N0 M0 Any PSA Any Gleason 
Any T N1 M0 Any PSA Any Gleason 
Any T Any N M1 Any PSA Any Gleason 
 
1.1.5 Prostate cancer treatment 
There are numerous treatment options with regard to the potentially optimal management of 
patients with organ-confined, locally advanced, and metastatic PCa. However, several factors 
should take into account before choosing the treatment options including the stage and grade of 
cancer, comorbidities, and life expectancy (41).  
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1.1.5.1 Deferred treatment (watchful waiting / active surveillance) 
 The recent screening and management strategies for PCa lead to the overdiagnosis of 
clinically insignificant tumors that may never need to be treated. The resultant overtreatment 
largely occurs because physicians cannot definitively distinguish the indolent from potentially 
aggressive disease. However, PCa is often a slowly progressive disease, and many men with PCa 
will not die from their disease, even in the absence of treatment (41). Two conservative 
management strategies of ‘watchful waiting’ and ‘active surveillance’ have been proposed for 
reducing the risk of overtreatment (38). Watchful waiting referred to the conservative 
management of PCa patient with life expectancy < 10 years, until the development of local or 
systemic progression with disease-related complaints. At this point, the patient would then be 
treated palliatively with transurethral resection of the prostate (TURP) for urinary tract 
obstruction, and hormonal therapy or radiotherapy for the palliation of metastatic lesions (38). As 
opposed to watchful waiting, active surveillance aims at the proper timing of curative treatment 
options (42). The strategy of active surveillance depends on a close monitoring for carefully 
selected patients with low risk PCa. These patients defined by a Gleason score of 6 or less, a PSA 
less than 10 ng/mL and cT1c-2a TNM classification (41). Patients under active surveillance must 
be followed-up carefully with serial PSA measurements, digital rectal examinations, and periodic 
prostate re-biopsies at 2, 5 and 10 years (41). However, an appropriate therapy for patients whose 
disease is reclassified as higher risk should be undertaken (39). 
1.1.5.2 Radical prostatectomy 
The surgical treatment of PCa consists of radical prostatectomy, which involves a removal of 
the entire prostate gland, along with sufficient surrounding tissues to obtain a negative margin 
(41). Radical prostatectomy remains the standard treatment for localized PCa (intracapsular 
disease). The retropubic approach is more commonly performed, as it enables a simultaneous 
pelvic lymph node assessment to be carried out. In men with localized PCa and a life expectancy 
of 10 years or more, the goal of the radical prostatectomy must be eradication of the disease and 
maintaining erectile function and urinary continence (39). 
1.1.5.3 Radiation therapy 
Radiotherapy for PCa can be divided into two types: external beam radiation therapy and 
brachytherapy (internal radiation). In external beam radiotherapy, a small amount of radiation is 
delivered to the prostate over a course of 7 to 8 weeks. On the contrary, radiation is delivered 
Prostate cancer 
 12 
from within the prostate itself in brachytherapy. To accomplish this, radioactive seeds are 
implanted directly into the prostate (41). Although, there are no randomized studies that compare 
radical prostatectomy with radiotherapy, particularly for localized PCa, radiotherapy continues to 
be an important and valid alternative to surgery as the sole form of curative therapy (39). 
1.1.5.4 Hormonal therapy 
Hormonal therapy is also called androgen deprivation therapy (ADT). The aim of ADT is to 
reduce the amount of testosterone and androgens in the bloodstream depriving many PCa cells of 
the fuel they need to grow. Once androgens are withdrawn, androgen-dependent PCa cells will 
slow or stop growing, while androgen-independent PCa cells will keep right on growing (43). 
ADT strategies become the mainstay of management of advanced PCa. More recently, there is a 
move towards the increasing use of ADT in younger men with earlier or recurrent disease (39). 
1.1.5.5 Experimental local treatment of prostate cancer 
The fight against PCa goes beyond radical prostatectomy, radiation therapy, and hormonal 
therapy. Temperature can also kill tumor cells and proves to be highly successful in this war on 
PCa. Cryosurgery of the prostate and high-intensity focussed ultrasound emerge as alternative 
therapeutic options (41). High-intensity focussed ultrasound kills the tumor cells by heat with 
highly focused ultrasonic beams. Nevertheless, it is still considered to be an experimental 
treatment (39;41). Cryosurgery of the prostate uses freezing techniques to induce cell death. 
These two techniques have been developed as minimally invasive procedures with the aim of 
equivalent oncological safety with reduced toxicity (38).  
1.1.5.6 Chemotherapy 
Until recently, chemotherapy was not a standard treatment for early PCa. However, 
chemotherapy should be considered as a treatment option when hormonal treatments fail and the 
cancer cells no longer respond to hormones, as well as in very advanced or metastatic disease 
(41). Although, the encouraging results of chemotherapy for the management of androgen-
independent PCa with metastatic disease, but when a cytotoxic regimen should be initiated is still 
a matter of controversy (39).  
Collectively, there are a variety of treatment options at every stage of PCa, the treatment 
approaches may involve individual therapy or some combination (39). The goals of the 
combination between different therapy types are the improvement of operability of the tumor, 
better local cancer control, and longer survival of the patients. However, the use of 
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neoadjuvant/adjuvant therapy continues to be studied as a way to maximize cure rates, as well as 
minimize rates of recurrence (41). 
Overdiagnosis of clinically insignificant tumors are attributed to using PSA as screening 
marker. Determining the most appropriate treatment regimen is a dilemma for many physicians 
because many aspects of the disease must be taken into consideration before making decisions 
about treatments. A refinement of prognostic factors for disease progression will be critical in 
resolving this therapeutic dilemma.  
PCa management becomes a major healthcare problem worldwide due to increased detection 
rate and life expectancy. Research into improving control of this disease is progressing on many 
fronts including cancer prevention. Since 90-95% of cancer cases are due to lifestyle and 
environmental factors. Diet may be one of the main environmental factors affecting progression 
from clinically insignificant to significant PCa, and therefore, diet is a promising candidate for 
future cancer prevention strategies. 
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1.2 Choline                                                                              
 
1.2.1 Choline structure 
In 1849 Adolph Strecker, a German chemist, isolated a compound from pig bile, to which he 
subsequently applied the name choline (from the Greeke, chole, bile) (44). In 1867, Bayer 
determined the chemical structure of choline (45). Choline (2-hydroxyethyl-trimethyl-
ammonium), a simple but unusual compound, consists of a 2-carbon chain in which one carbon is 
attached to a hydroxyl group and the other to an amine nitrogen. The particularly unusual quality 
of choline is that this amine nitrogen bonds with a total of four carbon atoms instead of with the 
usual three, and thus carries a partial positive charge (Figure 3) (46).  
 
 
 
1.2.2 Dietary choline 
Choline is widely distributed throughout the food supply. Excellent sources of dietary choline 
include liver, eggs, wheat germ, and dried soybeans. In foods, choline is found in free and 
esterified form [as phosphocholine (PCho), glycerophosphocholine (GPC), phosphatidylcholine 
(PtdCho), and sphingomyelin (SM)] (47). Dietary choline is absorbed from the lumen of the 
intestine via transporter proteins (48). The water-soluble forms choline, PCho, and GPC enter the 
portal circulation and are mostly absorbed by the liver and the rest pass into the systemic 
circulation. While the lipid-soluble forms PtdCho and SM are hydrolyzed to 
lysophosphatidylcholine (Lyso-PtdCho) and sphingosine, respectively, then absorbed into lymph 
as chylomicrons (46;49-51). Due to the differences in the pathways of digestion and absorption, 
have these forms different bioavailability (52). 
In 1998, the U.S. Institute of Medicine’s Food and Nutrition Board established an adequate 
intake (AI) and a tolerable upper limit (UL) for choline (49). The AI is 425 and 550 mg/day for 
women and men, respectively, with more recommended during pregnancy and lactation. The AI 
Figure 3. Structure of choline 
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for infants is estimated from the calculated intake from human breast milk. The main criteria for 
determining the AI and UL are the amount of choline needed to prevent liver damage, and the 
choline intake associated with hypotension (the critical adverse effect from high intake of 
choline), respectively (49). Table 3 summarizes the AI and UL of dietary choline according to 
the U.S. Institute of Medicine (49). 
Table 3: Dietary reference intake values for choline (49). 
Population Age Adequate intake (AI) Tolerable upper limit (UL) 
Infants 0 to 6 months 125 mg/day, 18 mg/kg Not possible to establish * 
 6 to 12 months 150 mg/day Not possible to establish * 
Children 1-3 years 200 mg/day 1000 mg/day 
 4-8 years 250 mg/day 1000 mg/day 
 9-13 years 375 mg/day 2000 mg/day 
Males 14-18 years 550 mg/day 3000 mg/day 
 19 years and older 550 mg/day 3500 mg/day 
Females 14-18 years 400 mg/day 3000 mg/day 
 19 years and older 425 mg/day 3500 mg/day 
Pregnancy All ages 450 mg/day Age-appropriate UL 
Lactation All ages 550 mg/day Age-appropriate UL 
* Not possible to establish; sources of intake should only be mother’s milk and infant formulas 
 
1.2.3 Endogenous choline synthesis 
Endogenous choline is produced by the sequential addition of three methyl groups to the amine 
nitrogen of phosphatidylethanolamine (PtdEth); this forms PtdCho, which can then be broken 
down to liberate the choline via the action of phospholipases (53). The methylation reactions are 
catalyzed by phosphatidylethanolamine N -methyltransferase (PEMT). During this process, S-
adenosylmethionine (SAM) is used as a methyl donor for the formation of a new choline moiety. 
This pathway is primarily active in the liver but also to a small extent within other tissues (54-
56).  
1.2.4 Sex, gene polymorphism and dietary choline requirement  
There are two major factors that affect choline requirements: estrogen status and genetic 
variation. Whereas 77% of men and 80% of postmenopausal women develop signs of choline 
deficiency when deprived of dietary choline for up to 42 days, 56% of premenopausal women did 
not (7). The difference in requirement is explained by inducing the expression of the PEMT by 
estrogen. Estrogen binds to its receptors which bind to estrogen response elements in the 
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promoters of the PEMT gene, resulting in an up-regulation in PEMT mRNA expression and 
increased hepatic enzyme activity (57). 
Beyond the estrogen status, additional reasons for this variation in dietary choline 
requirements must be taken into consideration because some men and women develop organ 
dysfunction when fed a diet-deprived of choline, while others do not. Choline, methionine, and 
folate metabolism are interrelated in the reactions of the methyl cycle (Figure 4). Thus, the 
requirement for dietary choline is modified by availability of these other nutrients in addition to 
the capacity of endogenous choline synthesis (58). Genetic variation likely underlies these 
differences in dietary requirements. Several very common single nucleotide polymorphisms 
(SNPs) in genes in choline and folate metabolism have a profound impact on choline needs 
(59;60). For example, the PEMT SNP (PEMT; rs12325817) has an obvious effect in women 
where one allele is sufficient to increase the risk of developing choline deficiency-induced organ 
dysfunction by 25 fold (60). Another SNP in the PEMT gene (PEMT; rs7946) is present more 
often in people with fatty liver (61). 
 
 
 
 
 
 
Figure 4. Interrelationships of choline, folate, and methionine in the methyl cycle. BADH, betaine 
aldehyde dehydrogenase; BHMT, betaine homocysteine methyltransferase; CHDH, choline  
dehydrogenase; MS, methionine synthase; mTHF, 5-methyl tetrahydrofolate; PEMT, 
phosphatidylethanolamine-N-methyltransferase; THF, tetrahydrofolate. 
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Polymorphisms in the folate metabolism can limit the availability of 5-methyl 
tetrahydrofolate (mTHF) and thereby increase the use of choline as a methyl donor. 
Premenopausal women who are carriers of the very common 5,10-methylenetetrahydrofolate 
dehydrogenase SNP (MTHFD1; rs2236225) are more than 15 times as likely as non-carriers to 
develop choline deficiency-induced organ dysfunction (59). Other genetic polymorphisms that 
modify choline requirements are choline dehydrogenase (CHDH; rs9001 and rs12676). The first 
has a protective effect on susceptibility to choline deficiency, while the second CHDH SNP 
(rs12676) is associated with increased susceptibility (60). Collectively, polymorphisms in the 
PEMT gene alter endogenous synthesis of choline, and polymorphisms in other genes of choline 
and folate metabolism influence dietary requirements by changing the utilization of choline 
moiety as a methyl donor. 
1.2.5 Choline biochemistry 
Choline is an essential nutrient that is needed for the normal functions of all cells and is 
crucial for sustaining life (62). Choline, or its metabolites contribute to numerous biological 
functions, include the structural integrity of cell membranes, methyl metabolism, cholinergic 
neurotransmission, transmembrane signaling, and lipid and cholesterol transport and metabolism 
(63). Growing experimental evidences identify important roles for choline in multiple metabolic 
processes such as gene expression (64), carcinogenesis (65), apoptosis (66), and early brain 
development (67). 
 1.2.5.1 Choline transport 
After ingestion and subsequent digestion of choline-containing compounds in foods, the free 
choline that is formed enters the portal circulation of the liver. The rest of the choline in portal 
venous blood passes into the systemic circulation (46). Choline is a normal constituent of the 
plasma with a concentration of around 10 μmol/L of free choline (5;49). However, choline is also 
found in other biological fluids (Table 4). All tissues accumulate choline by diffusion and 
mediated transport  (68). Four choline transporters are described showing different affinity for 
choline, specificity, and Na
+
-dependency (14) 
1.2.5.1.1 High-affinity choline transporters (CHTs) are attributed to CHT1 (also known as 
SLC5A7), which has a Km of 0.5-5 μM for choline. CHT1 is mainly expressed in cholinergic 
neurons and it is choline-specific and Na
+
-dependent (69;70).  
Choline  
 18 
1.2.5.1.2 Choline transporter-like proteins (CTLs) are characterized by intermediate-affinity (Km 
20–200 μM) and they are choline specific and Na+-independent. CTL1 (also known as SLC44A1) 
is ubiquitously expressed in most human tissues (14;69). It mediates the transport of choline 
across both mitochondrial and plasma membrane (69;71). The CTL proteins are identified in 
human, mouse, and rat (69). The CTL family comprises at least six genes where all gene products 
undergo complex alternative splicing (14).  
1.2.5.1.3 Organic cation transporters (OCTs) transfer organic cations in a Na
+
-independent and 
reversible manner. Since 1994, several members of the OCTs family are cloned from different 
tissues (OCT1, OCT2, and OCT3). They are part of the SLC22 gene family and carry out a low-
affinity choline transport in addition to the transport of other organic cations. OCTs facilitate 
polyspecific cationic transport, whereas their exact role in choline transport is unclear (69).  
1.2.5.1.4 Organic cation/carnitine transporters (OCTNs) are part of the SLC22 gene family also 
and exist as two isoforms. The OCTN1 (also known as SLC22A4) is pH-sensitive and functions 
in a Na
+
-independent manner. The OCTN2 (also known as SLC22A5) can function as a Na
+
-
dependent co-transporter for certain zwitterions, as well as a Na
+
-independent transporter of 
organic cations. OCTN1 and OCTN2 are structurally related. However, the exact role of OCTNs 
in choline transport is not known (72;73). 
Table 4: Free choline concentrations in human body fluids 
Body fluids Free choline * References 
Plasma 6.7-10.5 μmol/L (74;75) 
Serum 11.9-13.5 μmol/L (74;75) 
Urine 15.5 μmol/L, 1.7-2.6 mmol/mol creatinine (75;76) 
Cerebrospinal fluid 0.7-2.1 μmol/L (77;78) 
Amniotic fluid 22.8-24 μmol/L (79) 
Colostrum 132 μmol/L (80) 
Breast milk 210-228 μmol/L (80;81) 
Semen 16700-24200 μmol/L (82;83) 
Peritoneal dialysate 18.2 μmol/L (84) 
* Values are given as the range of the means or medians from the cited references 
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1.2.5.2 Acetylcholine biosynthesis 
Though only a small fraction of administered choline is acetylated, this pathway is important 
for synthesis of acetylcholine (ACh) as a neurotransmitter (68). Choline acetyltransferase (ChAT, 
EC 2.3.1.6) mediates a single reaction, the transfer of an acetyl group from acetyl-coenzyme A 
(acetyl-coA) to choline, which thereby generates the neurotransmitter acetylcholine in cholinergic 
neurons (85). This enzyme is highly concentrated in cholinergic nerve terminals. The availability 
of choline influence ChAT activity (68). In the brain, a specific carrier mechanism transports free 
choline across the blood brain barrier at a rate proportional to the serum choline concentration, 
whereas the cholinergic neurons have CHT1 transporter that helps them accumulate choline 
(70;86). Furthermore, both the PtdCho and the ACh are ultimately broken down to regenerate 
free choline, thus both of these compounds can also be considered ‘‘reservoirs’’ for free choline 
in the brain (46). 
1.2.5.3 Methyl group metabolism 
Methionine, mTHF, and choline important sources of methyl groups in humans (25). The 
methyl groups of choline can be made available for one-carbon metabolism upon oxidation to 
betaine. Liver and kidney are the major sites for choline oxidation. This process requires two 
enzymes: The mitochondrial choline dehydrogenase (CHDH) that converts choline to betaine 
aldehyde. The latter can then be oxidized in mitochondria or cytoplasm to betaine by betaine 
aldehyde dehydrogenase (BADH) (68). Betaine homocysteine methyl transferase (BHMT) 
mediates the transfer of the methyl group from betaine to homocysteine (Hcy) to produce 
methionine that is in turn converted into S-adenosylmethionine (SAM), the universal methyl 
donor (Figure 5). As discussed earlier, the metabolism of choline, folate, and methionine are 
interrelated and therefore disturbances in one of these metabolic pathways are associated with 
compensatory changes in the others. This means the methyl groups from mTHF, methionine, and 
choline can be interchangeable (5). For example, methionine can be formed from Hcy using 
methyl groups donated either by mTHF or by betaine (Figure 4) (58). 
1.2.5.4 Choline role in trimethylamine N-oxide metabolism 
Recently, Wang et al reported a new metabolic pathway involving gut flora (87). In this 
pathway intestinal microbiota metabolism of choline and PtdCho produces trimethylamine 
(TMA), which is further metabolized to trimethylamine N-oxide (TMAO) by means of hepatic 
flavin monooxygenases (FMOs) (Figure 6). TMAO has been reported to alter cholesterol and 
Choline  
 20 
sterol metabolism and contribute to the pathogenesis of atherosclerotic coronary artery disease in 
animal models (87;88). 
 
 
 
 
 
 
 
 
1.2.5.5 Choline role in phospholipid metabolism 
Phospholipid are a class of lipids that consist of two long-chain fatty acids esterified at the sn-
1 and sn-2 positions of glycerol, and contain a head group linked by a phosphate residue at the 
sn-3 position. The head group forms a hydrophilic region and determines the type of 
phospholipid. Choline forms the head group of PtdCho, Lyso-PtdCho, and SM (Figure 7) (89). 
Phospholipid make up the essential milieu of cellular membranes and play an important role in 
the lipoprotein metabolism and intracellular signaling (90). The variation in the composition of 
phospholipid head-group , and the attached fatty acids which vary in the chain length and the 
degrees of unsaturation resulting in a complexity of phospholipid species (90). 
Figure 5. One-carbon metabolism, the choline cycle. BADH, betaine aldehyde 
dehydrogenase; BHMT, betaine homocysteine methyltransferase; CHDH, choline 
dehydrogenase; PEMT, phosphatidylethanolamine N-methyltransferase. 
Figure 6. Gut flora-dependent metabolic pathway of choline and PtdCho.  
FMOs: flavin monooxygenases; PtdCho, Phosphatidylcholine; TMA: trimethylamine; 
TMAO: trimethylamine-N-oxide. 
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1.2.5.5.1 Choline role in membrane phospholipid metabolism 
Phospholipid are major components of the plasma membrane. PtdCho and its product SM are 
the predominant phospholipid in most mammalian membranes. In fact, the main metabolic fate of 
choline is the formulation of PtdCho that accounts for about 95% of the total choline pool in most 
animal tissues (91). All tissues form PtdCho via the Kennedy pathway (also called CDP-choline 
pathway) Figure 8 (92). PtdCho can also be produced via the PEMT pathway that is 
quantitatively significant only in the liver where it contributes approximately 30% of total hepatic 
PtdCho synthesis (91). 
The Kennedy pathway involves three reactions. In the first step, choline kinase (CHK) 
catalyzes the phosphorylation of choline into phosphocholine (PCho). This reaction can be a rate-
limiting step for PtdCho biosynthesis (93;94). The second reaction in the Kennedy pathway is 
catalyzed by the CTP-phosphocholine cytidylyltransferase (CCT) that yields cytidine diphosphate 
choline (CDP-Cho) from PCho and cytidine triphosphate (CTP). CCT mediates the rate-limiting 
step in the Kennedy pathway and its activity depends on the association with membrane 
structures, the phosphorylation state, and some transcription factors (92;95). In the final step, the 
CDP-Cho and diacylglycerol (DAG) are converted into PtdCho by 1,2-diacylglycerol 
cholinephosphotransferase (CPT1). CPT1 seems not to be a rate-limiting step in PtdCho 
biosynthesis (91;94). 
Figure 7. Chemical structure of phospholipid classes. 
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On the other hand, three classes of phospholipase mediated the catabolism of PtdCho. 
Phospholipase C (PLC) converts PtdCho into PCho, while phospholipase A (PLA) and 
phospholipase D (PLD) can liberate choline. There are three-step reactions that produce choline 
from PtdCho. First, phospholipase A2 (PLA2) catalyzes the hydrolysis of PtdCho yielding Lyso-
PtdCho, which is converted to glycerophosphocholine (GPC) by the enzyme lyso-phospholipase 
A1 (Lyso-PLA1). The enzyme GPC phosphodiesterase (GPC-PDE) then converts GPC into 
choline (14). In contrast, choline is produced from PtdCho in one-step reaction via either PLD1 
or PLD2 isoform (96). 
 
 
 
 
 
 
 
 
Figure 8. The enzymes involved in choline phospholipid metabolism in the cell. Black arrows represent 
the biosynthetic pathway. Gray arrows represent the catabolic pathway. ADP, Adenosine diphosphate; 
ATP, Adenosine triphosphate; CCT, CTP-phosphocholine cytidylyltransferase; CDP-Cho, cytidine 
diphosphate choline; CHK, choline kinase; CMP, cytidine monophosphate; CoA, Coenzyme A; CPT1, 
diacylglycerol cholinephosphotransferase 1; CTP, cytidine triphosphate; DAG, diacylglycerol; GPC, 
glycerophosphocholine; GPC-PDE, glycerophosphocholine phosphodiesterase; G3P, glycerol-3 
phosphate; Lyso-PLA1, lyso-phospholipase A1; Lyso-PtdCho, lysophosphatidylcholine; LPCAT, 
lysophosphatidylcholine acetyltransferase; PA, phosphatidic acid; PAF, Platelet-activating factor; 
PCho, phosphocholine; PLA2, phospholipase A2; PLC, phospholipase C; PLD, phospholipase D; PPi, 
diphosphate; PtdCho, phosphatidylcholine; SM, sphingomyelin; SMS, sphingomyelin synthase. 
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1.2.5.5.2 Lipoprotein metabolism 
Choline especially via its metabolite, PtdCho, plays an important role in the lipid metabolism. 
The liver is the major site for both the synthesis of phospholipid and the generation of plasma 
lipoproteins. Phospholipid, cholesterol and specific proteins, known as apolipoproteins (apos) 
form a monolayer on the lipoprotein surface surrounding the hydrophobic core of triacylglycerols 
(TG) and cholesteryl esters (Figure 9) (97). Choline-containing phospholipid (PtdCho, Lyso-
PtdCho, and SM) are the most abundant phospholipid components in all the lipoprotein classes 
(more than 90%) (Table 5) (98;99). SM is synthesized from PtdCho by transfer of PCho to 
ceramide (Cer) through SM synthase (SMS) (100), while Lyso-PtdCho is generated from PtdCho 
by phospholipase A2 (101) (Figure 8). 
 
 
Table 5: The phospholipid composition of VLDL, LDL and HDL of human serum 
lipoprotein classes (99). 
phospholipid class VLDL LDL HDL 
PtdCho 75.9% 74.2% 73.2% 
Lyso-PtdCho 4.3% 3.8% 16.6% 
SM 14.9% 19.1% 7.4% 
PtdEth 2.4% 0.9% 1.2% 
Other 2.5% 1.9% 1.5% 
HDL, high density lipoprotein; LDL, low density lipoprotein; Lyso-PtdCho, lysophosphatidylcholine; PtdCho, 
phosphatidylcholine; PtdEth, phosphatidylethanolamine; SM, sphingomyelin ; VLDL, very low density lipoprotein. 
 
TG produced by liver is delivered to other tissues, mainly in the form of very low-density 
lipoprotein (VLDL) (Figure 10) (102). PtdCho is the only phospholipid which is currently 
Figure 9. Generalized structure of a plasma lipoprotein. 
Choline  
 24 
known to be required for lipoprotein assembly and secretion (103). Impaired hepatic PtdCho 
biosynthesis, either via CDP-choline pathway or PEMT pathway, reduces the levels of circulating 
VLDL and associate with TG accumulation in the liver (steatosis) (91). Choline-deficient humans 
also show a decrease in low density lipoprotein (LDL) levels (104). Recent data indicated that 
impaired PtdCho biosynthesis reduces also plasma high density lipoprotein (HDL) by inhibiting 
hepatic HDL formation and by increasing HDL uptake from the circulation (103). 
 
 
 
 
 
 
 
1.2.5.5.3 Choline phospholipid-mediated signal transduction 
Besides the roles of choline phospholipid metabolites in membranes and lipoproteins 
metabolism, they function also as cell signaling modulators and mediators (105). The turnover of 
choline-containing phospholipid by means of specific enzymes, resulting in the formation of 
breakdown products that are signaling molecules by themselves such as DAG (106), or after 
conversion to signaling molecules such as phosphatidic acid (PA) (105). Another Important 
Figure 10. Schematic overview of lipoprotein transport and metabolism. Chylomicrons and 
VLDL are produced by the intestine and liver, respectively. TG is unloaded from chylomicrons 
and VLDL through the action of lipoprotein lipase. During this process, HDL functions as the 
acceptor for the relieved exchangeable apolipoproteins from both chylomicrons and VLDL 
particles. VLDL become more dense and transformed to an intermediate density lipoprotein 
(IDL), which is further converted into low-density lipoprotein (LDL). The liver takes up the 
resulting chylomicron remnants and LDL, the latter is also taken up by peripheral tissues. 
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signaling molecule is platelet-activating factor (PAF, alkyl-acetyl phosphatidylcholine), which 
has diverse physiological functions in addition to the intercellular signaling effect. PAF is 
produced mainly from Lyso-PtdCho, where Lyso-PtdCho acetyltransferase (LPCAT) catalyses 
the transfer of an acetyl residue from acetyl-CoA to Lyso-PtdCho (Figure 8) (107).  
1.2.6 Choline in health and disease 
Humans require choline for sustaining normal life. Studies in animals and humans provide 
results suggesting the involvement of choline in neurodevelopment and pathogenesis of various 
chronic diseases, as well as points to a role in risk assessment and disease prevention (108). 
When healthy humans are fed a choline-deficient diet for 21-42 days they develop biochemical 
changes such as diminished plasma choline and phosphatidylcholine concentrations, as well as 
elevated serum aminotransferases and creatine phosphokinase suggesting liver and muscle 
damage, respectively (7;104).  
Choline-deficient humans develop fatty liver owing to a lack of PtdCho, which limit the 
export of excess TG from liver via VLDL (91). Choline deficiency in humans is also associated 
with liver and muscle damage (7), and with DNA damage and cell death in peripheral 
lymphocytes (10). Choline-deficient humans are likely to accumulate Hcy, a risk factor for a 
wide range of diseases (7). In addition, women who have lower choline intakes during pregnancy 
have significantly increased risk of giving birth to a child with a neural tube defect (6). 
Furthermore, women who have lower dietary intakes of choline could have an increased risk and 
mortality from breast cancer (109;110). However, the implications for choline deficiency on 
human susceptibility to cancer are not fully elucidated, an important component is likely to be the 
modifications of DNA, changes in gene expression, and mistakes in DNA repair, in addition to 
other components that differ from cancer to cancer.  
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1.3 Prostate cancer and choline 
1.3.1 Background 
Animal studies demonstrated that choline deficiency can cause cancer, particularly 
hepatocarcinomas, in the absence of other carcinogens (11;12). Interestingly, choline-deficient 
rats are markedly sensitized to the effects of administered carcinogens and have higher tumor 
incidence than rats on the control diet. Choline deficiency is therefore considered to stimulate 
both cancer-initiating and cancer-promoting activities (12).  
Although animal studies imply a causal relationship between choline deficiency and 
carcinogenesis, the role of this nutrient in human carcinogenesis and tumor progression is not 
well understood. Few studies observed a positive association between the dietary choline intake 
or plasma concentration of choline and the risk of some types of cancer (8), including PCa (23), 
while other studies indicated that a higher intake of choline is associated with reduced risk of 
cancer (109;110). On the other hand, two studies observed no significant relationship (111;112). 
However, abnormal choline metabolism is a metabolic hallmark that is associated with 
oncogenesis and tumor progression, as well as one of the characteristic features of PCa (13;14). 
Multiple roles for choline in cancer development were suggested. Choline can affect DNA 
methylation and lead to a disruption of DNA repair. It can also modify cell signaling that is 
mediated by intermediary phospholipid metabolites, and it can support the synthesis of cell 
membranes and thus support cell proliferation. Dietary choline, as a major source of choline, 
phospholipid, and methyl groups is a potential modifiable risk factor or risk marker for PCa (15). 
1.3.2 Choline uptake in prostate cancer cells 
As discussed earlier, four different types of choline transporters mediate the cellular uptake 
of choline (14). An increase in the expression of choline transporters and the transport rate has 
been documented in PCa compared with normal prostate tissues (113). The transporters involved 
in increased uptake of choline in human PCa and the mechanism of this enhanced uptake are not 
completely clear. CTL1 is expressed in PCa cells and the kinetic properties of this transporter are 
similar to that of human CTL1 (intermediate affinity and Na
+
-independent). However, one study 
showed that choline transporters in the PCa cell line PC-3 have intermediate affinity, but are Na
+
-
dependent (14;113). Thus, combined transport systems (Na
+
-dependent and Na
+
-independent) 
might be involved. Therefore, a potential role for choline transporters in PCa deserves further 
investigations (15).  
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1.3.3 The role of choline as a methyl donor  
Through its function as a methyl donor, choline has important roles in regulation of gene 
expression via epigenetic mechanisms. Aberrant epigenetic events such as DNA hypo- and 
hypermethylation are observed in PCa and play essential roles in prostate carcinogenesis 
(19;114). Methylation of DNA requires SAM as a methyl donor, which is influenced by choline 
availability (64). Altered DNA methylation and disruption of DNA repair are reported in a wide 
variety of human cancers (115), including PCa (19). For example, the glutathione S-transferase 1 
can detoxify reactive chemical species through conjugation with reduced glutathione thus 
preventing or attenuating the development of cancer upon exposure to carcinogens (116). The 
lower expression of the π-class glutathione S-transferase 1 is related to hypermethylation of CpG 
island of the promoter region of π-class glutathione S-transferase 1 in more than 90 % of PCa 
cases (114). Nakayama et al. observed hypermethylation of the promoter region of the 
glutathione S-transferase 1 gene in the majority of areas of carcinoma and high grade prostatic 
intraepithelial neoplasia lesions, but not in the epithelium and hyperplastic epithelium (117). 
Therefore, the role of choline in carcinogenesis may be related to the extent of its utilization as a 
methyl group donor. Since epigenetic mechanisms precede the development of the tumor, follow-
up studies can provide information about a potential predictive value for choline levels in cancer. 
(15).  
1.3.4 The role of choline in phospholipid metabolism 
A major role for choline is the synthesis of membrane phospholipid. Enhanced choline 
phospholipid metabolism is reported in cancer cells that need phospholipid in large quantities to 
enable their rapid proliferation (14). The predominant membrane phospholipid is PtdCho, which 
with other phospholipid form the characteristic bilayer structure of cells and regulate membrane 
integrity (89). Biosynthesis and hydrolysis of PtdCho are also essential processes for mitogenic 
signal transduction events in cells (118). Cancer pathogenesis is discussed in relation to enzymes 
involved in the synthesis or the degradation of phospholipid.  
The enzyme CHK seems to enhance the malignant transformation of cancer cells (119). For 
example, CHK is overexpressed in PCa thus causing higher PCho and supporting malignant 
transformation (13). This in turn enhances choline uptake and membrane phospholipid synthesis 
in malignant cells (13;120). Furthermore, PCho might be involved as a second messenger in the 
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growth-signaling cascade (94). In line with this evidence, the inhibitors of CHK show antitumor 
activity and reduces tumor growth (94;120).  
Moreover, the endogenous synthesis of choline seems to be upregulated in cancer cells. The 
higher requirements of choline in cancer cells are supported by the enhanced choline transport 
activities and increased degradation of PtdCho. The activity of the enzyme PLD that synthesizes 
choline from PtdCho is increased in tumor cells (96;121). Several lines of evidence indicate that 
PLD might be implicated in cell proliferation, survival signaling, malignant transformation, 
tumor progression, and metastatic process (14;96). Furthermore, recent data demonstrate that 
GPC-PDE constitutes a source of choline from GPC for the Kennedy pathway (122;123). 
Moreover, GPC-PDE is demonstrated to play a critical regulatory role in cell migration in vitro 
(123). Recent studies point to a probable interaction between CHK, PLD, and GPC-PDE. A high 
co-expression of these enzymes in the tumor resulted in higher PCho and lower GPC and led to a 
characteristically switched PC/GPC ratio (122;123). 
PtdCho can be hydrolyzed by PLC to yield PCho as well as DAG, a critical second 
messenger that activates protein kinase C, an important player in several signal transduction 
cascades (118). Inhibition of PLC activity in PC3LN3 human prostate carcinoma cells shows a 
decrease in cell migration, suggesting a possible role for PLC in cell motility and invasion 
process (124).  
Taken together, the higher CHK expression in PCa supports tumor development via PCho 
formation. A higher uptake of choline by tumor cells might support the additional requirements 
of the cells (15).  
1.3.5 Choline metabolism in relation to oncogenic signaling, hormonal therapy, and hypoxia 
Molecules derived by the breakdown of choline-containing phospholipid such as DAG and 
PCho can act as second messengers in mitogenic signal transduction pathways. Other molecules 
like lyso-phosphatidic acid can activate enzymes involved in choline metabolism such as PLD 
(96;118;121). Moreover, PA, the precursor of lyso-phosphatidic acid and DAG, has regulatory 
properties that are implicated in oncogenic signaling and activation of enzymes involved in 
choline metabolism (14). The interactions between oncogenic signaling pathways and the choline 
metabolic pathway are summarized in Table 6. 
PCa hormonal therapy or ADT might influence choline metabolism or choline uptake, but 
the evidence is not consistent (35;125;126). The influence of ADT on the uptake of radiolabelled 
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choline (
11
C-choline) is tested by using PET/CT. ADT lowers choline uptake in prostate tissues in 
two studies that tested patients before and after ADT treatment (35;125). A third study reports 
enhanced choline uptake in patients treated with ADT compared to those not treated with this 
therapy’s type (126). Experimental studies show that androgens increase choline uptake (2.0-
fold) and cause accumulation of phospholipid (2.5 fold) in androgen-dependent human prostate 
LNCaP cell (127;128). In contrast, choline uptake in androgen-independent PC-3 cell is similar 
both in the presence and the absence of androgens (128). These findings suggest a potential 
influence of androgens on choline metabolism, but this effect might differ with each cancer type. 
Hypoxia might occur because of the decrease in the vascular support when PCa cells grow. 
The subsequent activation of hypoxia-inducible factor 1 (129) might cause resistance to 
hormonal, radio- and chemo-therapy (128;129). However, the hypoxia-inducible factor 1 is 
shown to increase PCho levels in PCa cells (128;130) and to induce the expression of CHK in 
PC-3 cells, resulting in raised levels of total choline and PCho (130). Furthermore, hypoxia might 
decrease the uptake of choline in PCa cells, while the choline uptake is enhanced under aerobic 
conditions (128). Therefore, the relationship between hypoxia and choline metabolism in PCa 
seems to affect both choline uptake and utilization. 
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Table 6. The interaction between oncogenic signaling and the choline phospholipid metabolism  
Oncogenic 
signaling 
Choline 
transporter 
CHK CCT PLD PLC PLA2 
RAS GTPase  
↑ CHK activity 
(131) 
 ↑ PLD activity (132) 
↑ PLC activity 
(133) 
PLA2 mediate 
downstream of RAS 
(134) 
RAF kinases    ↑ PLD activity 
‡  (96)   
MAPK/ERK   
↓ CCT activity 
(135) 
  
↑ PLA2 activity 
(136) 
PI3K 
PI3K inhibition 
reduce the 
choline uptake 
(137) 
↑ CHK activity 
(131) 
 ↑ PLD activity (138)    
RALGDS  
↑ CHK activity 
(131) 
 
↑ PLD activity ‡ 
(138) 
  
JNK   
↓ CCT activity 
(139) 
  
↑ PLA2 activity 
(136) 
hypoxia-inducible 
factor 1 
 
↑ CHK transcription 
(130) 
    
activator protein 1  
↑ CHK transcription 
(140) 
    
SREBP   
↑ CCT activity 
(141) 
   
Specificity Protein 
1 
↑ hCTL1 
transcription 
(142) 
 
↑ CCT 
transcription 
(141;143) 
↑ PLD transcription 
(144) 
  
‡ negative feedback pathway. CCT, CTP-phosphocholine cytidylyltransferase; CHK, choline kinase; ERK, extracellular signal-regulated kinase; hCTL1, human 
choline transporter-like protein 1; JNK, JUN N-terminal kinase; MAPK,  mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; PLA2, 
phospholipase A2; PLC, phospholipase C; PLD, phospholipase D; RAF, rapidly accelerated fibrosarcoma; RALGDS, RAL GTPase guanine nucleotide 
dissociation stimulator; RAS, rat sarcoma; SREBP, sterol regulatory element binding protein.  
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1.3.6 Choline phospholipid metabolites in prostate cancer 
Accurate clinical staging of PCa is very important for the management of the disease and 
optimization of the therapy regimen. Total choline levels in prostate tissue have been shown to be 
positively related to the Gleason score and tumor aggressiveness in patients with PCa (145). 
Several PET/CT techniques indicate that 
11
C-choline might be helpful in monitoring the 
recurrence of PCa, but not for initial staging of the tumor (33;146). MRSI techniques showed that 
total choline and PCho are correlated with the stage of PCa. Therefore, MRSI might be used for 
diagnosing and monitoring the progression of PCa (32;33). The low sensitivity and low accuracy 
of PET/CT in comparison with MRSI might explain the differences in the diagnostic utility of 
both methods.   
The relationship between choline and ethanolamine metabolites levels and PCa stage has 
been recently investigated in benign and prostate tissues by using MRSI. In addition to Eth, four 
choline- and ethanolamine (Eth)-containing metabolites (PCho, GPC, and their Eth counterparts 
phosphoethanolamine (PEth) and glycerophosphoethanolamine (GPE)), were tested (145;147). 
One study indicated that PCho levels were significantly higher, while Eth levels were lower in 
cancer versus benign prostate tissues. The other metabolites, PEth, GPE and GPC, showed no 
significant differences (147). Furthermore, PCho/PEth ratio provided the best discrimination 
between benign and PCa tissues. Moreover, PCho/PEth, PCho/GPC, PEth/Eth, and GPE/Eth 
ratios also increased significantly in PCa tissues compared with benign prostate tissues (147). 
Another study confirmed lower levels of Eth and higher PCho levels in PCa versus benign 
prostate tissues (145). The levels of PEth, GPE, and GPC were higher in PCa compared with 
benign prostate tissues in this study. Additionally, the levels of the choline-containing 
metabolites (PCho and GPC) were significantly elevated in high-grade PCa versus benign 
prostate tissues whereas the Eth- containing metabolites (Eth, PEth, and GPE) were significantly 
higher in low-grade PCa versus benign prostate tissues (145). Therefore, it seems that the Eth-
containing metabolites (PEth + GPE) can discriminate between individual benign and low-grade 
PCa tissues. Moreover, the choline- containing metabolites (PCho + GPC) seem to discriminate 
between high- and low-grade PCa tissues (145). 
Taken together, choline may be related to PCa risk via several mechanisms. Choline can 
affect DNA methylation and lead to a disruption of DNA repair. It can also modify cell signaling 
that is mediated by intermediary phospholipid metabolites, and it can support the synthesis of cell 
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membranes and thus support cell proliferation. However, choline metabolism in PCa might be 
dysregulated in order to meet the tumor requirements for phospholipid and methyl groups. 
Furthermore, androgens, folate and methionine status, and common polymorphisms in genes 
involved in choline metabolism can interact with choline metabolism and affect its requirements. 
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1.4 Study aims 
PCa is one of the most common cancers in men. The prevalence has been increasing over 
the last few decades, largely due to early detection procedures (148). However, risk factors such 
as age, ethnicity, family history, lifestyle, and androgens were also discussed in relation to the 
PCa risk (19;22). There are several evidences that dietary factors can contribute to the risk of 
PCa. A higher intake or status of the nutrient choline in plasma has been related to higher PCa 
risks (23). Multiple roles for choline in cancer development have been suggested. Choline can 
affect DNA methylation and lead to a disruption of DNA repair. It can also modify cell signaling 
that is mediated by intermediary phospholipid metabolites, and it can support the synthesis of cell 
membranes and thus support cell proliferation (15). 
We hypothesized that the concentrations of choline and choline metabolites in plasma will 
be higher in men with PCa than those with BPH. The main aim of this study was to investigate 
the metabolites of one-carbon metabolism [choline, betaine, DMG, total folate, SAH, SAM, 
tHcy, cystathionine (Cys), and methylmalonic acid (MMA) (marker of vitamin B12 status)] and 
phospholipid classes in cases and controls. Moreover, choline metabolites were studied in 
relation to tumor grad, age, and statin use. Since choline is a dietary component, the study allows 
to a better understanding of a potential modifiable factor in PCa. 
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2. Materials and methods                                                                              
 
2.1 Subjects and study design 
  The study was conducted at the Saarland University Hospital, Department of Clinical 
Chemistry and Laboratory Medicine - Central Laboratory, Homburg, Germany in collaboration 
with Department of Urology, Saarland University Hospital, Homburg, Germany. This is a case 
control study. Participants are men (age > 50 y) with primary PCa (cases, n=152) or with BPH 
(controls, n=89). Patients were recruited before carrying out the radical prostatectomy surgery, or 
TURP surgery. Exclusion criteria were: vitamin B supplementation (folic acid> 400 µg / day; 
B12> 10 µg / day; B6> 10 mg / day), renal failure, advanced liver disease, chronic alcohol 
consumption, metastases, or methotrexate therapy. The study design is illustrated in Figure 11. 
The ethics commission of the Saarland approved the study (ref. Nr: 90/12 July 2012). The 
study was performed according to the Helsinki Declaration and all participants were informed 
and signed informed consent documents. Patients and controls were recruited between July 2012 
and March 2013. Seven patients and sixteen controls were excluded from the study due to 
exclusion criteria: 9 had renal failure, 2 had advanced liver disease, 2 used vitamin B 
supplements, one patient used methotrexate therapy, and 9 controls had co-existing cancers 
Figure 11.  
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2.2 Blood collection 
Blood samples were collected by venous puncture in tubes containing an anticoagulant 
EDTA and in tubes without anticoagulant. The collected blood in dry tubes was allowed to clot 
for 30 minutes at room temperature and samples were centrifuged at 4,000 x g and 4°C for 
10 minutes. Blood collected in anticoagulated tubes was centrifuged within 30 minutes at 
4,000 x g and 4°C for 10 minutes. Serum and plasma were immediately separated, divided into 
aliquots, and stored at -70°C until analysis. For the SAH and SAM measurement, 500 µL EDTA 
plasma was acidified using 50 µL 1 N acetic acid and mixed thoroughly, since SAM has to be 
immediately stabilized by acidifying the sample to avoid the degradation to SAH. For quality 
control in all UPLC-MS/MS methods, pool samples of serum and EDTA plasma were prepared. 
Figure 11. Study design. Cys, cystathionine; DMG, dimethylglycine; MMA, methylmalonic acid; 
SAH, S-adenosyl homocysteine; SAM, S-adenosyl methionine; tHcy, total homocysteine. 
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2.3 Materials 
2.3.1 Equipments and chemicalss 
Lists of the chemicals and equipments used are provided in Appendix A and Appendix B.  
General equipments 
- Aurius CE2041 Spectrophotometer (CECIL Instruments Ltd., Cambridge, UK) 
- Eppendorf centrifuge 5810 R, A-4-62 Rotor (Eppendorf AG, Hamburg, Germany) 
- Eppendorf concentrator 5301 (Eppendorf AG)  
- Hettich Mikro 20 centrifuge (Andreas Hettich GmbH & Co. KG, Tuttlingen, Germany) 
- RM5-40 Horizontal Mixer (Bennett Scientific Ltd., Newton Abbot, UK) 
- Schott Intruments Lab 870 pH meter and N 6000 A electrode (SI Analytics GmbH, 
Mainz, Germany)  
- Thermo Scientific Haake Open-Bath Circulators C10-W19 (Thermo Fischer Scientific, 
Waltham, USA)  
- VARIOMAG Monotherm Heatable Magnetic Stirrer (VARIOMAG-USA, Daytona 
Beach, USA) 
- Waters Acquity UPLC coupled to a MicroMass Quattro Premier XE (Waters Corporation, 
Milford, USA) 
General chemicals 
- Acetic acid (glacial; >99.99%; Sigma Aldrich, Munich, Germany) 
- Acetonitrile (ULC/MS grade; Biosolve, Valkenswaard, The Netherlands) 
- Ammonium acetate (ULC/MS grade; Biosolve) 
- Ammonia solution analaR NORMAPUR (25%; VWR International GmbH, Darmstadt, 
Germany) 
- Chloroform (Merck) 
- Formic acid (ULC/MS grade; Biosolve) 
- Isopropanol (ULC/MS grade; Biosolve) 
- Methanol (ULC/MS grade; Biosolve) 
- MTBE tert-Butyl methyl ether (for HPLC; >99.8%; Chromasolv) 
- Water (18.2 MΩ; Milli-Q water purification system; Millipore, Molsheim, France) 
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2.4 Methods 
2.4.1 Ultra-performance liquid chromatography tandem mass spectrometry  
Liquid chromatography technique is frequently used in analytical chemistry and 
biochemistry. In 2004, UPLC technology was introduced by Waters Corporation. The using of 
smaller particles that are efficiently packed into columns enhances the column efficiency and 
enables improved results in resolution, speed, and sensitivity. The coupling of a LC system to a 
mass spectrometer (MS) (Figure 12), which is known as LC-MS leads to a more sensitive and far 
more specific detection of the analytes. For mass spectrometric analysis the molecules are ionized 
and later on sorted and identified according to the m/z ratios (149;150).  
 
 
 
 
 
 
Tandem MS, also known as MS/MS employs two stages of mass analysis in order to 
examine selectively the fragmentation of particular ions in a mixture of ions. The most widely 
used MS/MS instrument is the triple quadrupole. It consists of three sets of quadrupoles in series. 
MS 1 and MS 2 are used as mass analyzers, In between there is a non mass-resolving quadrupole 
Figure 12.  Schematic representation of an UPLC system coupled to a mass spectrometer. The sample is 
injected via injector device into the UPLC system and separated by the UPLC column. The mobile phase is 
pumped at high pressure through the column. After separation of the analytes, the sample is ionized in the ion 
source via ESI or APCI. Identification occurs by means of the mass-to-charge (m/z) ratio. Using a triple 
quadrupole, a specific analyte can be structurally investigated by fragmentation using a collision gas, creating 
precursor and product ions. ESI, electrospray; APCI, atmospheric-pressure chemical ionization. 
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that used as a collision cell where the fragmentation and focusing of ions is carried out (Figure 
13). Finally, the streams of sorted ions pass from the analyzer to the detector, which records the 
relative abundance of each ion type (149;150). 
 
 
 
 
The quantification of analytes using UPLC-MS/MS involves the comparison of the 
intensity of the analyte signal in a sample with that obtained from standards containing known 
amounts of the analyte. The internal standard is added as early as possible in the same 
concentration, correcting the possible loss of analyte during the sample preparation or the sample 
inlet. Internal standards generally match the analyte of interest as closely as possible but not 
completely. Stable isotopes labeled analogues of the analytes contain unusual isotopes (e.g. 
replacing hydrogen with deuterium) in their chemical composition. Since the stable isotopes and 
the analytes have different masses they can be distinguished from each other without difficulty by 
MS. For all UPLC-MS/MS methods, the data acquisition was performed by MassLynx V4.1 and 
the QuanLynx software. Calculations and statistics are presented in Chapter 6.5. 
Figure 13. Assembly and functionality of a single quadrupole and a triple quadrupole in multiple reaction 
monitoring mode of a mass spectrometer. The quadrupole consists of four parallel metallic rods; one pair is at 
a positive electrical potential, the other one at a negative potential. Constant DC and RF voltages are applied. 
Ions of a given m/z ratio will resonate and can be detected for a given amplitude of the RF and DC voltages, 
while nonresonant ions hit the rods. The triple quadrupole consists of three sets of quadrupoles (MS 1, 
collision cell, and MS 2) in series. In multiple reaction monitoring (MRM) mode, a selected precursor-ion is 
isolated in MS 1, fragmented in the collision cell, and a selected product-ion is detected in MS 2. 
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2.4.1.1Quantification of betaine, choline, and dimethylglycine 
Concentrations of betaine, choline, and DMG in plasma samples were measured by using 
an UPLC-MS/MS method according to Kirsch et al (75). The method comprises a protein 
precipitation using acetonitrile. The preparation of stock solutions, calibrators, and quality control 
samples were described earlier (75). 
Standards and internal standards 
- Betaine anhydrous (Sigma Aldrich) 
- Choline chloride (Sigma Aldrich) 
- N,N,-dimethylglycine (DMG; Sigma Aldrich) 
- N,N,N-trimethyl-d9-glycine hydrochloride (d9-betaine; Isotec, Sigma Aldrich) 
- Choline chloride-trimethyl-d9 (d9-choline; Isotec) 
- N,N-dimethyl-d6-glycine HCl (d6-DMG; CDN Isotopes) 
Sample preparation  
EDTA plasma samples were thawed and vortexed, then centrifuged at 10000×g for 5 min at 
room temperature. EDTA samples, calibrators, and quality controls (100 µL) were added to a 1.5 
mL tube containing 300 µL internal standard mix (10 µmol/L d9-betaine, d9-choline, and d6-
DMG) in acetonitrile. The addition of acetonitrile caused protein precipitation and the analytes 
were extracted by vigorous vortexing of the sample for 30 s. The samples were centrifuged for 5 
min at 10,000×g at room temperature; the supernatants were transferred to glass vials. Sealed 
vials were immediately measured. 
2.4.1.2 Quantification of S-adenosyl homocysteine and S-adenosyl methionine 
Concentrations of SAH and SAM in acidified EDTA plasma samples were measured by 
using an UPLC-MS/MS method according to Kirsch et al (151). The method comprises a 
phenylboronic acid-containing SPE procedure. The preparation of stock solutions, calibrators, 
and quality control samples were described in detail earlier (151). 
Solid-phase extraction column 
- Varian Bond Elut PBA columns (Varian Inc., Palo Alto, USA)  
Standards and internal standards    
- S-(5’-adenosyl)-L-homocysteine, crystalline (SAH; Sigma Aldrich) 
- S-(5′-adenosyl)-L-methionine p-toluenesulfonate salt, from yeast (SAM; Sigma Aldrich) 
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- S-adenosyl-L-methionine-d3-tetra(p-toluenesulfonate) salt ([
2
H3]-SAM; CDN Isotopes, 
Quebec, Canada) 
- S-(5’-adenosyl)-L-homocysteine ([13C5]-SAH; Henkjan Gellekink group, Radboud 
University Nijmegen Medical Centre, Nijmegen, The Netherlands) 
Sample preparation  
Acidified plasma samples were thawed and centrifuged at 2000×g for 5 min at 4 °C. 500 µL 
of the supernatant was neutralized with 50 µL of 1 mol/L ammonia to a pH of 7.4-7.5. 25 µL 
internal standard solution mix (concentrations: 3.0µmol/L [
2
H3]-SAM and 0.82µmol/L 
[
13
C5]-SAH, leading to final concentrations of 195 nmol/L [
2
H3]-SAM and 64 nmol/L 
[
13
C5]-SAH) was added. Sample cleanup was performed with solid-phase extraction (SPE) 
columns containing phenylboronic acid (Varian Bond Elut PBA columns, Varian Inc., USA). 
Before loading the samples, the SPE columns were preconditioned with 1 mL of aqueous acetic 
acid (pH 2.636), then 5×1 mL of 20 mmol/L aqueous ammonium acetate (pH 7.4). Columns were 
centrifuged at 500×g for 1 min at 4 °C after each washing step. Each sample was then loaded on 
top of the cartridges and centrifuged at 250×g (slow start) for 2 min at 4 °C. Water-soluble 
impurities were removed by washing the column with two 1-mL volumes of 20 mmol/L 
ammonium acetate, pH 7.4 (500 g, 1 min, 4 °C). Finally, SAM and SAH were eluted from the 
column using 3×350 µL of aqueous acetic acid (pH 2.636) with a centrifugation step every time 
at 250×g for 2 min at 4 °C (slow start). The eluates were stored at -70 °C until analysis on UPLC-
MS/MS system. 
2.4.1.3 Quantification of phospholipid 
Concentrations of phospholipid classes (PtdCho, PtdEth, Lyso-PtdCho and SM) in EDTA 
plasma samples were measured by using an UPLC-MS/MS method according to Rabagny et al 
(152). The method comprises a lipid extraction procedure (153) , followed by sample separation 
and detection using an UPLC-MS/MS system. The preparation of stock solutions, calibrators, and 
quality control samples were described in detail earlier (152). 
Standards and internal standards 
- 1,2-dimyristoyl-sn-glycero-3-phosphocholine (PtdCho 28:0; Sigma Aldrich) 
- 1,2-dioleoyl-sn-glycero-3-phosphocholine (PtdCho 36:2; Avanti) 
- N-nervonoyl-D-erythro-sphingosylphosphorylcholine (SM 24:1; Avanti)  
- N-palmitoyl-D-erythro-sphingosylphosphorylcholine (SM 16:0; Avanti)  
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- 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (PtdEth 36:2; Avanti)  
- 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (PtdEth 16:0/16:0; Sigma Aldrich)  
- 1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (Lyso-PtdCho 18:0; Avanti)  
- 1-palmitoyl-sn-glycero-3-phosphocholine (Lyso-PtdCho 16:0; Sigma Aldrich) 
- 1,2-dipentadecanoyl-sn-glycero-3-phosphocholine (PtdCho 15:0/15:0; Avanti) 
- N-hexanoyl-D-erythro-sphingosylphosphorylcholine (SM 6:0; Avanti) 
- 1,2-dipentadecanoyl-sn-glycero-3-phosphoethanolamine (PtdEth 15:0/15:0; Avanti) 
- 1-heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (Lyso-PtdCho 17:0; Avanti)  
Sample preparation  
EDTA plasma samples were thawed, and plasma lipids were extracted using MTBE 
according to Matyash et al (153). Fifty microliters of an internal standard mix consisting of 3 
mmol/L PtdCho 15:0/15:0, 1 mmol/L SM 6:0, 200 μmol/L PtdEth 15:0/15:0, and 2 mmol/L 
Lyso-PtdCho 17:0 was added into a clean dry glass tube and dried under N2 gas. Plasma, 
calibrator or control samples (25 µL), and methanol (200 µL) were added to the dried internal 
standard and mixed thoroughly. MTBE (650 µL) was added and incubated with the samples for 
15 min on a horizontal shaker followed by adding water (650 µL), mixing, and incubation at 
room temperature for 10 min in the dark. This mix was then centrifuged for 10 min at 5,000×g 
and 20°C. The upper organic phase was transferred to a 1.5-mL glass vial. The extraction step 
with MTBE was repeated on the remaining aqueous phase after the first extraction, and the final 
extract was vacuum dried at 45°C. The dried lipids were resuspended in 500 µL methanol and 
immediately measured. 
2.4.2 Gas chromatography tandem mass spectrometry 
2.4.2.1 Quantification of homocysteine, cystathionine, and methylmalonic acid 
The quantification of tHcy, Cys, and MMA was performed by a modified GC-MS method 
according to Allen et al  and Stabler et al  (154;155). Cys and tHcy were simultaneously 
determined in serum. The GC-MS system consisted of a HP GC System, 6890 Series, G 1530 
with a HS 5973 Mass Selective Detector, G 1099AX and a HP-5ms GC column (cross-linked 5% 
PH ME siloxane; 30 m x 0.25 mm x 0.25 µm; Agilent Technologies, Waldbronn, Germany). 
Solid-phase extraction  
- Poly-prep chromatography columns, 0.8 x 4 cm  
- Anionic resin: AG MP-1, 100 – 200 mesh, chloride form (Bio-RAD) 
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Internal standards  
- Methyl-d3-malonic acid (d3-MMA; CDN Isotopes) 
- DL-homocystine-3,3,3’,3’,4,4,4’,4’-d8 (d8-Hcy; Cambridge Isotope Laboratories Inc., 
Andover, USA) 
- DL-(2-amino-2-carboxyethyl)-homocysteine-3,3,4,4-d4 (d4-Cys; CDN Isotopes) 
Additional chemicals and equipment 
- Acetic acid, glacial EMPROVE (Merck Chemicals) 
- Dithiothreitol (AppliChem GmbH, Darmstadt, Germany) 
- Hydrochloric acid (Merck Chemicals) 
- N-methyl-N-tert-butyldimethylsilyltrifluoro-acetamid (MBDSTFA; Machery and Nagel, 
Düren, Germany) 
- Sodium hydroxide (Merck Chemicals) 
- 5 mL glass tubes (5-SV – EPA Screw Top Vials; Chromacol) 
- Panasonic NN-5256 microwave (Panasonic Deutschland GmbH, Hamburg, Germany) 
Column preparation 
Anionic resin was washed with 1 N HCl, then methanol. The resin was left to dry for 1-
2 days at 50°C. Poly-prep columns were packed with ~100 mg anionic resin and 1 mL methanol 
was added. 
Methylmalonic acid assay 
In 5 mL glass tubes, 1 mL water, 200 µL sample, and 50 µL d3-MMA (1.635 nmol/L) were 
added. Methanol was removed from the poly-prep columns and columns were conditioned with 
3.3 mL water. Preparated samples were loaded using glass Pasteur pipettes. The columns were 
washed with 3 mL water and 3 x 3 mL of 0.01 N acetic acid/methanol solution. The samples 
were eluted using 800 µL elution solution (4 N acetic acid/1 N HCl (9:1, v/v)).  
Total homocysteine and cystathionine assay 
In 5 mL glass tubes, 1 mL water, 200 µL sample, 15 µL d8-Hcy (392 µmol/L), 20 µL 
d4-Cys (413.36 pmol/50 µL), and 30 µL DTT (10 mg/mL in 1 N NaOH; freshly prepared) were 
added. DTT is necessary for releasing the protein bound Hcy. After vortexing, the samples were 
incubated at 45°C for 35 minutes for the reduction of disulfides of homocystine to Hcy. The 
methanol was removed from the poly-prep columns and the columns were conditioned with 1 mL 
methanol and 800 µL water. Preparated samples were loaded using glass Pasteur pipettes. The 
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columns were washed with 3 x 3 mL water and 3 mL methanol. The samples were eluted in a 
glass vial using 1.1 mL elution solution (0.4 N acetic acid in methanol).  
Derivatization of the analytes 
Eluted samples from both assays were taken to dryness at 60°C in an Eppendorf 
concentrator. Dried samples were derivatized with 20 µL acetonitrile and 10 µL MBDSTFA. 
After vortexing, the samples were treated in the microwave at 440 Watts for 5 minutes. The 
samples were vortexed and analyzed by GC-MS. For both assays, serum pool samples were 
included at each batch of samples. The reference ranges for the analytes determined by this 
method were: tHcy < 12 µmol/L, Cys < 301 nmol/L, and MMA ≤ 271 nmol/L. 
2.4.3 Quantification of total folate 
The quantification of total folate was performed using a chemiluminescent microparticle 
immunoassay performed on the ARCHITECT i System (Abbott). After the release of folate from 
endogenous folate binding protein by traetment with dithiothreitol. Folate Binding Protein (FBP) 
coated paramagnetic microparticles is added. Folate present in the sample binds to the FBP 
coated microparticles. After washing, pteroic acid-acridinium labeled conjugate is added and 
binds to unoccupied sites on the FBP-coated microparticles. Following hydrogen peroxide and 
sodium hydroxide (pre-trigger and trigger solutions) are then added to the reaction mixture; the 
resulting chemiluminescent reaction is measured as relative light units. An inverse relationship 
exists between the amount of folate in the sample and the relative light units detected by the 
ARCHITECT i optical system. The assay has a linearity from 1.6 to 20 ng/mL, and a measuring 
interval from 1.5 to 20.0 ng/mL. Specimens with a folate serum value exceeding 20.0 ng/mL are 
diluted using the automated dilution procedure. Limit of detection (LOD) was 0.5 ng/mL (1.1 
nmol/L), and the limit of quantitation (LOQ) was 1.5 ng/mL (3.4 nmol/L). The interassay CV 
was ≤ 12% for serum samples from 3.5 to 20 ng/mL, and the Standard Deviation (SD) ≤ 0.42.  
2.4.4 Determination of routine parameters 
The blood count was determined from EDTA WB either by the SYSMEX SF 3000 or the 
SYSMEX XE 5000 platform (SYSMEX Germany GmbH, Norderstedt, Germany). From lithium-
heparin plasma following parameters were determined using the automated Roche/Hitachi 
Cobas
®
 8000 modular analyzer (Roche Diagnostics GmbH): creatinine, uric acid, urea, glucose, 
glomerular filtration rate (GFR), alanine aminotransferase (ALAT), aspartate aminotransferase 
(ASAT), gamma glutamyl transferase (gamma-GT), Alkaline phosphatase (ALP), C-reactive 
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protein (CRP). Total PSA in serum was determined using the automated Roche/Hitachi Cobas
®
 
8000 modular analyzer (Roche Diagnostics GmbH). Reference ranges for the routine parameters 
are summarized in Appendix C. 
2.5 Calculations and statistical analyses 
For all UPLC-MS/MS assays, calibrators were used for the construction of a standard curve 
by plotting the response (y = area analyte/area internal standard) against the corresponding 
concentrations (c) of the calibrators. The slope (m) and the intercept (i) of the standard curve are 
used for calculating the concentration of the unknown sample: 
m
iy
analyteunknowntheofionConcentrat

       (1) 
Recovery [%] was calculated as: 
100
addedionconcentrationconcentratExpected
ionconcentratMeasured
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
     (2) 
Quantification of tHcy, Cys, and MMA was carried out using following equations: 
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Statistics 
Statistical analyses were performed using SPSS (Statistical Package for the Social Sciences, 
version 19.0). ANOVA and the Tamhane-T test were used for testing possible differences in the 
means of continuous variables between several groups. The differences in continuous variables 
between two independent groups were tested by the Mann-Whitney-U test and those in 
categorical variables by the Chi square test. The correlation analyses were performed by using the 
Spearman-Rho test. All tests used were 2-sided and p values ≤ 0.05 were considered to be 
statistically significant. 
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3. Results   
The study included 152 patients and 89 controls. According to the exclusion criteria, 23 
participants (7 patients, 16 controls) were excluded from the study: 9 had renal failure, 2 had 
advanced liver disease, 2 used vitamin B supplements, one patient used methotrexate, and 9 
controls had co-existing cancers. Since data indicated that the metabolic phenotype showed a 
strong age-dependent variation, as well as an altered hormone status with aging (156-158). For 
instance, elderly men showed higher choline and betaine levels than younger men (159). 
Furthermore, early-onset PCa exhibits important biological differences compared to late-onset 
PCa (160). Therefore, we divided the study population in two groups according to age for 
statistical comparison of variables (young, ≤65years; elderly, >66 years). 
3.1 Young group 
65 patients [median (10
th – 90th percentiles) age = 60.2 (53.0-64.1) years] and 22 controls 
60.5 (53.0-64.6) years were compared. The main characteristics and routine markers for younger 
participants are presented in Table 7. There were no significant differences in routine markers 
according to age between patients and controls. The concentrations of PSA were significantly 
higher in patients with PCa compared to those with BPH (median 8.1 vs. 3.6 ng/mL, p= 0.001) in 
the younger participants. 
   
Table 7: Characteristic and routine markers of the prostate cancer patients and 
controls (age ≤65 years) 
Variable 
Benign prostatic 
hyperplasia 
Prostate cancer p 
Number 22 65 - 
Age, years  60.5 (53.0-64.6) 60.2 (52.6-64.1) 0.359 
GFR, ml/min  76.3 (57.9-106.7) 83.7 (68.9-100.7) 0.061 
Glucose, mg/dl  92 (81-142) 96 (77-116) 0.792 
GOT, U/L  25 (20-38) 25 (18-38) 0.822 
GPT, U/L  26 (19-43) 28 (19-51) 0.497 
gamma GT, U/L  31 (17-69) 32 (17-80) 0.594 
Alk phosphatase, U/L  66 (44-84) 64 (45-77) 0.353 
Hb, g/dl  14.7 (13.7-16.8) 15.1 (13.9-15.9) 0.484 
Hct, %  43 (40-49) 43 (40-46) 0.646 
MCV, fl  89 (81-95) 87 (84-94) 0.301 
CRP, mg/L  1.1 (0.4-8.1) 1.5 (0.4-4.7) 0.615 
PSA, ng/mL  3.6 (0.7-12.0) 8.1 (3.8-34.3) 0.001 
The data are medians (10
th – 90th percentiles). 
p values are according to the Mann-Whitney-U test. 
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Concentrations of plasma and serum choline biomarkers of the young group are presented 
in Table 8. Choline, betaine, and DMG concentrations were lower in PCa patients, but without 
significant differences. Only SAM showed significant difference and was lower in PCa patients 
compared to controls (median 112 vs. 127 nmol/L, p=0.046). 
 
  Table 8: Metabolite concentrations of the prostate cancer patients and controls 
(age ≤65 years) 
Analyte 
Benign prostatic 
hyperplasia 
Prostate cancer p 
Number 22 65 - 
Betaine, µmol/L 40 (29-62) 36 (25-53) 0.074 
Choline, µmol/L 9.6 (6.6-12.7) 8.4 (6.0-11.5) 0.080 
DMG, µmol/L 3.9 (2.4-6.3) 3.1 (2.4-5.4) 0.084 
Choline/betaine ratio 0.24 (0.15-0.34) 0.24 (0.15-0.35) 0.632 
Betaine/DMG ratio 10.2 (7.2-16.3) 10.8 (6.3-16.8) 0.755 
Total folate, nmol/L  16.1 (8.8-27.9) 18.4 (9.3-34.2) 0.099 
MMA, nmol/L 192 (143-566) 194 (124-276) 0.470 
tHcy, µmol/L 15.4 (10.1-19.7) 13.7 (10.8-19.3) 0.476 
Cys, nmol/L 280 (149-1048) 222 (143-481) 0.062 
SAH, nmol/L 16.1 (7.0-27.9) 14.7 (10.4-21.3) 0.770 
SAM, nmol/L 127 (100-168) 112 (91-152) 0.046 
SAM/SAH ratio 7.8 (4.8-15.5) 7.6 (6.2-10.9) 0.482 
The data are medians (10
th – 90th percentiles). 
p values are according to the Mann-Whitney-U test. 
 
Plasma concentrations of phospholipid classes without consideration of statin use are 
summarized in Table 9. Median concentrations of SM 14:0 and 20:0 were significantly higher in 
the young patients compared to controls (10.8 vs. 9.4 µmol/L, p=0.033 and 16.2 vs. 13.6 µmol/L, 
p= 0.004), respectively. 
 
Table 9: Phospholipid classes and species of the prostate cancer patients and 
controls (age ≤65 years, without consideration of statin use) 
Analyte 
Benign prostatic 
hyperplasia 
Prostate cancer p 
Number 22 65 - 
PtdCho, µmol/L    
PtdCho 32:1 12.8 (3.1-29.9) 14.4 (3.5-29.5) 0.615 
PtdCho 34:1 267.3 (211.6-444.1) 282.3 (205.4-381.9) 0.961 
PtdCho 34:2 522.0 (409.3-703.6) 526.2 (415.2-671.5) 0.946 
PtdCho 34:3 11.6 (7.2-22.8) 13.3 (6.7-22.2) 0.703 
PtdCho 36:2 294.3 (235.4-360.6) 289.1 (207.9-361.5) 0.482 
PtdCho 36:3 126.7 (97.7-171.2) 127.0 (97.7-173.7) 0.755 
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Table 9: Phospholipid classes and species of the prostate cancer patients and 
controls (age ≤65 years, without consideration of statin use) 
Analyte 
Benign prostatic 
hyperplasia 
Prostate cancer p 
PtdCho 36:4 175.3 (137.0-244.2) 182.7 (129.2-244.7) 0.755 
PtdCho 36:5 24.5 (13.5-45.4) 24.3 (11.5-43.8) 0.938 
PtdCho 38:3 38.3 (24.7-60.3) 39.5 (23.5-61.1) 0.488 
PtdCho 38:4 126.2 (106.9-197.9) 125.5 (89.0-177.7) 0.682 
PtdCho 38:5 63.3 (42.2-83.0) 60.7 (45.7-86.2) 0.977 
PtdCho 38:6 62.4 (37.6-101.6) 64.2 (42.9-103.8) 0.899 
Sum of PtdCho 1716 (1417-2255) 1789 (1413-2291) 0.899 
Lyso-PtdCho, µmol/L    
Lyso-PtdCho 16:0  88.9 (57.4-125.9) 88.5 (61.4-113.5) 0.876 
Lyso-PtdCho 18:0 24.1 (17.1-34.2) 23.4 (14.7-35.0) 0.807 
Lyso-PtdCho 18:1 20.5 (13.1-28.3) 18.9 (11.4-26.9) 0.565 
Lyso-PtdCho 18:2 20.3 (14.2-36.2) 19.7 (11.1-32.3) 0.407 
Lyso-PtdCho 20:4 5.2 (3.6-7.0) 4.9 (1.5-8.2) 0.612 
Sum of Lyso-PtdCho 160 (111-207) 156 (112-206) 0.625 
PtdEth, µmol/L    
PtdEth 34:1 2.2 (1.0-4.4) 2.1 (0.8-3.8) 0.558 
PtdEth 34:2 1.6 (0.8-2.9) 1.4 (0.6-3.1) 0.283 
PtdEth 36:2 5.5 (2.3-10.2) 4.9 (2.3-8.9) 0.401 
PtdEth 36:3 2.2 (1.0-4.5) 2.4 (0.9-4.6) 0.660 
PtdEth 36:4 2.0 (1.0-4.0) 2.0 (1.1-4.2) 0.977 
PtdEth 38:4 2.8 (1.2-4.7) 2.8 (1.1-5.2) 0.838 
PtdEth 38:5 3.3 (2.0-6.9) 3.5 (1.6-5.8) 0.675 
PtdEth 38:6 2.7 (1.6-5.1) 2.7 (1.3-5.8) 0.876 
PtdEth 40:5 0.7 (0.3-1.8) 1.0 (0.5-2.2) 0.069 
Sum of PtdEth 25.0 (12.7-41.1) 23.6 (11.8-40.8) 0.605 
SM, µmol/L    
SM 14:0 9.4 (5.5-14.1) 10.8 (8.3-16.0) 0.033 
SM 16:0 88.1 (68.8-123.1) 94.5 (69.4-115.4) 0.458 
SM 16:1 12.9 (10.2-17.7) 14.0 (10.9-18.2) 0.056 
SM 18:0 18.5 (13.0-26.2) 20.4 (14.6-28.6) 0.105 
SM 18:1 7.8 (4.6-10.7) 8.1 (5.5-12.0) 0.109 
SM 20:0 13.6 (9.6-21.5) 16.2 (12.1-21.0) 0.004 
SM 22:0 23.8 (16.3-34.1) 26.2 (19.6-34.8) 0.103 
SM 22:1 17.5 (13.0-27.6) 20.7 (15.0-25.7) 0.051 
SM 23:0 10.8 (6.7-14.9) 11.4 (8.3-15.2) 0.105 
SM 23:1 8.6 (6.4-14.6) 10.6 (6.8-13.7) 0.059 
SM 23:2 5.2 (3.4-8.1) 5.0 (3.2-8.0) 0.807 
SM 24:0 18.2 (11.1-24.7) 20.8 (14.0-27.2) 0.133 
SM 24:1 49.6 (35.3-73.0) 52.4 (39.1-73.6) 0.211 
SM 24:2 20.1 (16.2-29.0) 22.3 (16.0-31.1) 0.423 
Sum of SM 302 (239-437) 333 (254-414) 0.072 
The data are medians (10
th – 90th percentiles). 
p values are according to the Mann-Whitney-U test. 
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3.2 Elderly group 
The elderly group consisted of 80 patients [median (10
th – 90th percentiles) age = 70.7 (66.6-
77.8)] years and 51 controls [median (10
th – 90th percentiles) age = 73.9 (66.6-82.1) years]. The 
main characteristics and routine markers are presented in Table 10. Age showed a significant 
difference between patients and controls (p=0.011). The concentrations of PSA showed 
significant differences between patients with PCa and patients with BPH (median 6.4 vs. 3.4 
ng/mL, p<0.001). Concentrations of Hct and MCV were significantly lower in patients compared 
to controls (42 vs. 43% and 88 vs. 90 fl, p= 0.038 and 0.034), respectively. 
 
  Table 10: Characteristic and routine markers of the prostate cancer patients and 
controls (age >65 years) 
Variable 
Benign prostatic 
hyperplasia 
Prostate cancer p 
Number 51 80 - 
Age, years  73.9 (66.6-82.1) 70.7 (66.6-77.8) 0.011 
GFR, ml/min  72.4 (55.2-97.0) 74.2 (55.1-92.9) 0.770 
Glucose, mg/dl  96 (80-156) 100 (80-139) 0.662 
GOT, U/L  24 (17-33) 25 (17-34) 0.522 
GPT, U/L  25 (16-41) 26 (17-39) 0.715 
gamma GT, U/L  34 (18-69) 30 (18-68) 0.545 
Alk phosphatase, U/L  61 (46-93) 62 (42-87) 0.458 
Hb, g/dl  15.0 (13.3-16.0) 14.6 (12.8-16.1) 0.350 
Hct, % 43 (39-47) 42 (37-46) 0.038 
MCV, fl  90 (82-95) 88 (82-92) 0.034 
CRP, mg/L  1.7 (0.4-9.2) 1.2 (0.4-6.8) 0.119 
PSA, ng/ml  3.4 (0.9-8.1) 6.4 (1.3-15.8) <0.001 
The data are medians (10
th – 90th percentiles). 
p values are according to the Mann-Whitney-U test. 
 
Concentrations of plasma and serum biomarkers in the elderly group are presented in Table 
11. Choline, betaine, and DMG concentrations in PCa patients were comparable with those of the 
controls, and did not show significant differences. MMA concentrations were significantly lower 
in PCa patients compared to controls (median 203 vs. 228 nmol/L, p= 0.025). After adjusting for 
age, the difference in MMA between patients and controls became non-significant (p=0.939). 
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Table 11: Metabolite concentrations of the prostate cancer patients and controls 
(age >65 years) 
Analyte 
Benign prostatic 
hyperplasia 
Prostate cancer p
 a
 p
 b
 
Number 51 80 - - 
Betaine, µmol/L 41 (25-60) 40 (26-59) 0.661  
Choline, µmol/L 9.7 (6.9-13.8) 10.0 (6.6-14.8) 0.944  
DMG, µmol/L 3.6 (2.6-6.1) 3.7 (2.5-5.7) 0.895  
Choline/betaine ratio 0.25 (0.16-0.35) 0.25 (0.17-0.36) 0.887  
Betaine/DMG ratio 10.6 (6.8-15.6) 10.7 (7.6-16.7) 0.861  
Total folate, nmol/L 17.4 (10.0-39.2) 19.9 (9.3-35.7) 0.819 0.925 
MMA, nmol/L 228 (171-390) 203 (140-401) 0.025 0.939 
tHcy, µmol/L 16.0 (11.3-25.8) 16.2 (11.4-22.0) 0.730 0.649 
Cys, nmol/L 312 (185-754) 314 (173-927) 0.781 0.634 
SAH, nmol/L 18.8 (10.0-32.4) 18.2 (11.7-29.9) 0.494 0.805 
SAM, nmol/L 137 (105-179) 128 (101-188) 0.174 0.982 
SAM/SAH ratio 7.4 (4.4-12.6) 6.9 (5.1-9.8) 0.681 0.309 
The data are medians (10
th – 90th percentiles).  
a
 p values are according to the Mann-Whitney-U test.  
b
 p values are according to Multivariable analysis, adjusted for age. 
 
Phospholipid concentrations in elderly group without consideration of statin use are 
summarized in Table 12. Contrary to the young group, SM 14:0 did not exhibit a significant 
difference between patients and controls (p=0.182). On the other hand, SM 16:0, 18:0, 18:1, 20:0, 
22:0, 23:0, 23:1, and 24:1 were significantly lower in patients compared to controls. After 
adjusting for age, the differences remained significant for these SM species. In addition, the 
differences in SM 22:1 (p: 0.116→0.034), 24:0 (p: 0.052→0.007), and 24:2 (p: 0.058→0.019) 
between patients and controls became significant after adjusting for age. 
 
Table 12: Phospholipid classes and species of the prostate cancer patients and controls 
(age >65 years, without consideration of statin use)  
Analyte 
Benign prostatic 
hyperplasia 
Prostate cancer p
 a
 p
 b
 
Number 51 80 - - 
PtdCho, µmol/L     
PtdCho 32:1 11.9 (5.4-22.6) 11.7 (2.5-30.6) 0.962  
PtdCho 34:1 248.4 (194.5-334.7) 246.7 (181.2-371.7) 0.674  
PtdCho 34:2 489.3 (377.1-655.2) 489.6 (351.7-636.6) 0.388  
PtdCho 34:3 11.2 (7.2-17.6) 10.6 (5.2-21.0) 0.582  
PtdCho 36:2 264.0 (192.5-340.0) 257.0 (170.6-329.3) 0.902  
PtdCho 36:3 110.4 (84.6-147.6) 115.7 (85.7-152.0) 0.552  
PtdCho 36:4 161.9 (117.1-220.5) 167.9 (131.9-224.4) 0.124  
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Table 12: Phospholipid classes and species of the prostate cancer patients and controls 
(age >65 years, without consideration of statin use)  
Analyte 
Benign prostatic 
hyperplasia 
Prostate cancer p
 a
 p
 b
 
PtdCho 36:5 20.3 (8.7-48.2) 22.7 (8.7-57.0) 0.661  
PtdCho 38:3 34.3 (22.8-54.1) 35.7 (22.0-50.5) 0.947  
PtdCho 38:4 117.4 (77.0-155.4) 118.7 (86.1-160.5) 0.293  
PtdCho 38:5 59.3 (42.5-84.6) 61.3 (42.4-95.9) 0.336  
PtdCho 38:6 68.4 (38.7-103.0) 68.0 (48.1-109.0) 0.872  
Sum of PtdCho 1634 (1294-1981) 1610 (1236-2094) 0.865  
Lyso-PtdCho, µmol/L     
Lyso-PtdCho 16:0  83.7 (52.7-123.0) 75.9 (52.7-107.8) 0.143  
Lyso-PtdCho 18:0 22.0 (14.6-30.7) 19.7 (13.9-28.0) 0.155  
Lyso-PtdCho 18:1 16.8 (10.6-25.7) 17.5 (11.1-25.6) 0.759  
Lyso-PtdCho 18:2 18.0 (10.2-28.6) 17.5 (10.6-29.6) 0.966  
Lyso-PtdCho 20:4 4.7 (2.1-7.4) 4.1 (2.1-6.9) 0.395  
Sum of Lyso-PtdCho 156 (96-205) 138 (93-188) 0.333  
PtdEth, µmol/L     
PtdEth 34:1 1.8 (0.8-4.4) 1.6 (0.6-3.9) 0.247  
PtdEth 34:2 1.5 (0.3-2.5) 1.3 (0.4-2.4) 0.249  
PtdEth 36:2 4.3 (1.7-9.0) 4.0 (2.0-8.3) 0.865  
PtdEth 36:3 2.1 (0.9-3.9) 1.9 (0.7-4.8) 0.614  
PtdEth 36:4 2.0 (0.5-4.2) 1.7 (0.7-3.2) 0.574  
PtdEth 38:4 2.6 (1.2-6.5) 2.3 (1.3-4.6) 0.555  
PtdEth 38:5 3.4 (1.2-7.1) 3.0 (1.3-6.8) 0.234  
PtdEth 38:6 3.4 (1.0-6.7) 2.5 (1.2-6.6) 0.167  
PtdEth 40:5 0.9 (0.2-2.2) 0.9 (0.3-2.3) 0.955  
Sum of PtdEth 21.5 (10.0-47.9) 19.4 (10.2-40.0) 0.350  
SM, µmol/L     
SM 14:0 10.4 (6.8-14.4) 9.4 (6.6-14.8) 0.182 0.676 
SM 16:0 93.5 (71.2-121.0) 83.2 (61.0-103.7) 0.001 <0.001 
SM 16:1 13.8 (9.8-16.5) 12.7 (6.6-16.7) 0.246 0.297 
SM 18:0 21.0 (15.5-26.9) 18.6 (14.1-23.3) 0.002 <0.001 
SM 18:1 8.1 (5.7-11.5) 7.5 (5.0-10.2) 0.040 0.018 
SM 20:0 15.5 (10.4-20.9) 14.2 (9.7-18.5) 0.034 0.008 
SM 22:0 23.6 (17.0-31.4) 21.2 (15.1-28.1) 0.017 0.002 
SM 22:1 19.0 (13.7-24.0) 17.9 (13.0-22.9) 0.116 0.034 
SM 23:0 11.1 (7.0-14.7) 9.3 (6.0-12.7) 0.005 0.001 
SM 23:1 10.5 (7.7-13.0) 8.9 (6.4-11.8) 0.002 0.001 
SM 23:2 4.9 (3.2-7.0) 4.7 (3.1-6.7) 0.970 0.931 
SM 24:0 16.8 (11.2-23.2) 15.2 (10.8-20.1) 0.052 0.007 
SM 24:1 50.9 (37.5-67.2) 46.5 (33.9-61.4) 0.018 0.006 
SM 24:2 21.9 (15.6-29.0) 19.6 (13.5-27.8) 0.058 0.019 
Sum of SM 324 (241-399) 297 (218-361) 0.005 0.001 
The data are medians (10
th – 90th percentiles). 
a
 p values are according to the Mann-Whitney-U test. 
b
 p values are 
according to ANOVA test, adjusted for age. 
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3.3 Comparison of phospholipid and metabolite concentrations between 
controls, low-grade, and high-grad prostate cancer 
To assess the relationship between the pathologic grade and the metabolic biomarker, we 
divided PCa patients for statistical comparisons according to Gleason score into two groups [low-
grade (≤3+4) and high-grade (≥4+3)]. We tested the differences in the metabolite concentrations 
in the young and elderly groups. 
3.3.1 In the young group 
The young group consisted of 62 patients (40 low-grade and 22 high-grade PCa), and 22 
controls. The metabolite concentrations are presented in Tables 13, 14. PSA showed a significant 
difference either between controls and low-grade (mean 5.2 vs. 10.3 ng/mL, p=0.001) or between 
controls and high-grade PCa (mean 5.2 vs. 21.1 ng/mL, p=0.001). There were no significant 
differences associated to statin users distribution between the three groups according to Chi-
square test (p=0.421).  Mean concentrations of SM 14:0 and 20:0 were significantly higher in 
low-grade PCa compared to controls (12.1 vs. 10.0 µmol/L, p=0.035 and 16.6 vs. 14.1 µmol/L, 
p= 0.027), respectively. A similar observation has been shown between patients and controls in 
young group (age ≤ 65 years, without consideration of statin use) (Table 9). 
 
Table 13: Comparison of metabolite concentrations between controls, low-grade, and high-
grad prostate cancer (age ≤65 years)  
Analyte Controls Prostate cancer p
 a
 
  low-grade (≤3+4) high-grad (≥4+3)  
Number 22 40 22 - 
Betaine, µmol/L 43 (13.3) 37 (11.0)  41 (13.6) ns 
Choline, µmol/L 9.4 (2.1) 8.3 (2.0) 8.8 (2.4) ns 
Choline/betaine ratio 0.23 (0.07) 0.24 (0.06) 0.23 (0.07) ns 
Total folate, nmol/L 7.4 (3.5) 9.5 (3.9) 9.9 (6.7) ns 
MMA, nmol/L 252 (183) 205 (137) 207 (56) ns 
tHcy, µmol/L 16.2 (7.9) 14.2 (3.4) 15.5 (6.0) ns 
Cys, nmol/L 434 (413) 318 (490) 309 (177) ns 
SAH, nmol/L 16.6 (8.4) 14.4 (4.1) 15.8 (4.0) ns 
SAM, nmol/L 128 (25.3) 110 (17.3) 
c (p=0.012)
 126 (29.6) ns 
SAM/SAH ratio 9.9 (6.6) 8.2 (2.2) 8.2 (1.9) ns 
PSA, ng/ml 5.2 (4.5) 10.3 (8.2) 
c
 21.1 (25.0) 
c
 0.001 
The data are mean (SD). 
a
 p values are according to ANOVA and Tamhane-T tests unless otherwise specified. 
b
 p 
value is according to chi-square test. 
c
 significant differences with controls. ns, non-significant. 
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Table 14: Comparison of phospholipid classes and species between controls, low-grade, and 
high-grad prostate cancer (age ≤65 years)  
Analyte Controls Prostate cancer p
 a
 
  low-grade (≤3+4) high-grad (≥4+3)  
Number 22 40 22 - 
Statins user n (%) 3 (13.6%) 6 (15%) 5 (22.7%) 0.421 
b
 
PtdCho, µmol/L     
PtdCho 32:1 15.0 (10.6) 15.0 (11.3) 15.9 (6.8) ns 
PtdCho 34:1 285.8 (81.3) 279.5 (73.2) 272.0 (42.6) ns 
PtdCho 34:2 534.7 (94.4) 535.5 (86.9) 506.5 (104.2) ns 
PtdCho 34:3 13.5 (6.3) 13.4 (5.9) 13.1 (4.5) ns 
PtdCho 36:2 298.0 (50.8) 291.2 (48.6) 268.8 (66.0) ns 
PtdCho 36:3 130.0 (27.4) 133.5 (26.2) 122.0 (22.1) ns 
PtdCho 36:4 182.2 (35.4) 185.7 (46.3) 181.8 (41.1) ns 
PtdCho 36:5 26.3 (13.1) 29.0 (18.2) 22.2 (9.2) ns 
PtdCho 38:3 40.1 (12.7) 42.6 (14.2) 38.9 (11.3) ns 
PtdCho 38:4 134.2 (32.1) 131.7 (37.3) 127.0 (32.5) ns 
PtdCho 38:5 64.0 (15.5) 67.3 (19.6) 57.3 (10.8) ns 
PtdCho 38:6 65.8 (20.4) 72.7 (29.9) 61.1 (15.8) ns 
Sum of PtdCho 1790 (297) 1797 (294) 1687 (265) ns 
Lyso-PtdCho, µmol/L     
Lyso-PtdCho 16:0  87.6 (22.1) 89.8 (22.5) 82.5 (16.8) ns 
Lyso-PtdCho 18:0 24.6 (6.7) 24.9 (7.4) 22.4 (6.0) ns 
Lyso-PtdCho 18:1 20.3 (5.9) 20.0 (7.5) 18.4 (6.4) ns 
Lyso-PtdCho 18:2 22.3 (8.1) 21.0 (8.6) 20.8 (10.8) ns 
Lyso-PtdCho 20:4 5.2 (1.3) 4.9 (2.9) 5.5 (2.1) ns 
Sum of Lyso-PtdCho 160 (35.1) 161 (43.1) 150 (36.8) ns 
PtdEth, µmol/L     
PtdEth 34:1 2.5 (1.3) 2.2 (1.3) 2.2 (1.0) ns 
PtdEth 34:2 1.7 (0.8) 1.5 (1.0) 1.4 (0.8) ns 
PtdEth 36:2 5.8 (2.8) 5.4 (2.9) 5.0 (3.7) ns 
PtdEth 36:3 2.5 (1.2) 2.4 (1.5) 2.3 (1.2) ns 
PtdEth 36:4 2.2 (1.0) 2.3 (1.5) 2.2 (1.0) ns 
PtdEth 38:4 2.9 (1.4) 2.9 (1.3) 2.9 (1.5) ns 
PtdEth 38:5 3.8 (1.7) 3.8 (2.2) 3.3 (1.4) ns 
PtdEth 38:6 3.0 (1.4) 3.2 (1.9) 3.0 (1.6) ns 
PtdEth 40:5 1.0 (0.7) 1.2 (0.8) 1.0 (0.5) ns 
Sum of PtdEth 25.5 (9.4) 24.9 (12.4) 23.4 (10.4) ns 
SM, µmol/L     
SM 14:0 10.0 (3.6) 12.1 (3.4) 
c (p=0.09)
 10.4 (2.6) 0.035 
SM 16:0 92.6 (17.0) 95.7 (17.0) 90.5 (19.5) 0.522 
SM 16:1 13.3 (2.5) 14.8 (2.9) 13.4 (2.6) 0.070 
SM 18:0 18.9 (4.7) 20.7 (4.9) 21.0 (5.0) 0.304 
SM 18:1 7.3 (2.1) 8.2 (2.3) 8.3 (2.5) 0.303 
SM 20:0 14.1 (4.2) 16.6 (3.0) 
c (p=0.06)
 15.7 (3.1) 0.027 
SM 22:0 24.5 (6.7) 27.3 (5.4) 25.3 (5.3) 0.155 
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Table 14: Comparison of phospholipid classes and species between controls, low-grade, and 
high-grad prostate cancer (age ≤65 years)  
Analyte Controls Prostate cancer p
 a
 
  low-grade (≤3+4) high-grad (≥4+3)  
SM 22:1 18.8 (4.8) 21.0 (3.5) 19.3 (4.3) 0.086 
SM 23:0 10.5 (2.9) 11.8 (2.5) 10.8 (2.4) 0.103 
SM 23:1 9.5 (3.1) 10.8 (2.3) 9.7 (3.0) 0.115 
SM 23:2 5.3 (1.5) 5.3 (1.8) 5.4 (1.7) 0.954 
SM 24:0 18.6 (5.5) 20.5 (4.8) 19.9 (5.1) 0.387 
SM 24:1 51.0 (12.1) 55.1 (10.5) 51.6 (13.7) 0.354 
SM 24:2 21.6 (4.2) 23.5 (5.2) 20.7 (5.7) 0.101 
Sum of SM 316 (65.3) 343 (55.4) 322 (65.9) 0.186 
The data are mean (SD). 
a
 p values are according to ANOVA and Tamhane-T tests unless otherwise specified. 
b
 p 
value is according to chi-square test. 
c
 significant differences with controls. ns, non-significant. 
 
3.3.2 In the elderly group 
The elderly group consisted of 72 patients (50 low-grade and 22 high-grade PCa) and 51 
controls. PSA was higher in low-grade PCa compared to controls (mean 7.8 vs. 4.4 ng/mL, 
p=0.001). There were no significant differences in the prevalence of statin users between the 
three groups according to Chi-square test (p=0.863).  Mean concentrations of SM 16:0 and 18:0 
were significantly lower either between controls and low-grade or between controls and high-
grade PCa. Whereas, SM 18:1, 22:0, 23:0, and 23:1 were significantly lower in low-grade 
patients compared to the controls (Tables 15, 16). 
 
Table 15: Comparison of metabolite concentrations between controls, low-grade, and high-
grad prostate cancer (age >65 years)  
Analyte Controls Prostate cancer p
 a
 
  low-grade (≤3+4) high-grad (≥4+3)  
Number 51 50 22 - 
Betaine, µmol/L 42 (14.4) 43 (11.9) 
d (p=0.03)
 36 (10.0) ns 
Choline, µmol/L 10.2 (2.6) 10.3 (3.1) 9.8 (2.5) ns 
Choline/betaine ratio 0.26 (0.08) 0.25 (0.07) 0.28 (0.07) ns 
Total folate, nmol/L 9.4 (5.4) 10.5 (5.2) 
d (p=0.034)
 7.6 (3.6) ns 
MMA, nmol/L 258 (93) 247 (154) 232 (114) ns 
tHcy, µmol/L 17.4 (5.5) 16.7 (5.0) 17.3 (5.7) ns 
Cys, nmol/L 418 (302) 396 (330) 412 (265) ns 
SAH, nmol/L 20.9 (9.7) 20.0 (7.3) 18.7 (5.9) ns 
SAM, nmol/L 142 (32.8) 136 (35.3) 135 (36.7) ns 
SAM/SAH ratio 7.7 (2.9) 7.3 (2.0) 7.6 (2.2) ns 
PSA, ng/ml 4.4 (3.9) 7.8 (5.3) 
c 
 9.8 (9.8) 0.001 
The data are mean (SD). 
a
 p values are according to ANOVA and Tamhane-T tests unless otherwise specified. 
b
 p 
value is according to chi-square test. 
c
 significant differences with controls. 
d
 significant differences between low- 
and high-grad. ns, non-significant. 
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Table 16: Comparison of phospholipid classes and species between controls, low-grade, and 
high-grad prostate cancer (age >65 years)  
Analyte Controls Prostate cancer p
 a
 
  low-grade (≤3+4) high-grad (≥4+3)  
Number 51 50 22 - 
Statins user n (%) 15 (29.4%) 20 (40%) 6 (27.3%) 0.863 
b
 
PtdCho, µmol/L     
PtdCho 32:1 12.8 (6.4) 12.1 (9.4) 14.6 (8.8) ns 
PtdCho 34:1 258.2 (54.9) 247.9 (70.4) 262.3 (54.5) ns 
PtdCho 34:2 503.0 (102.9) 475.6 (99.8) 512.4 (80.3) ns 
PtdCho 34:3 11.7 (4.2) 11.0 (5.6) 11.9 (5.4) ns 
PtdCho 36:2 259.9 (56.1) 252.9 (57.8) 266.9 (35.8) ns 
PtdCho 36:3 115.5 (22.5) 113.3 (25.5) 126.8 (21.4) ns 
PtdCho 36:4 162.4 (39.2) 167.9 (37.5) 184.0 (50.1) ns 
PtdCho 36:5 25.5 (18.2) 26.0 (19.4) 28.3 (23.0) ns 
PtdCho 38:3 36.8 (11.3) 33.3 (10.5) 40.7 (10.3) ns 
PtdCho 38:4 116.5 (30.5) 118.5 (30.6) 127.3 (35.4) ns 
PtdCho 38:5 60.5 (16.5) 62.0 (17.1) 64.8 (19.5) ns 
PtdCho 38:6 73.3 (25.7) 69.3 (20.6) 74.7 (26.6) ns 
Sum of PtdCho 1636 (264) 1590 (295) 1715 (264) ns 
Lyso-PtdCho, µmol/L     
Lyso-PtdCho 16:0  85.0 (24.2) 80.6 (21.4) 77.0 (19.8) ns 
Lyso-PtdCho 18:0 22.2 (6.2) 21.2 (5.7) 19.4 (4.3) ns 
Lyso-PtdCho 18:1 17.5 (5.5) 18.6 (5.9) 16.6 (5.1) ns 
Lyso-PtdCho 18:2 18.8 (6.9) 20.3 (6.7) 17.4 (5.9) ns 
Lyso-PtdCho 20:4 4.6 (1.8) 4.6 (1.8) 3.9 (1.9) ns 
Sum of Lyso-PtdCho 148 (40.5) 145 (35.4) 134 (33.7) ns 
PtdEth, µmol/L     
PtdEth 34:1 2.2 (1.4) 1.9 (1.3) 1.7 (1.4) ns 
PtdEth 34:2 1.5 (0.9) 1.5 (0.9) 1.1 (0.8) ns 
PtdEth 36:2 5.0 (3.1) 4.6 (2.3) 4.7 (2.9) ns 
PtdEth 36:3 2.4 (1.4) 2.4 (1.5) 2.0 (1.6) ns 
PtdEth 36:4 2.1 (1.4) 1.9 (0.8) 1.8 (1.5) ns 
PtdEth 38:4 3.0 (1.9) 2.7 (1.1) 2.5 (1.5) ns 
PtdEth 38:5 4.2 (2.8) 3.5 (2.0) 3.3 (2.5) ns 
PtdEth 38:6 3.7 (2.4) 3.1 (1.8) 3.3 (3.3) ns 
PtdEth 40:5 1.1 (0.9) 1.0 (0.6) 1.1 (1.0) ns 
Sum of PtdEth 25.2 (13.5) 22.6 (10.4) 21.5 (14.7) ns 
SM, µmol/L     
SM 14:0 10.5 (2.6) 10.1 (3.6) 10.7 (3.3) 0.681 
SM 16:0 95.0 (17.8) 82.9 (16.4) 
c
 85.6 (13.3) 
c
 0.001 
SM 16:1 13.5 (3.1) 12.5 (2.8) 13.9 (2.8) 0.102 
SM 18:0 21.2 (4.5) 18.6 (3.5) 
c
 18.4 (3.1) 
c
 0.002 
SM 18:1 8.4 (2.3) 7.4 (1.9) 
c
 7.5 (1.9) 0.035 
SM 20:0 15.5 (3.5) 14.2 (3.1) 14.4 (2.7) 0.088 
SM 22:0 23.8 (5.2) 21.4 (4.7) 
c
 22.0 (4.4) 0.045 
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Table 16: Comparison of phospholipid classes and species between controls, low-grade, and 
high-grad prostate cancer (age >65 years)  
Analyte Controls Prostate cancer p
 a
 
  low-grade (≤3+4) high-grad (≥4+3)  
SM 22:1 19.1 (3.8) 17.6 (3.6) 18.4 (3.8) 0.162 
SM 23:0 10.9 (3.0) 9.4 (2.3) 
c
 9.5 (2.6) 0.012 
SM 23:1 10.5 (2.2) 9.3 (2.2) 
c
 9.3 (2.1) 0.012 
SM 23:2 4.9 (1.6) 4.9 (1.7) 5.0 (1.5) 0.985 
SM 24:0 16.9 (4.3) 15.3 (3.6) 16.1 (4.3) 0.117 
SM 24:1 51.0 (10.3) 46.3 (10.2) 46.6 (9.6) 0.052 
SM 24:2 22.1 (4.9) 19.8 (5.3) 21.0 (4.9) 0.092 
Sum of SM 322 (57.5) 290 (52.4) 
c
 298 (50.4) 0.008 
The data are mean (SD). 
a
 p values are according to ANOVA and Tamhane-T tests unless otherwise specified. 
b
 p 
value is according to chi-square test. 
c
 significant differences with controls. 
 
3.4 Choline metabolites and SM species according to age 
SM concentrations increased with age in controls. These age changes were reversed in 
patients group, therefore, we tested the differences of metabolite concentrations in controls and 
patients groups according to age. 
3.4.1 In the controls 
This group consisted of 22 young and 51 elderly participants (median age 60.5 vs. 73.9, 
p<0.001). The main characteristics and metabolites values are presented in Table 17. No 
significant difference of PSA levels between young and elderly were observed. MMA was 
significantly lower in elderly compared to young group (median 171 vs. 192 nmol/L, p=0.025). 
 
 Table 17: Metabolite concentrations in the controls according to age 
Analyte age ≤65 years age >65 years p 
Number 22 51 - 
Age, years 60.5 (53.0-64.6) 73.9 (66.6-82.1) <0.001 
Betaine, µmol/L 40 (29-61) 41 (25-60) 0.857 
Choline, µmol/L 9.6 (6.6-12.8) 9.7 (6.9-13.8) 0.342 
DMG, µmol/L 3.9 (2.4-6.3) 3.6 (2.8-6.1) 0.639 
Choline/betaine ratio 0.24 (0.15-0.34) 0.25 (0.16-0.35) 0.279 
Betaine/DMG ratio 10.2 (7.2-16.3) 10.6 (6.8-15.6) 0.971 
Total folate, nmol/L  17.2 (10.0-33.3) 16.3 (7.9-62.1) 0.107 
MMA, nmol/L 192 (143-566) 171 (228-390) 0.025 
tHcy, µmol/L 15.4 (10.1-19.7) 16.0 (11.3-25.8) 0.186 
Cys, nmol/L 280 (149-1048) 312 (185-754) 0.501 
SAH, nmol/L 16.1 (7.0-27.9) 18.8 (10.0-32.4) 0.075 
SAM, nmol/L 127 (100-168) 137 (105-179) 0.092 
SAM/SAH ratio 7.8 (4.8-15.5) 7.4 (4.4-12.6) 0.186 
PSA, ng/ml  3.6 (0.7-12.0) 3.4 (0.9-8.1) 0.696 
The data are medians (10
th – 90th percentiles). p values are according to the Mann-Whitney-U test.  
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There were no significant differences associated to statin users distribution between the 
controls according to Chi-square test (p=0.237). Although most SM species were higher in 
elderly group, only SM 23:1 showed a significant difference compared to the young group 
(median 10.5 vs. 8.6 µmol/L, p=0.046) (Table 18). 
 
Table 18: SM species in the controls according to age 
Analyte age ≤65 years age >65 years p a 
Statins user n (%) 3 (13.6%) 15 (29.4%) 0.237 
b
 
SM, µmol/L    
SM 14:0 9.4 (5.5-14.1) 10.4 (6.8-14.4) 0.414 
SM 16:0 88.1 (68.8-123.1) 93.5 (71.2-130.0) 0.486 
SM 16:1 12.9 (10.2-17.7) 13.8 (9.8-16.5) 0.631 
SM 18:0 18.5 (13.0-26.2) 21.0 (15.5-26.9) 0.068 
SM 18:1 7.8 (4.6-10.7) 8.1 (5.7-11.5) 0.086 
SM 20:0 13.8 (9.6-21.5) 15.5 (10.4-20.9) 0.068 
SM 22:0 23.8 (16.3-34.1) 23.6 (17.0-31.4) 0.773 
SM 22:1 17.5 (13.0-27.6) 19.0 (13.7-24.0) 0.580 
SM 23:0 10.8 (6.7-14.9) 11.1 (7.0-14.7) 0.456 
SM 23:1 8.6 (6.4-14.6) 10.5 (7.7-13.0) 0.046 
SM 23:2 5.2 (3.4-8.1) 4.9 (3.2-7.0) 0.414 
SM 24:0 18.2 (11.1-24.7) 16.8 (11.2-23.2) 0.248 
SM 24:1 49.6 (35.3-73.0) 50.9 (37.5-67.2) 0.847 
SM 24:2 20.1 (16.2-29.0) 21.9 (15.6-29.0) 0.674 
Sum of SM 302 (239-437) 324 (241-399) 0.449 
The data are medians (10
th – 90th percentiles). 
a
 p values are according to the Mann-Whitney-U test 
unless otherwise specified. 
b
 p value is according to chi-square test. 
 
3.4.2 In the patients 
The PCa group contained 65 young and 80 elderly patients (median age 60.2 vs. 70.7, 
p<0.001). The main characteristics and metabolites concentrations are presented in Table 19. 
Choline was significantly higher in elderly group compared to young group (median 10.0 vs. 8.4 
µmol/L, p=0.001). In addition, tHcy, Cys, SAH, and SAM showed significant differences and 
were higher in elderly group compared to young group (Table 19).  
There were no significant differences in the prevalence of statin users between the groups 
according to Chi-square test (p=0.010). In contrary to the observation in the controls, all SM 
species, except SM 23:2 were significantly lower in elderly group compared to young group 
(Table 20). After adjusting for statin use the differences in SM concentrations between the young 
and elderly patients became non-significant. 
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Table 19: Metabolite concentrations in patients according to age 
Analyte age ≤65 years age >65 years p 
Number 65 80 - 
Age, years 60.2 (52.6-64.1) 70.7 (66.6-77.8) <0.001 
Betaine, µmol/L 36 (25-53) 40 (26-59) 0.129 
Choline, µmol/L 8.4 (6.0-11.5) 10.0 (6.6-14.8) 0.001 
DMG, µmol/L 3.1 (2.4-5.4) 3.7 (2.5-5.7) 0.052 
Choline/betaine ratio 0.24 (0.15-0.35) 0.25 (0.17-0.36) 0.191 
Betaine/DMG ratio 10.8 (6.3-16.8) 10.7 (7.6-16.7) 0.735 
Total folate, nmol/L  18.3 (9.3-34.1) 19.8 (9.3-35.7) 0.982 
MMA, nmol/L 194 (124-276) 203 (140-401) 0.070 
tHcy, µmol/L 13.7 (10.8-19.3) 16.2 (11.4-22.0) 0.004 
Cys, nmol/L 221 (143-481) 314 (173-926) <0.001 
SAH, nmol/L 14.7 (10.4-21.3) 18.2 (11.7-29.9) <0.001 
SAM, nmol/L 112 (91-152) 128 (101-188) <0.001 
SAM/SAH ratio 7.6 (6.2-10.9) 6.9 (5.1-9.8) 0.014 
PSA, ng/ml  8.1 (3.8-34.3) 6.4 (1.3-15.8) 0.029 
The data are medians (10
th – 90th percentiles). 
p values are according to the Mann-Whitney-U test.  
 
 
Table 20: SM species in the patients according to age 
Analyte age ≤65 years age >65 years p a p c 
Statins user n (%) 11 (16.9%) 29 (36.3%) 0.010 
b
  
SM, µmol/L     
SM 14:0 10.8 (8.3-16.0) 9.4 (6.6-14.8) 0.001 0.324 
SM 16:0 94.5 (69.4-115.4) 83.2 (61.0-103.7) <0.001 0.713 
SM 16:1 14.0 (10.9-18.2) 12.7 (9.6-16.7) 0.002 0.891 
SM 18:0 20.4 (14.6-28.6) 18.6 (14.1-23.3) 0.007 0.344 
SM 18:1 8.1 (5.5-12.0) 7.5 (5.0-10.2) 0.043 0.636 
SM 20:0 16.2 (12.1-21.0) 14.2 (9.7-18.5) <0.001 0.563 
SM 22:0 26.2 (19.6-34.8) 21.2 (15.1-28.1) <0.001 0.591 
SM 22:1 20.7 (15.0-25.7) 17.9 (13.0-22.9) <0.001 0.937 
SM 23:0 11.4 (8.3-15.2) 9.3 (6.0-12.7) <0.001 0.750 
SM 23:1 10.6 (6.8-13.7) 8.9 (6.4-11.8) 0.002 0.622 
SM 23:2 5.0 (3.2-8.0) 4.7 (3.1-6.7) 0.083 0.756 
SM 24:0 20.8 (14.0-27.2) 15.2 (10.8-20.1) <0.001 0.306 
SM 24:1 52.4 (39.1-73.6) 46.5 (33.9-61.4) <0.001 0.514 
SM 24:2 22.3 (16.0-31.1) 19.6 (13.5-27.8) 0.013 0.366 
Sum of SM 333 (254-414) 297 (218-361) <0.001 0.604 
The data are medians (10
th – 90th percentiles). 
a
 p values are according to the Mann-Whitney-U test unless otherwise 
specified. 
b
 p value is according to chi-square test. 
c
 p values adjusted for statin use. 
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3.4.3 In the patients with low- and high-grad PCa 
Since several SM species showed significant differences between controls and patients 
according to Gleason score, especially in low-grad PCa group, we tested the differences of 
metabolite concentrations in high- and low-grad PCa groups according to age. 
3.4.3.1 In the patients with low-grad PCa 
The low-grad PCa group consisted of 38 young and 49 elderly participants (median age 
59.5 vs. 69.9, p<0.001). The main characteristics and metabolites concentrations are presented in 
Table 21. Choline, betaine, and DMG were significantly higher in elderly compared to young 
participants. In addition, MMA, tHcy, Cys, SAH, and SAM were also significantly higher in 
older participants. 
 
 Table 21: Metabolite concentrations in low-grad PCa according to age 
Analyte age ≤65 years age >65 years p 
Number 38 49 - 
Age, years 59.5 (49.8-64.0) 69.9 (66.3-75.4) <0.001 
Betaine, µmol/L 33 (23-50) 41 (29-61) 0.022 
Choline, µmol/L 8.3 (5.7-10.6) 10.1 (6.5-15.1) 0.004 
DMG, µmol/L 3.0 (2.2-4.3) 3.9 (2.7-5.7) 0.001 
Choline/betaine ratio 0.24 (0.15-0.32) 0.23 (0.17-0.36) 0.620 
Betaine/DMG ratio 11.5 (7.7-17.0) 10.7 (7.6-18.0) 0.350 
Total folate, nmol/L  21.3 (9.9-33.6) 22.0 (11.1-38.7) 0.506 
MMA, nmol/L 177 (119-267) 209 (133-390) 0.019 
tHcy, µmol/L 13.3 (11.0-18.0) 16.1 (11.4-23.6) 0.006 
Cys, nmol/L 201 (134-352) 309 (173-723) <0.001 
SAH, nmol/L 14.1 (9.2-16.9) 17.7 (11.7-30.7) <0.001 
SAM, nmol/L 108 (87-132) 129 (101-191) <0.001 
SAM/SAH ratio 7.6 (6.4-11.4) 6.9 (4.8-9.8) 0.047 
PSA, ng/ml  8.1 (4.3-21.1) 7.0 (1.5-15.5) 0.208 
The data are medians (10
th – 90th percentiles). 
p values are according to the Mann-Whitney-U test.  
 
The prevalence of statin users was higher in the elderly group compared with the young 
group. Similar to the observation of SM concentrations in the patients according to age, all SM 
species, except SM 18:0, 18:1; and 23:2 were significantly lower in the elderly group compared 
to the young group (Table 22). After adjusting for statin use the differences of SM concentrations 
between the two groups became non-significant, except SM 24:0 (p=0.049). In addition, the 
difference related to SM 18:0 became significant (p=0.031).  
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Table 22: SM species in low-grad PCa according to age 
Analyte age ≤65 years age >65 years p a p c 
Statins user n (%) 6 (15.8%) 20 (40.8%) 0.011 
b
  
SM, µmol/L     
SM 14:0 11.8 (8.3-16.2) 9.4 (6.5-14.3) 0.002 0.404 
SM 16:0 94.5 (70.4-113.8) 82.2 (58.1-109.1) 0.001 0.182 
SM 16:1 14.1 (11.0-17.9) 12.6 (9.2-15.9) <0.001 0.616 
SM 18:0 19.8 (15.1-28.4) 18.5 (13.9-22.9) 0.075 0.031 
SM 18:1 8.1 (5.6-11.7) 7.4 (4.8-10.0) 0.142 0.084 
SM 20:0 16.7 (12.6-21.4) 14.3 (9.7-18.5) 0.001 0.179 
SM 22:0 26.5 (19.3-34.8) 21.2 (15.0-27.6) <0.001 0.189 
SM 22:1 20.6 (16.6-25.2) 18.1 (12.4-22.0) <0.001 0.276 
SM 23:0 11.5 (8.6-15.5) 9.6 (6.0-12.7) <0.001 0.264 
SM 23:1 10.8 (8.1-13.4) 9.2 (6.1-11.8) 0.003 0.396 
SM 23:2 5.0 (3.1-7.4) 4.6 (3.1-7.0) 0.239 0.370 
SM 24:0 20.9 (13.4-26.1) 15.1 (11.0-20.0) <0.001 0.049 
SM 24:1 52.4 (43.1-69.6) 46.5 (33.3-61.6) <0.001 0.077 
SM 24:2 22.7 (16.9-31.1) 19.5 (13.5-27.2) 0.002 0.067 
Sum of SM 337 (259-418) 297 (210-359) <0.001 0.091 
The data are medians (10
th – 90th percentiles). 
a
 p values are according to the Mann-Whitney-U test unless otherwise 
specified. 
b
 p value is according to chi-square test. 
c
 p values adjusted for statin use. 
 
3.4.3.2 In the patients with high-grad PCa 
The high-grad PCa group consisted of 21 young 19 elderly participants (median age 60.3 
vs. 72.3, p<0.001). The main characteristics and metabolites values are presented in Table 23. No 
significant differences in metabolite concentrations between young and elderly were observed. 
  
 Table 23: Metabolite concentrations in high-grad PCa according to age 
Analyte age ≤65 years age >65 years p 
Number 21 19 - 
Age, years 60.3 (54.3-64.2) 72.3 (66.6-77.8) <0.001 
Betaine, µmol/L 38 (26-65) 32 (23-52) 0.173 
Choline, µmol/L 8.1 (6.9-13.6) 9.9 (7.2-10.9) 0.074 
DMG, µmol/L 3.6 (2.7-6.9) 3.2 (2.3-6.4) 0.222 
Choline/betaine ratio 0.24 (0.12-0.31) 0.27 (0.23-0.41) 0.037 
Betaine/DMG ratio 10.6 (5.6-17.1) 10.4 (4.9-13.7) 0.814 
Total folate, nmol/L  18.3 (9.3-37.7) 14.7 (9.3-30.1) 0.238 
MMA, nmol/L 229 (134-290) 186 (141-431) 0.944 
tHcy, µmol/L 14.6 (9.3-20.9) 16.5 (11.4-21.5) 0.133 
Cys, nmol/L 223 (140-670) 316 (149-937) 0.139 
SAH, nmol/L 14.7 (10.8-21.0) 17.5 (11.2-24.5) 0.060 
SAM, nmol/L 116 (91-173) 121 (106-164) 0.336 
SAM/SAH ratio 8.8 (5.8-10.9) 7.2 (5.0-11.3) 0.213 
PSA, ng/ml  11.6 (4.6-41.4) 6.8 (1.2-26.0) 0.062 
The data are medians (10
th – 90th percentiles). p values are according to the Mann-Whitney-U test.  
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The prevalence of statin users was not significantly different according to age in the group 
of high-grad PCa patients. Only SM 22:0 and 24:0 were significantly lower in elderly group 
compared to young group (Table 24). 
Table 24: SM species in high-grad PCa according to age  
Analyte age ≤65 years age >65 years p a 
Statins user n (%) 5 (23.8%) 6 (31.6%) 0.731 
b
 
SM, µmol/L    
SM 14:0 10.0 (6.0-13.8) 9.6 (7.5-15.5) 0.707 
SM 16:0 91.4 (64.2-117.6) 88.0 (61.7-102.0) 0.398 
SM 16:1 13.5 (9.7-17.9) 12.9 (10.2-18.3) 0.814 
SM 18:0 20.8 (13.1-27.2) 19.0 (13.8-22.1) 0.064 
SM 18:1 8.2 (4.6-11.9) 7.6 (5.0-10.3) 0.302 
SM 20:0 15.1 (10.8-20.6) 14.6 (11.4-18.5) 0.189 
SM 22:0 25.5 (16.7-32.5) 21.8 (14.9-29.1) 0.033 
SM 22:1 18.7 (13.8-26.8) 19.1 (13.6-23.1) 0.639 
SM 23:0 10.6 (7.3-14.3) 9.8 (6.1-12.6) 0.133 
SM 23:1 9.5 (6.1-15.1) 10.0 (6.4-11.7) 0.869 
SM 23:2 4.8 (4.1-8.5) 5.3 (2.5-6.8) 0.725 
SM 24:0 18.7 (13.9-27.2) 16.9 (10.6-24.0) 0.039 
SM 24:1 50.7 (34.3-75.4) 49.2 (31.7-59.5) 0.302 
SM 24:2 20.6 (13.4-31.0) 22.1 (12.7-28.2) 0.725 
Sum of SM 320 (235-409) 304 (214-357) 0.302 
The data are medians (10
th – 90th percentiles). 
a
 p values are according to the Mann-Whitney-U test 
unless otherwise specified. 
b
 p value is according to chi-square test. 
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3.5 Choline metabolites and phospholipid classes according to statin use 
Since we found significant difference for SM species, especially in the elderly group, we 
examined the association of statin use in controls and patients groups. 
3.5.1 In the controls 
This group consisted of 18 statin users and 55 non-statin users (median age 71.8 vs. 69.5, 
p=0.219). The main characteristics and metabolites concentrations are presented in Table 25. No 
significant differences between statin users and non-statin users were observed. 
  
 Table 25: Metabolite concentrations in the controls according to statin use 
Analyte non-statin users statin users p 
Number 55 18 - 
Age, years 69.5 (56.0-80.5) 71.8 (63.2-82.8) 0.219 
Betaine, µmol/L 40 (27-57) 41 (25-65) 0.556 
Choline, µmol/L 9.7 (6.8-12.9) 9.9 (6.5-14.1) 0.556 
DMG, µmol/L 3.6 (2.6-5.7) 4.4 (2.6-7.7) 0.481 
Choline/betaine ratio 0.25 (0.16-0.35) 0.23 (0.15-0.38) 0.980 
Betaine/DMG ratio 10.6 (7.0-16.7) 9.9 (6.2-14.8) 0.711 
Total folate, nmol/L  17.2 (10.0-33.3) 16.3 (7.9-62.1) 0.673 
MMA, nmol/L 215 (164-355) 218 (140-509) 0.908 
tHcy, µmol/L 15.6 (10.9-24.4) 16.1 (11.1-37.4) 0.609 
Cys, nmol/L 286 (164-908) 323 (180-749) 0.682 
SAH, nmol/L 17.7 (8.6-27.4) 20.9 (9.7-49.1) 0.058 
SAM, nmol/L 132 (103-177) 136 (103-201) 0.450 
SAM/SAH ratio 7.8 (4.8-13.4) 6.7 (3.6-12.0) 0.073 
The data are medians (10
th – 90th percentiles). 
p values are according to the Mann-Whitney-U test.  
 
 On the other hand, statin users had lower concentrations of all SM species compared to 
non-statin users. These decreases were significant except for SM 14:0, 18:0, 18:1, and 20:0 
(Table 26).  
 
Table 26: Phospholipid classes in the controls according to statin use 
Analyte non-statin users statin users p 
Number 55 18 - 
PtdCho, µmol/L    
PtdCho 32:1 12.3 (5.7-22.9) 11.8 (2.9-24.5) 0.514 
PtdCho 34:1 259.4 (213.1-357.0) 241.0 (149.4-365.0) 0.318 
PtdCho 34:2 530.4 (407.7-662.1) 461.8 (322.8-563.6) 0.002 
PtdCho 34:3 11.5 (8.3-20.0) 9.9 (2.4-18.2) 0.131 
PtdCho 36:2 291.3 (206.4-353.4) 225.5 (167.1-288.2) <0.001 
PtdCho 36:3 118.5 (98.4-158.2) 103.6 (77.0-137.6) 0.001 
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Table 26: Phospholipid classes in the controls according to statin use 
Analyte non-statin users statin users p 
PtdCho 36:4 169.1 (124.2-238.1) 163.0 (94.2-238.5) 0.155 
PtdCho 36:5 20.2 (9.7-48.6) 23.7 (6.4-45.4) 0.898 
PtdCho 38:3 38.5 (24.2-59.2) 31.8 (21.8-41.1) 0.008 
PtdCho 38:4 121.1 (88.9-185.6) 117.5 (68.0-140.5) 0.060 
PtdCho 38:5 61.4 (43.8-84.4) 57.8 (35.0-81.4) 0.163 
PtdCho 38:6 68.4 (41.6-104.2) 63.1 (33.0-97.2) 0.420 
Sum of PtdCho 1704 (1430-2146) 1513 (1043-1792) 0.002 
Lyso-PtdCho, µmol/L    
Lyso-PtdCho 16:0  92.6 (58.6-113.9) 77.0 (38.3-129.5) 0.163 
Lyso-PtdCho 18:0 23.4 (16.8-32.6) 18.2 (11.0-29.8) 0.007 
Lyso-PtdCho 18:1 17.9 (11.6-25.2) 15.6 (8.3-27.8) 0.344 
Lyso-PtdCho 18:2 19.0 (13.8-30.9) 16.5 (7.8-28.6) 0.094 
Lyso-PtdCho 20:4 4.8 (3.0-6.9) 4.0 (1.1-7.6) 0.219 
Sum of Lyso-PtdCho 160 (106-206) 133 (72-223) 0.082 
PtdEth, µmol/L    
PtdEth 34:1 2.0 (0.9-4.1) 2.1 (0.6-6.3) 0.427 
PtdEth 34:2 1.5 (0.5-2.6) 1.7 (0.4-2.6) 0.654 
PtdEth 36:2 4.4 (2.0-9.2) 4.8 (1.9-10.8) 0.959 
PtdEth 36:3 2.1 (0.9-3.8) 2.4 (1.2-6.5) 0.300 
PtdEth 36:4 2.0 (0.7-3.8) 2.1 (0.6-4.2) 0.489 
PtdEth 38:4 2.6 (1.1-5.1) 2.7 (1.5-7.2) 0.898 
PtdEth 38:5 3.3 (1.3-6.4) 4.3 (1.5-12.0) 0.331 
PtdEth 38:6 3.1 (1.1-6.2) 3.4 (1.5-9.7) 0.489 
PtdEth 40:5 0.7 (0.2-2.1) 1.3 (0.2-2.9) 0.063 
Sum of PtdEth 23.9 (10.5-40.6) 23.0 (10.3-57.5) 0.591 
SM, µmol/L    
SM 14:0 10.4 (7.0-14.4) 9.3 (6.4-13.6) 0.073 
SM 16:0 94.5 (83.4-123.3) 79.6 (62.6-115.4) <0.001 
SM 16:1 13.5 (11.1-17.5) 11.2 (6.8-16.2) 0.006 
SM 18:0 21.0 (15.0-26.0) 19.2 (15.2-29.7) 0.565 
SM 18:1 8.1 (5.2-10.9) 7.3 (5.5-12.5) 0.692 
SM 20:0 15.0 (10.5-21.1) 13.2 (9.7-19.6) 0.138 
SM 22:0 24.9 (16.9-32.8) 19.8 (13.8-24.9) 0.001 
SM 22:1 19.4 (14.9-25.5) 16.8 (12.8-22.6) 0.010 
SM 23:0 11.6 (7.6-15.4) 8.5 (6.4-13.4) 0.014 
SM 23:1 10.5 (7.3-14.4) 8.5 (6.5-12.7) 0.043 
SM 23:2 5.2 (3.4-7.1) 3.8 (2.2-7.1) 0.030 
SM 24:0 18.5 (13.1-24.0) 12.7 (9.8-20.6) <0.001 
SM 24:1 52.3 (38.3-71.3) 43.6 (34.6-55.8) 0.002 
SM 24:2 22.9 (17.8-29.4) 19.0 (13.4-23.5) 0.002 
Sum of SM 334 (255-411) 271 (230-364) 0.001 
The data are medians (10
th – 90th percentiles). 
p values are according to the Mann-Whitney-U test.  
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3.5.2 In the patients 
The PCa group contained 40 statin users and 105 non-statin users (median age 68.6 vs. 
64.3, p=0.047). The main characteristics and metabolites concentrations are presented in Table 
27. In addition to age, MMA, Cys, SAH, and SAM showed significant differences and were 
higher in the statin users group compared to non-statin users.  
 
Table 27: Metabolite concentrations in the prostate cancer patients  
according to statin use 
Analyte non-statin users statin users p 
Number 105 40 - 
Age, years 64.3 (54.9-76.2) 68.6 (58.3-75.3) 0.047 
Betaine, µmol/L 35 (25-57) 41 (30-61) 0.029 
Choline, µmol/L 8.6 (6.1-13.0) 9.8 (6.9-14.3) 0.105 
DMG, µmol/L 3.2 (2.4-5.3) 3.8 (2.6-6.1) 0.026 
Choline/betaine ratio 0.24 (0.17-0.36) 0.24 (0.17-0.33) 0.757 
Betaine/DMG ratio 10.7 (7.5-16.7) 10.9 (6.7-17.5) 0.958 
Total folate, nmol/L  18.4 (9.3-32.9) 23.6 (10.4-40.8) 0.110 
MMA, nmol/L 195 (124-296) 211 (142-427) 0.043 
tHcy, µmol/L 14.9 (11.3-20.6) 15.9 (11.1-22.0) 0.335 
Cys, nmol/L 242 (150-673) 339 (182-916) 0.035 
SAH, nmol/L 15.6 (10.8-24.5) 18.2 (13.8-28.8) 0.002 
SAM, nmol/L 116 (97-160) 133 (104-177) 0.005 
SAM/SAH ratio 7.3 (5.3-10.7) 6.8 (5.5-9.8) 0.158 
The data are medians (10
th – 90th percentiles). 
p values are according to the Mann-Whitney-U test. 
 
In comparison with SM species in controls groups, all SM species were significantly lower 
in statin users group, with one exception for SM 18:0 (Table 28). 
 
Table 28: Phospholipid classes in the prostate cancer patients  
according to statin use 
Analyte non-statin users statin users p 
Number 105 40 - 
PtdCho, µmol/L    
PtdCho 32:1 13.5 (3.2-29.5) 11.8 (3.4-33.1) 0.782 
PtdCho 34:1 262.0 (199.8-373.9) 246.8 (143.1-372.0) 0.110 
PtdCho 34:2 526.3 (421.1-655.3) 423.0 (304.7-601.2) <0.001 
PtdCho 34:3 12.6 (5.8-21.3) 10.7 (6.1-17.1) 0.039 
PtdCho 36:2 281.6 (220.3-356.1) 235.7 (149.2-316.9) <0.001 
PtdCho 36:3 125.5 (96.2-168.8) 113.6 (77.5-159.6) 0.010 
PtdCho 36:4 175.4 (129.2-225.1) 184.1 (141.2-276.4) 0.033 
PtdCho 36:5 24.3 (9.3-51.8) 22.9 (9.7-47.8) 0.611 
Results  
 64 
Table 28: Phospholipid classes in the prostate cancer patients  
according to statin use 
Analyte non-statin users statin users p 
PtdCho 38:3 37.6 (24.0-58.4) 37.5 (20.6-53.6) 0.071 
PtdCho 38:4 116.0 (85.9-168.3) 132.9 (92.1-203.4) 0.024 
PtdCho 38:5 60.7 (44.4-94.9) 64.3 (42.0-93.9) 0.898 
PtdCho 38:6 67.4 (43.1+113.2) 62.5 (49.1-87.9) 0.222 
Sum of PtdCho 1735 (1378-2186) 1582 (1160-2090) 0.012 
Lyso-PtdCho, µmol/L    
Lyso-PtdCho 16:0  84.8 (60.2-109.3) 72.4 (52.7-121.7) 0.004 
Lyso-PtdCho 18:0 22.6 (14.6-30.0) 19.6 (13.0-30.0) 0.028 
Lyso-PtdCho 18:1 18.4 (11.2-25.8) 17.1 (10.8-26.5) 0.374 
Lyso-PtdCho 18:2 19.0 (11.5-30.3) 17.8 (10.1-29.6) 0.476 
Lyso-PtdCho 20:4 4.2 (1.6-6.9) 5.4 (2.5-8.2) 0.018 
Sum of Lyso-PtdCho 149 (106-200) 129 (91-201) 0.032 
PtdEth, µmol/L    
PtdEth 34:1 1.8 (0.7-3.5) 2.0 (0.8-5.1) 0.386 
PtdEth 34:2 1.4 (0.5-3.1) 1.3 (0.6-2.7) 0.901 
PtdEth 36:2 4.8 (2.1-9.2) 4.2 (2.2-7.7) 0.465 
PtdEth 36:3 2.0 (0.8-4.6) 2.4 (1.1-4.8) 0.408 
PtdEth 36:4 1.8 (0.8-3.7) 1.9 (1.0-3.4) 0.195 
PtdEth 38:4 2.4 (1.1-4.9) 3.2 (2.0-4.3) 0.004 
PtdEth 38:5 3.0 (1.5-6.1) 3.7 (1.8-7.1) 0.040 
PtdEth 38:6 2.6 (1.2-5.7) 2.9 (1.5-6.7) 0.157 
PtdEth 40:5 1.0 (0.3-2.2) 1.0 (0.4-2.2) 0.204 
Sum of PtdEth 21.2 (10.1-40.3) 23.2 (14.0-41.6) 0.263 
SM, µmol/L    
SM 14:0 10.6 (8.0-16.3) 8.6 (5.1-13.4) <0.001 
SM 16:0 93.5 (74.7-112.1) 72.5 (57.9-95.8) <0.001 
SM 16:1 13.9 (11.1-18.3) 11.5 (8.3-15.6) <0.001 
SM 18:0 19.9 (15.0-26.7) 17.8 (13.4-24.9) 0.004 
SM 18:1 7.9 (5.5-11.1) 7.4 (4.6-10.6) 0.180 
SM 20:0 15.7 (11.7-19.7) 13.8 (9.6-18.6) 0.002 
SM 22:0 24.9 (18.9-32.9) 19.6 (14.0-27.0) <0.001 
SM 22:1 20.1 (14.8-25.0) 16.1 (12.4-22.9) <0.001 
SM 23:0 10.9 (8.2-14.3) 8.1 (5.7-12.4) <0.001 
SM 23:1 10.4 (7.5-13.1) 7.7 (5.4-12.0) <0.001 
SM 23:2 5.1 (3.4-7.6) 4.5 (2.6-6.5) 0.013 
SM 24:0 17.8 (13.2-25.9) 13.8 (10.3-20.8) <0.001 
SM 24:1 52.3 (40.7-68.7) 40.2 (29.2-54.0) <0.001 
SM 24:2 22.3 (16.4-29.5) 16.8 (12.6-25.4) <0.001 
Sum of SM 332 (266-403) 254 (198-333) <0.001 
The data are medians (10
th – 90th percentiles). 
p values are according to the Mann-Whitney-U test. 
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3.5.3 The interactions of disease and statin use on SM species in the elderly group 
Our results showed that statin use has similar lowering effect on SM species concentrations 
either between controls or patients. In addition, a similar observation was obtained in PCa 
patients in elderly group. Thereby, we tested for interactions between statin use and PCa disease 
in elderly group. 
The non- user’s elderly group consisted of 51 patients and 36 controls. SM species 16:0, 
18:0, 23:0, and 23:1were significantly lower in patients compared to controls. However, there is 
tendency that PCa patients have lowers concentrations of the other SM species compared to 
controls (Table 29). 
 
Table 29: Sphingomyelin species in the non-statin users in the prostate cancer 
patients and controls (age >65 years) 
Analyte 
Benign prostatic 
hyperplasia 
Prostate cancer p 
Number 36 51 - 
SM, µmol/L    
SM 14:0 10.4 (7.2-14.7) 9.7 (7.2-16.8) 0.343 
SM 16:0 96.8 (76.6-123.0) 91.4 (67.4-109.1) 0.014 
SM 16:1 14.7 (10.5-17.5) 13.2 (9.6-18.2) 0.569 
SM 18:0 21.5 (14.4-25.5) 19.7 (14.2-24.1) 0.040 
SM 18:1 8.2 (5.3-11.0) 7.6 (4.6-10.2) 0.205 
SM 20:0 15.6 (10.1-21.1) 14.4 (10.4-18.5) 0.168 
SM 22:0 24.9 (16.6-32.1) 22.7 (16.2-28.9) 0.069 
SM 22:1 20.1 (13.7-24.4) 19.1 (12.6-23.1) 0.326 
SM 23:0 11.8 (6.7-15.7) 9.9 (6.3-12.8) 0.039 
SM 23:1 10.9 (7.4-13.6) 10.1 (6.8-11.7) 0.017 
SM 23:2 5.2 (2.0-7.0) 5.2 (2.3-7.0) 0.952 
SM 24:0 18.2 (11.4-23.9) 17.0 (10.4-22.8) 0.138 
SM 24:1 53.6 (36.9-71.2) 49.3 (35.6-62.3) 0.155 
SM 24:2 23.2 (15.8-29.4) 22.0 (13.5-28.4) 0.322 
Sum of SM 337 (253-410) 311 (227-374) 0.059 
The data are medians (10
th – 90th percentiles). 
p values are according to the Mann-Whitney-U test. 
 
The stain user’s elderly group consisted of 29 patients and 15 controls. Similar to non-stain 
user’s elderly group SM species 18:0, 23:0, and 23:1were significantly lower in patients 
compared to controls. Whereas, SM 16:0 showed a difference in the same direction and tended to 
be significant (p= 0.052). Additionally, SM 24:1 showed a significant difference in the same 
direction (Table 30). 
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Table 30: Sphingomyelin species in the statin users in the prostate cancer patients 
and controls (age >65 years) 
Analyte 
Benign prostatic 
hyperplasia 
Prostate cancer p 
Number 15 29 - 
SM, µmol/L    
SM 14:0 9.4 (6.3-13.9) 8.6 (5.1-13.5) 0.407 
SM 16:0 78.3 (61.9-115.5) 72.8 (57.9-90.3) 0.050 
SM 16:1 11.3 (6.7-16.3) 11.3 (7.8-14.7) 0.720 
SM 18:0 20.1 (14.8-30.7) 16.8 (13.7-21.6) 0.030 
SM 18:1 7.5 (6.0-13.3) 7.4 (4.6-10.2) 0.141 
SM 20:0 15.1 (9.8-20.5) 12.3 (9.4-18.5) 0.116 
SM 22:0 21.3 (14.0-26.3) 18.2 (13.3-25.2) 0.141 
SM 22:1 16.9 (12.8-23.1) 15.3 (10.6-21.9) 0.281 
SM 23:0 8.7 (6.4-13.8) 7.4 (5.5-11.4) 0.046 
SM 23:1 8.6 (7.4-13.4) 7.5 (5.3-12.0) 0.019 
SM 23:2 3.7 (2.0-7.3) 4.4 (2.5-6.5) 0.450 
SM 24:0 13.4 (9.4-20.7) 12.6 (10.1-16.9) 0.480 
SM 24:1 44.3 (35.3-56.8) 40.1 (28.5-50.0) 0.028 
SM 24:2 20.2 (13.0-23.9) 16.1 (12.5-22.7) 0.128 
Sum of SM 278 (223-376) 250 (189-327) 0.069 
The data are medians (10
th – 90th percentiles). 
p values are according to the Mann-Whitney-U test. 
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4. Discussion   
Choline can influence cancer development with several suggested mechanisms; choline, via 
betaine, is important for choline-mediated one-carbon metabolism and can affect DNA 
methylation. It also plays a central role in phospholipid metabolism and can modify cell signaling 
and support structural integrity of cell membranes. One-carbon metabolism consists of a set of 
interrelated pathways: remethylation (betaine and folate cycle), transmethylation (methionine 
cycle), and transsulfuration of Hcy via Cys by the cystathionine-β-synthase enzyme. On the other 
hand, Kennedy and PEMT pathways are involved in choline phospholipid metabolism. Abnormal 
choline metabolism is a metabolic hallmark associated with tumor onset and progression. We 
hypothesized that the concentrations of choline and choline metabolites in plasma will be higher 
in cancer patients than noncancer matched controls. In this case-control study, we investigated for 
differences in blood concentrations of one-carbon metabolism related metabolites (choline, 
betaine, DMG, total folate, SAH, SAM, tHcy, Cys, and MMA) and phospholipid metabolites 
(phospholipid: PtdCho, PtdEth, Lyso-PtdCho and SM) in males with PCa and those with BPH. 
Furthermore, we studied these metabolites in relations to tumor grade, age, and statin use. 
4.1 One-carbon metabolism  
4.1.1 One-carbon metabolites in PCa and BPH  
Our study found no significant differences in the concentrations of choline, betaine, DMG, 
total folate, tHcy, Cys, and MMA between cases and controls, in the young or elderly groups 
(Table 8 & 11). However, all one-carbon metabolism metabolites except of total folate were 
slightly lower in the PCa patients compared to controls in the young group. On the other hand, 
choline, DMG, total folate, tHcy, and Cys were slightly higher in the PCa patients compared to 
controls in the elderly group. MMA was significantly lower in the elderly PCa patients, but this 
difference became non-significant after adjustment for age (Table 11). Our results do not support 
differences in plasma concentrations of choline or other one-carbon metabolites between the 
patients and controls. However, all studies showed that folate and tHcy blood levels were not 
associated with PCa risk (161-165), whereas circulating MMA concentration showed an inverse 
association with the risk of PCa (23). Our findings on total folate and tHcy are in accordance with 
those of some other studies (161-165).  
Two studies examined the relation between choline and the risk of PCa. In one case-control 
study from the Northern Sweden Health and Disease Cohort, there was a positive association 
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between elevated plasma choline concentrations and an increased risk of PCa (23), while other 
epidemiological prospective study found that dietary choline intake was associated with an 
increased risk of lethal PCa (166). Nevertheless, betaine concentration was not associated with 
PCa risk (23). No studies regarding the association between DMG and cancer risk exist in the 
literature. Although the Northern Sweden Health and Disease Cohort study showed a positive 
association between plasma choline levels and PCa risk (23), the differences of choline and 
betaine concentrations between PCa patients and controls (healthy subjects) were not statistically 
significant (10.4 vs. 10.0 µmol/L, p=0.07 for choline, and 32.7 vs. 31.4 µmol/L, p=0.18 for 
betaine), respectively (23). The young group in our study had a similar median age compared 
with that of the Northern Sweden Health and Disease Cohort study (60.2 vs. 59.8 years), 
respectively. In comparison, our results for choline and betaine were also non-significant, but on 
the contrary, we found slightly lower concentrations of betaine and choline in the PCa patients 
compared to BPH (8.4 vs. 9.6 µmol/L, p=0.08 for choline, and 36.0 vs. 40.0 µmol/L, p=0.07 for 
betaine), respectively. The control group by the above mentioned study consisted of healthy 
subjects, therefore differ markedly from the representative group in our study (BPH patients), and 
this is likely to be one cause of difference. One other possible explanation might be that the blood 
collection occurred after diagnosis in our study, thus disease effects on metabolites 
concentrations cannot be ruled out. In the Northern Sweden Health and Disease Cohort study, the 
median time between blood collection and diagnosis was about 6.9 years, suggesting that most 
participants were apparent healthy and free of cancer. 
Since betaine demethylation is the only pathway known to produce DMG, this metabolite 
may serve as an index of the methyl group transfer from betaine to Hcy (167). Although the 
DMG concentrations were slightly lower in the young PCa and slightly higher in the elderly PCa 
patients compared to controls in each group, betaine/DMG as well as choline/betaine ratios were 
closed or equal to the corresponding ratios in controls in the two groups, supporting no 
differences in methylation process of Hcy via betaine cycle between the PCa and BPH patients. 
4.1.2 One-carbon metabolites in low-grade, high-grade PCa, and BPH  
Our data showed that choline and betaine concentrations were slightly lower in the young 
high-grade and low-grade PCa patients compared to controls, but these differences were not 
significant (8.8 and 8.3 vs. 9.4 µmol/L, p=0.13 for choline, and 41.0 and 37.0 vs. 43.0 µmol/L, 
p=0.19 for betaine), respectively. We found also no significant differences in the concentrations 
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of choline between high-grade, low-grade PCa, and controls in the elderly group (9.8, 10.3, and 
10.2 µmol/L, p=0.81), respectively. Changes in the concentrations of choline have been observed 
in PCa tissues using MRSI techniques (32). These concentrations vary between benign, low-
grade, and high-grade PCa tissues (145;147). Moreover, an enhanced choline uptake has been 
documented in PCa compared with normal prostate tissues (113). However, the relationship 
between blood and intracellular choline has not been sufficiently studied (168;169). It is not clear 
if plasma levels reflect the tissues variation. Our results cannot demonstrate differences in 
circulating plasma choline concentrations between groups due to the tumor grade.  
Interestingly, the elderly high-grade PCa patients showed significantly lower concentrations 
of betaine and total folate compared to low-grade PCa (36.0 vs. 43.0 µmol/L, p=0.03 for betaine, 
and 6.7 vs. 10.5 nmol/L, p=0.03 for total folate), respectively, probably because of higher 
requirements of the advanced prostate tumor to methyl groups via betaine and folate. However, 
further studies will have to test whether the circulating concentrations of choline, betaine, or 
folate are representative of concentrations in prostatic tissues and whether either concentration is 
correlated with prostate cancer cell proliferation.  
4.2 SAM and SAM/SAH ratio 
In our study, no significant differences were found in SAM, SAH or their ratio between 
PCa and controls in the young and in the elderly group. SAM/SAH ratios were slightly lower in 
the PCa groups compared to controls (7.6 vs. 7.8, p=0.48 in the young group, and 6.9 vs. 7.4, 
p=0.31 in the elderly group), respectively. SAM does not readily cross the plasma membrane, 
hence each mammalian cell is responsible for synthesizing its own SAM from circulating 
methionine, Hcy, or SAH (170). SAH, in contrast, leaks from the cell once its accumulation 
exceeds the buffering capacity of specific SAH-binding proteins in the cytoplasm. Moreover, 
SAM/SAH ratio could be altered due to changes in activity of SAM-dependent 
methyltransferases, particularly glycine N-methyltransferase (GNMT) and PEMT (171), and 
accordingly GNMT- or PEMT- knockout mice showed increased SAM availability accompanied 
with aberrant DNA methylation (172-174). For all these reasons, plasma SAM/SAH ratio may 
not provide a meaningful index of intracellular methylation status. 
Only the young PCa patients showed a marginally significant decrease in SAM 
concentrations compared to controls (median 112 vs. 127 nmol/L, p=0.046). In addition, we 
observed that the young PCa patients displayed slightly higher PtdCho sum concentrations 
Discussion  
 70 
accompanied with slightly lower sum concentrations of PtdEth compared to controls. The 
indicators of such inverse relation suggest an increased synthesis of PtdCho from PtdEth by 
PEMT, and this may be the reason of decreased SAM concentrations in the young PCa patients. 
Interestingly, Tchantchou et al. indicated that SAM can exert a direct effect on glutathione S-
transferase activity, where the reduced levels of SAM were associated with an impaired activity 
of glutathione S-transferase (175). In accordance with previos study, low levels of glutathione S-
transferase activity was associated with an elevated risk for developing PCa at a young age (176). 
4.3 Choline phospholipid metabolism 
4.3.1 Phospholipid classes in PCa and BPH  
To the best of our knowledge, this is the first study investigating plasma phospholipid in 
patients with PCa compared to BPH. Our results showed that the sum concentrations of PtdCho 
and SM were slightly higher and that of Lyso-PtdCho and PtdEth slightly lower in the young PCa 
patients compared to controls, but these differences were not significant. The further analysis of 
the results according to the pathological grade showed also no significant differences in the sum 
concentrations of phospholipid classes between the low-grade, high-grade young PCa and 
control. However, we observed that the increase in concentrations of PtdCho and its product SM 
were associated with a decrease in PtdEth and choline concentrations. Therefore, we can argue 
that such correlations may be reflecting the enhanced synthesis of PtdCho from choline via 
Kennedy pathway, and from PtdEth via PEMT pathway by cancer cells. Since choline /betaine 
ratios were almost equal without significant differences in the young PCa and controls, it is 
plausible that choline in the young patients is used to build up more PtdCho instead of using to 
generate the methyl donor betaine. These data, in conjunction with the previous suggestion that 
the young PCa patients had a raised synthesis of PtdCho from PtdEth due to the elevated PEMT 
activity, support the hypothesis of enhanced synthesis of PtdCho from choline and PtdEth. In 
accordance, men whose diagnosed with PCa at a young age have a faster growing and more 
aggressive cancer than men diagnosed at an older age (160), thus they have to synthesize more 
PtdCho and SM to meet the increased demand of cell membrane synthesis. 
In the elderly group, the results of PtdCho and SM were in the other direction, where the 
sums of PtdCho and SM concentrations decreased slightly in the elderly patients compared to 
controls, but the differences were significant only for the sum of SM (P=0.001) (Table 12). Here, 
on the contrary, choline concentrations were unexpectedly almost equal without significant 
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differences in the elderly PCa and controls (10.0 vs. 9.7 µmol/L, p=0.944), respectively. Thus, 
unlike the young group, the inverse association between PtdCho and choline levels was not 
observed. However, the decrease in the sum concentrations of phospholipid might be explained 
by higher statin usage in elderly PCa compared to young PCa (36.3 % vs. 16.9 %), respectively. 
An additional possible explanation is that the majority of older men have slow-growing or 
indolent disease (41;160), which might have a close demand of PtdCho to that of BPH.  
Lipids, including fatty acids, triglycerides, cholesterol, and phospholipid, were found to be 
associated with malignant tumors (177). There are increasing evidences showed that blood and 
tissues fatty acids levels are associated with PCa risk (178). New recent studies highlighted the 
potential of plasma phospholipid fatty acids (179-182), as well as phospholipid in biological 
fluids to serve as biomarkers of PCa (183-186). However, these studies showed inconsistent 
results (Table 31). The variations in assessment methods may partially explain the inconsistent 
results (179;187). Moreover, the studies differed in the blood materials used to measure 
phospholipid and phospholipid fatty acids (181;183;188). Another reason may well be the 
differences in study population between countries. The methodological considerations played 
also a role in these conflicting findings. 
However, three studies have investigated plasma phospholipid in PCa patients (184-186). 
The first study by Cvetkovic et al investigated four classes of plasma phospholipid in PCa 
patients and healthy subjects. In this study, PCa patients displayed significantly lower levels of 
PtdCho, Lyso-PtdCho, PtdEth, and SM compared to controls. Moreover, these four classes 
decreased in high-grade PCa patients (Gleason score ≥7) compared to low-grade PCa patients 
(Gleason score <7) (184). In the second, Zhou et al showed a different pattern, where plasma 
levels of phospholipid classes PtdCho, Lyso-PtdCho, PtdEth, and SM have significantly 
increased in PCa patients compared to controls (1.9-2.7 fold). Furthermore, many phospholipid 
species were suggested as plasma phospholipid biomarkers for diagnosis of PCa including; three 
PtdCho species (38:4, 38:5, and 40:7), four Lyso-PtdCho species (18:0, 18:1, 18:2, and 20:4), and 
three SM species (16:0, 16:1, and 18:0). Several other species such as PtdCho (34:1, and 36:1), 
Lyso-PtdCho (16:0), PtdEth (36:2), and SM (18:1, 22:0, and 24:0) showed significant differences 
between PCa patients and control, but they had a lower diagnostic sensitivity (185). In the third 
study, Patel et al analyzed serum phospholipid in newly diagnosed PCa patients compared to 
healthy subject, he indicated that PtdCho species (38:5, 40:3, and 42:4) may serve as early 
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predictive serum markers for the presence of PCa (186). Our findings regarding PtdCho and SM 
in the young group are in line with that of Zhou et al’s study that had participants with a similar 
mean age (63.6±8.5 year) to the young group in our study (median age 60.2 years) (185). On the 
other hand, Cvetkovic et al’s study that analyzed plasma phospholipid in newly diagnosed elderly 
patients (median age 74 years) had a similar observation to the elderly group in our study 
(median age 70.7 years) (184).  
Lyso-PtdCho levels were slightly lower in the PCa patients in the young and the elderly 
group. This reduction can be attributed to the increased enzymatic activity of 
lysophosphatidylcholine acyltransferase (LPCAT) in PCa (189;190), the enzyme involved in PAF 
biosynthesis from Lyso-PtdCho (Figure 8) and in the Lyso-PtdCho remodelling (191). In 
accordance, new data referred that LPCAT overexpression might greatly affect biological 
activities of cancer and correlates to the progression of PCa (189;192). Our results regarding 
Lyso-PtdCho are in line with previous reports that showed a decrease in Lyso-PtdCho 
concentrations in cancer patients (184;193;194). 
Table 31: Selected lipids metabolomics studies in prostate cancer. 
Study 
design 
Experimental 
model 
Key results Reference 
phospholipid fatty acids studies   
Case-control 
PCa vs. BPH 
(plasma and tissue) 
-Decrease in arachidonic (20:4) and 
docosapentaenoic (22:5) acids in phospholipid 
of malignant tissues.  
-Higher levels of oleic acid (18:1) in plasma 
and tissue phospholipid in PCa patients.  
(182) 
Nested case-
control 
Incident PCa vs. 
controls (plasma) 
-Positive association between palmitic acid 
(16:0) and risk of low-grade PCa. 
-Inverse association between stearic (18:0) acid 
and the risk of low-grade PCa. 
-Positive associations between myristic (14:0), 
α-Linolenic (18:3, ω3), and eicosapentaenoic 
(20:5, ω3) acids and risk of high-grade PCa. 
(179) 
Nested case-
control 
Incident PCa vs. 
controls (plasma) 
-Higher levels of long chain ω3-
polyunsaturated fatty acids (20:5, 22:5, and 
22:6) are associated with increased PCa risk. 
(180) 
Nested case-
control 
Incident PCa vs. 
controls (plasma) 
-Higher levels of long chain ω3-
polyunsaturated fatty acids (20:5, 22:5, and 
22:6) are associated with increased PCa risk. 
-Higher linoleic acid (18:2, ω6) level is 
associated with reduced PCa risk.  
(181) 
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Table 31: Selected lipids metabolomics studies in prostate cancer. 
Study 
design 
Experimental 
model 
Key results Reference 
Nested case-
control 
Incident PCa vs. 
controls (WB) 
-Higher long chain ω3-polyunsaturated fatty 
acids (20:5, 22:5, and 22:6) levels were 
inversely related to PCa risk. 
(188) 
phospholipid studies   
Case-control 
PCa vs. control 
subjects (plasma) 
-Decrease in PtdCho, Lyso-PtdCho, PtdEth, and 
SM levels in PCa patients compared to controls. 
-Decrease in PtdCho, Lyso-PtdCho, PtdEth, and 
SM levels in high grade-PCa patients (Gleason 
score ≥7) compared to low grade-PCa patients 
(Gleason score <7). 
(184) 
Case-control 
PCa vs. control 
subjects (plasma) 
-Increase in PtdCho, Lyso-PtdCho, PtdEth, and 
SM levels in PCa patients compared to controls. 
(185) 
Case-control 
PCa vs. control 
subjects (serum) 
-PtdCho 40:3, PtdCho 42:4, and egg PtdCho 
38:5 identified as unique candidate for PCa 
diagnosis 
(186) 
 
4.3.2 Phospholipid species in PCa and BPH   
Our results showed that, in general, there is a slightly increase in SM species in the young 
PCa patients compared to BPH, but the differences were significant only for SM 14:0 and 20:0 
(10.8 vs. 9.4 µmol/L, p=0.033 and 16.2 vs. 13.6 µmol/L, p= 0.004), respectively (Table 9). The 
results according to Gleason score showed also similar observations regarding SM 14:0 and 20:0, 
but the significant differences were only between the low-grade young PCa patients and BPH 
(12.1 vs. 10.0 µmol/L, p=0.035 for SM 14:0, and 16.6 vs. 14.1 µmol/L, p= 0.027 for SM 20:0) 
(Table 14). Zhou et al’s study reported higher SM species (16:0, 16:1, 18:0, 18:1, 22:0, 22;1, 
24:0, and 24:1) concentrations in the PCa patients compared to controls (185). This is in line with 
our finding of higher SM species in the young PCa group. This overall increase in concentrations 
of SM species in the young PCa may be related to increased activity of SMS that synthesize SM 
by transfer PCho moiety from PtdCho to Cer, and resulting in release of DAG (Figure 8). Indeed, 
the biological roles of SMSs go beyond formation of SM. Several lines of evidence indicated that 
SMSs have considerable biological potential as a regulator of the proapoptotic factor Cer and 
mitogenic factor DAG, hence they play a critical role in cell growth and survival (195;196). 
However, we can argue that the increase in SM 14:0 and 20:0 concentrations may reflect an 
increased production of their precursors Cer 14:0 and 20:0 than other Cer subspecies. In other 
word, increased proportion of myristic (C14:0) and arachidic (C20:0) acids in SM. Accordingly, 
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a positive association between serum- or plasma phospholipid myristic acid and PCa risk has 
been reported (179;197;198). In addition, one study reported a higher serum phospholipid 
arachidic acid in the PCa cases compared to controls (197).  
In the elderly group, SM species (16:0, 18:0, 18:1, 20:0, 22:0, 22;1, 23:0, 23:1 24:0, 24:1, 
and 24:2) were significantly lower in the PCa cases than controls (Table 12). The further data 
analysis according to the pathological grade showed that SM 16:0 and 18:0 concentrations were 
significantly lower among the low-grade, high-grade PCa compared to the controls. Whereas, SM 
18:1, 22:0, 23:0, and 23:1 concentrations were significantly lower in the low-grade PCa 
compared to controls (Table 16). The higher usage of statin in the elderly PCa compared to 
controls (36.3 % vs. 29.4 %) might contribute to this decrease, but it does not fully explain these 
differences. However, this decrease may be partly resulting from the decrease of SM precursors 
PtdCho or Cer. Apparent Cer production via Cer synthases (CerS) has been reported in cancer 
cells (199;200). The different substrate selectivity and genetic variation of CerS family have also 
a significant effect on the biosynthesis of some SM species. For example, the CerS4 SNPs 
showed an association with circulating SM 18:0, 18:1, 20:0, and 20:1 (100;201) . However, SM 
biosynthesis is modified by many additional factors such as aging, obesity, and the delivery of 
Cer to SMS that involves the Cer transport protein (100;202). Alteration in SM metabolism 
affects many aspects of cell behavior, such as the sensitivity of cells to proapoptotic agents (100). 
Unfortunately, we did not find any information on SM species among the elderly PCa patients. 
However, the findings from lipid studies have documented a positive association between 
palmitic acid (C16:0) and PCa risk (179;197;198;203), and an inverse association for stearic acid 
(C18:0) (179). Plasma phospholipid oleic acid (C18:1) levels were significantly lower in the PCa 
cases in one study (203), and higher in another study (182).  
Taken together, our findings showed variations in phospholipid metabolism between PCa 
and controls. We even observed a different tendency of variations with respect to the age at 
diagnosis, supporting the hypothesis that there are important metabolic differences between 
young and elderly PCa. Our results highlight that SM 14:0 and 20:0 may differentiate between 
young patients (≤ 65 years) with PCa and those with BPH, and SM 16:0 and 18:0 can distinguish 
between elderly PCa patients (>65 years) and BPH patients. 
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4.4 Metabolites concentrations according to age 
The present study showed also age-related differences in metabolites concentrations in the 
controls and the PCa group. These changes were stronger in the PCa group. Although some of the 
differences can be attributed in part to age-associated changes in the metabolism process, but they 
more strongly suggest an effect of cancer on the levels of these metabolites.  
4.4.1 In the control group 
The comparisons of metabolite concentrations between the older and younger controls 
showed slightly differences which were not statistically significant, unlike that of MMA and SM 
23:1 (Table 17 & 18). Concentrations of choline, betaine, and DMG were markedly unchanged 
with age. This is in line with previous results showing that betaine levels remain stable for years 
in normal subjects (204). The concentration of MMA decreased significantly in the elderly 
compared to young controls (median 171 vs. 192 nmol/L, p=0.025). Elevated serum MMA is a 
marker of vitamin B 12 deficiency. Such deficiency is very frequent in the elderly population and 
is associated with increase of MMA concentration (205). However, as we excluded participant 
with vitamin B12 supplementation, the decrease of MMA levels in the elderly control is 
unexpected and the reason for this decrease is unclear, but it may be attributed to the small size of 
the young controls in our study (22 vs. 51 elderly controls) than vitamin B12 status.  
SM 23:1 concentration was marginally significantly higher in the elderly controls (median 
10.5 vs. 8.6 µmol/L, p=0.046). Since the difference in the distribution of statin users between 
young and elderly controls was not significant, the change in SM 23:1 levels was unexplained by 
differences in statin use. The information about this SM specie is very rare in literatures, it is only 
referred that SM 23:1 could be a useful biomarker for predicting treatment response to 
rosiglitazone in type 2 diabetes (206). Moreover, there is only very poor information about 
tricosenoic acid (C23:1), the corresponding fatty acid that contains one double bond at an 
unspecified position.  
4.4.2 In the PCa group 
The differences in the patient groups were greater than in controls. Several one-carbon 
metabolites showed a significantly increased tendency with age, including choline, tHcy, Cys, 
SAH, and SAM (Table 19&21). Choline was significantly higher in the elderly PCa compared to 
the young PCa patients (median 10.0 vs. 8.4 µmol/L, p=0.001). Our findings agree with the 
results of Konstantinova et al that found an increase in choline concentrations among elderly men 
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and women with metabolic disorders (159). As we discussed earlier, the lower choline 
concentrations in the younger PCa might be partly a result of the increased choline use for 
PtdCho synthesis in the young PCa patients. In the low-grade PCa group, choline, betaine, and 
DMG concentrations were significantly higher in the low-grade elderly PCa compared to the low-
grade young PCa. These three metabolites are positively correlated with each other (74). Since 
choline/betaine and betaine/DMG ratios showed no differences between these groups, thus this 
increase may result from the increase of their precursor choline. 
Concentrations of tHcy, Cys, SAH, and SAM increased significantly with higher age, while 
the SAM/SAH ratio decreases in the PCa and low-grade PCa groups. The differences in the high-
grade PCa group had a similar tendency, but without a statistical significance. Studies showed 
that the serum or plasma concentrations of tHcy, SAH, and SAM increase in elderly patients with 
diseases such as multiple sclerosis, stroke, and peripheral neuropathy, while the SAM/SAH ratio 
decreases (207;208). We could confirm these findings in our study. The physiological decline in 
renal function might explain the increase in the tHcy concentrations in the elderly (209). 
Increased Hcy led to elevated SAH levels and thus decreased SAM/SAH ratios (210), which may 
explain the differences in SAM/SAH ratio. However, the results in controls group showed similar 
trends, but without statistical power, suggesting an additional effect of disease on these 
metabolites. 
SM species were almost significantly lower in the elderly compared to the young PCa. In 
contrary to the controls group, the difference in the distribution of statin users between young and 
elderly patients was significant. After adjusting for statin use the differences of SM species 
concentrations between the young and elderly PCa became non-significant. However, since the 
decrease tendency of SM species is only observed among the PCa patients, thus it seems to be 
more strongly related to the disease itself. Interestingly, we observed that SM 24:0 concentrations 
decreased slightly with higher age in the controls and PCa groups. This decrease was significant 
in the low-grade and high-grade PCa groups. Recently, Collino et al reported a similar 
observation, and noted that SM 24:0 decrease with age (156). Combining this finding with our 
present data suggesting that SM 24:0 might be only age-dependent variable. As a whole, these 
results indicate that phospholipid and one-carbon metabolism is altered due to age and disease.  
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4.5 Metabolites concentrations according to statin use 
Statin inhibit 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase, thus block 
the rate-limiting step of cholesterol biosynthesis (211). The relation between statin use and cancer 
risk is controversial. Animal studies showed that statins may be carcinogenic (212). In contrast, 
other evidences found that statin have cancer chemopreventive properties, through inducing 
apoptosis, inhibiting angiogenesis, and suppressing tumor growth and metastatic process 
(213;214). The data on statin and PCa risk is inconsistent. Whereas some studies showed no 
association between statin use and PCa risk (215;216), others observed that statin was associated 
with elevated overall risk (217). However, a recent meta-analysis of 27 (15 cohort and 12 case-
control) studies showed that statins reduce the risk of PCa (218). We examined the effect of statin 
on phospholipid concentrations among patients and control, as well as the interactions between 
disease and statin use in the PCa group. 
4.5.1 In the control group 
32.7 percent of the controls used statin in the present study, age and one-carbon metabolism 
metabolites did not significantly differ between statin and non-statin users. Statin users showed a 
significant decrease in the sum concentrations of PtdCho and SM compared to non-statin user. 
Furthermore, many phospholipid species were significantly lower in statin users among the 
controls including; four PtdCho species (34:2, 36:2, 36:3, and 38:3), one Lyso-PtdCho specie 
(18:0), and most SM species (SM 16:0, 16:1, 22:0, 22:1, 23:0, 23:1, 23:2, 24:0, 24:1 and 24:2). In 
general, we observed a decrease tendency in the concentrations of most SM, PtdCho and Lyso-
PtdCho species. PtdEth concentrations showed no significant differences with statin use. 
Statin exert multiple effects on lipid profile, their predominant actions are inhibition 
cholesterol synthesis, increased LDL catabolic rate, and decreased LDL and VLDL production 
(219;220). Phospholipid constitute 20-30 % of the lipids of LDL and VLDL (97). By far, the 
main phospholipid constituents of these lipoprotein classes are PtdCho and SM (90-93%) (99). 
Whereas Lyso-PtdCho constitutes about 4 % and PtdEth less than 2% of LDL and VLDL 
phospholipid (99). Therefore, we can argue that the decrease in LDL and VLDL levels due to 
statin therapy resulting in a subsequent decrease of phospholipid concentrations, especially 
PtdCho and SM. Furthermore, SM content is higher in LDL and VLDL than other lipoprotein 
classes (2-2.5 fold) (97;99), thus SM are likely to be more affected by statin than other 
phospholipid and this might explain the stronger observed variation in SM species.   
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4.5.2 In the PCa group 
The PCa statin users (38.1% of PCa patients) displayed significant increases in 
concentrations of betaine, DMG, Cys, SAH, and SAM compared to non-statin users (Table 27). 
The statin users in this group had a higher median age than the non-statin users with significant 
difference (68.6 vs. 64.3, p=0.047), which may explain the cause of these differences. Moreover, 
various factors such as comorbidities and decline in renal function play roles in this tendency as 
discussed earlier.  
Similar to controls, the sum concentrations of PtdCho and SM decreased also significantly 
in the PCa statin users. But, unlike controls, the decrease of Lyso-PtdCho sum concentrations was 
significant among patients who used statin. Furthermore, these decreases were accompanying 
with the decrease of additional phospholipid species, including PtdCho (34:3, 36:4, and 38:4), 
Lyso-PtdCho (16:0, and 20:4), and SM (14:0, 18:0, and 20:0). Moreover, two PtdEth species 
(38:4, and 38:5) displayed a significant increase with the use of statin. As discussed earlier, such 
variations may be not only related to statin effect but also to the age and disease itself.  
However, distinct alterations in the phospholipid profile of plasma and membrane lipids 
were observed in diseases. For example, cancer patients showed changes in the phospholipid 
composition in the blood cells (221). Alterations in phospholipid species pattern of lipids and 
lipoproteins in several diseases were also documented (222-224). Hiukka et al attributed these 
alterations to the increased hydrolysis susceptibility of SM by sphingomyelinase (SMase) (223). 
These observations suggest possible disease-related factors behind the decrease in phospholipid 
concentrations among the PCa patients. In accordance, the non-statin user with PCa in our study 
showed a decrease tendency in SM levels compared to the controls without statin treatment.  
SM 16:0 and 18:0 concentrations decreased significantly in the elderly PCa in both the statin 
user and the non-statin user groups compared to the controls in each group, suggesting that this 
decrease is independent of statin use. This confirm our previous conclusion that SM 16:0 and 
18:0 have the potential to distinguish between the elderly PCa and BPH patients. Collectively, 
our findings suggest that PCa affect the circulating phospholipid profile. Furthermore, a synergic 
interaction effect between statin use and disease on phospholipid concentrations was observed in 
this study. 
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5. Conclusions 
Abnormal choline metabolism has been reported in malignant transformation; therefore 
there is much interest in choline metabolic pathways related either to one-carbon metabolism or 
phospholipid metabolism as a tumor marker and for therapeutic objectives. Our main aim was to 
investigate plasma concentrations of choline and its related metabolites in patients with PCa and 
those with BPH. The novel findings of this study are: 
 Plasma choline showed no significant differences between PCa patients and BPH 
controls. Further explanations include that selection of the control group (not 
healthy) may not be appropriate or to the fact that choline pool is large and free 
plasma choline may not be the best marker for tissue choline.  
 Younger men (age ≤65 years) diagnosed with PCa showed significantly higher 
plasma concentrations of SM species 14:0 and 20:0 compared to those with BPH. 
 Elderly low-grade, high-grade, and PCa patients (age >65 years) had significantly 
lower plasma concentrations of SM species 16:0 and 18:0 compared to the elderly 
BPH controls. Therefore, SM 16:0 and 18:0 can distinguish between the elderly PCa 
and BPH patients.  
 PCa was associated with a specific phospholipid profile pattern. 
 Age was associated with significantly higher choline, tHcy, Cys, SAH, and SAM 
levels in the PCa patients. 
 Statin use was associated with lower plasma phospholipid levels, especially PtdCho 
and SM. This lowering effect is synergized by the presence of PCa. 
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Appendix 
Appendix A: Standards and chemicals  
 
Chemical Purity Company CAS number 
Catalogue 
number 
     
Choline related metabolites: standards and internal standards 
Betaine anhydrous ultra; ≥ 99.0% Sigma Aldrich, Munich, Germany 107-43-7 61962 
Choline chloride ≥ 99% Sigma Aldrich, Munich, Germany 67-48-1 C7017 
N,N,-Dimethylglycine 
(= DMG) 
99% Sigma Aldrich, Munich, Germany 1118-68-9 D1156 
N,N,N-Trimethyl-d9-glycine 
hydrochloride 
(= d9-betaine) 
98 atom % D 
Isotec, Sigma Aldrich, Munich, 
Germany 
285979-85-3 616656 
Choline chloride-trimethyl-d9 
 (=d9-choline) 
98 atom % D 
Isotec, Sigma Aldrich, Munich, 
Germany 
61037-86-3 492051 
N,N-Dimethyl-d6-glycine HCl  
(= d6-DMG) 
99 atom % D CDN Isotopes, Quebec, Canada 347840-03-3 D-3509 
SAH and SAM: standards and internal standards 
S-(5’-Adenosyl)-L-homocysteine, 
crystalline 
(= SAH) 
≥98% (HPLC) Sigma Aldrich, Munich, Germany 979-92-0 A9384 
S-(5′-Adenosyl)-L-methionine p-
toluenesul-fonate salt, from yeast (L-
methionine enriched) 
(= SAM) 
≥80% (HPLC) 
 
Sigma Aldrich, Munich, Germany 17176-17-9 A2408 
S-Adenosyl-L-methionine-d3 (S-methyl-
d3) tetra(p-toluenesulfonate) salt  
(= [
2
H3]-SAM) 
85% chemical 
purity;  
99 atom % D 
CDN Isotopes, Quebec, Canada 
17176-17-9 
(unlabeled 
compound) 
D-4093 
S-(5’-Adenosyl)-L-homocysteine 
(= [
13
C5]-SAH) 
 
Henkjan Gellekink group, Radboud 
University Nijmegen Medical 
Centre, Nijmegen, The Netherlands 
979-92-0 
(unlabeled 
compound) 
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Appendix A: Standards and chemicals (continued) 
 
Chemical Purity Company CAS number 
Catalogue 
number 
Phospholipid: standards and internal standards 
1,2-dimyristoyl-sn-glycero-3-
phosphocholine (=PtdCho 28:0) 
≥99% Sigma Aldrich, Munich, Germany 18194-24-6 P2663  
1,2-dioleoyl-sn-glycero-3-phosphocholine 
(=PtdCho 36:2) 
>99% Avanti  4235-95-4 850375P 
N-nervonoyl-D-erythro-
sphingosylphosphorylcholine (=SM 24:1) 
>99% Avanti 94359-13-4 860593P 
N-palmitoyl-D-erythro-
sphingosylphosphorylcholine (=SM 16:0) 
>99% Avanti 254-89-3 860584P 
1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (=PtdEth 36:2) 
>99% Avanti 4004-5-1 850725P 
1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine (=PtdEth 16:0/16:0) 
≥97% Sigma Aldrich, Munich, Germany 923-61-5 P1348 
1-stearoyl-2-hydroxy-sn-glycero-3-
phosphocholine (=Lyso-PtdCho 18:0) 
>99% Avanti 19420-57-6 855775P 
1-palmitoyl-sn-glycero-3-phosphocholine 
(=Lyso-PtdCho 16:0) 
≥99% Sigma Aldrich, Munich, Germany 17364-16-8 L5254 
1,2-dipentadecanoyl-sn-glycero-3-
phosphocholine (=PtdCho 15:0/15:0) 
>99% Avanti  3355-27-9 850350P 
N-hexanoyl-D-erythro-
sphingosylphosphorylcholine (=SM 6:0) 
>99% Avanti  182493-45-4 860582P 
1,2-dipentadecanoyl-sn-glycero-3-
phosphoethanolamine (=PtdEth 15:0/15:0) 
>99% Avanti  109032-52-2 850704P 
1-heptadecanoyl-2-hydroxy-sn-glycero-3-
phosphocholine (=Lyso-PtdCho 17:0) 
>99% Avanti  50930-23-9 855676P 
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Appendix A: Standards and chemicals (continued) 
 
 
Chemical Purity Company CAS number 
Catalogue 
number 
Homocysteine, methylmalonic acid, cystathionine: internal standards 
DL-(2-Amino-2-carboxyethyl)-
homocysteine-3,3,4,4-d4  
(= d4-Cys) 
98.0 atom % D CDN Isotopes, Quebec, Canada 146764-57-0  D-3349 
DL-Homocystine-3,3,3’,3’,4,4,4’,4’-d8  
(= d8-Hcy) 
98.0 atom % D CDN Isotopes, Quebec, Canada 108641-82-3 D-3030 
Methyl-d3-malonic acid  
(= d3-MMA) 
99.7 atom % D CDN Isotopes, Quebec, Canada 42522-59-8 D-2810 
Other chemicals 
2-propanol ULC/MS grade 
Biosolve, Valkenswaard, The 
Netherlands 
67-63-0 162641 
Acetic acid, glacial +99.99% Sigma Aldrich, Munich, Germany 64-19-7 338826 
Acetonitrile ULC/MS grade 
Biosolve, Valkenswaard, The 
Netherlands 
75-05-8 01204102 
Ammonia solution analaR NORMAPUR 25% 
BDH Prolabo (VWR International 
GmbH, Darmstadt, Germany) 
1336-21-6 1133.2500 
Ammonium acetate ULC/MS grade 
Biosolve, Valkenswaard, The 
Netherlands 
631-61-8 01244156 
Ammonium formate ULC/MS grade 
Biosolve, Valkenswaard, The 
Netherlands 
540-69-2 01984156 
Butylhydroxytoluol (BHT) ≥99.0% (GC) Sigma Aldrich, Munich, Germany 128-37-0 
34750 
Fluka 
Chloroform ≥99.8% (GC) Merck, Darmstadt, Germany 67-66-3 
102444250
0 
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Appendix A: Standards and chemicals (continued) 
 
 
Chemical Purity Company 
CAS 
number 
Catalogue 
number 
Other chemicals 
Dithiothreitol  
(= DTT) 
≥ 99.5% 
AppliChem GmbH, Darmstadt, 
Germany 
27565-41-9 A2948 
Ethylenediaminetetraacetic acid disodium 
salt dihydrate  
(= EDTA) 
99.6% Sigma Aldrich, Munich, Germany 6381-92-6 E4884 
Formic acid 
ULC/MS grade; 
99% 
Biosolve, Valkenswaard, The 
Netherlands 
64-18-6 06914131 
Hydrochloric acid 
fuming, pro 
analysis; 37% 
Merck Chemicals, Darmstadt, 
Germany 
7647-01-0 100317 
Methanol, absolute ULC/MS grade 
Biosolve, Valkenswaard, The 
Netherlands 
67-56-1 13684102 
N-Methyl-N-tert-
butyldimethylsilyltrifluoro-acetamid 
(= MBDSTFA) 
 
Machery and Nagel, Düren, 
Germany 
77377-52-7 701440.201 
β-Mercaptoethanol 
cell culture 
tested 
Sigma Aldrich, Munich, Germany 60-24-2 M7522 
Sodium hydroxide, solid 
pro analysis; ≥ 
99% 
Merck Chemicals, Darmstadt, 
Germany 
1310-73-2 106495 
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Appendix B: Equipment 
 
Equipment Description Company 
Analytical balance 
Sartorius CP224S-0CE 
Sartorius AG, Göttingen, Germany 
Sartorius ME215P-0CE 
Blood collection 
Citrate: S-Monovette 5 mL 9NC, 
92 x 11 mm 
Sarstedt, Nümbrecht, Germany 
EDTA: S-Monovette 2.7 mL K3E, 
66 x 11 mm; S-Monovette 9 mL 
K3E, 92 x 16 mm 
Li-Hep: S-Monovette 4.7 mL LH-
Gel, 75 x 15 mm 
Needle: Safety-Multifly 21G tube 
200 mm 
Serum: S-Monovette 4.7 mL Z-
Gel, 75 x 15 mm 
Centrifuge 
Eppendorf centrifuge 5810 R, A-
4-62 Rotor 
Eppendorf AG, Hamburg, Germany 
Hettich Mikro 20 
Andreas Hettich GmbH & Co.KG, 
Tuttlingen, Germany 
Sigma 3K12,  
Sigma Laborzentrifugen GmbH, 
Osterode, Germany 
Optima LE-80K Preparative 
Ultracentrifuge, Type 50.2 Ti 
Rotor 
Beckman Coulter GmbH, Krefeld, 
Germany 
Cooling 
Ziegra Ice machine ZBE 70-35 
Ziegra Eismaschinen GmbH, 
Isernhagen, Germany  
Heraeus HERA freeze HFU-Basic 
Series, -86°C 
Thermo Fischer Scientific, 
Waltham, USA  
Concentrator Eppendorf concentrator 5301 Eppendorf AG, Hamburg, Germany 
DNA isolation QIAamp DNA blood mini kit Qiagen GmbH, Hilden, Germany 
Gases 
ALPHAGAZ 1 Argon 
AIR LIQUIDE Deutschland GmbH, 
Düsseldorf, Germany 
Cmc instruments NGM nitrogen-
membrane-generator (LCMS) 
Cmc instruments GmbH, Eschborn, 
Germany 
Heating 
Thermo Scientific Haake Open-
Bath Circulators C10-W19  
Thermo Fischer Scientific, 
Waltham, USA 
HPLC system Waters 2795 alliance HT Waters Corporation, Milford, USA 
Mass 
spectrometer 
MicroMass Quattro Micro API 
(coupled to HPLC system) 
Waters Corporation, Milford, USA 
MicroMass Quattro Premier XE 
(coupled to UPLC system) 
Microwave NN-5256, 900 watts 
Panasonic Deutschland GmbH, 
Hamburg, Germany 
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Equipment Description Company 
Mixer/Shaker/Vortex 
IKA MS2 Minishaker 
IKA – Werke GmbH & Co. KG, 
Staufen, Germany 
RM5-40 Horizontal Mixer 
Bennett Scientific Ltd., Newton 
Abbot, UK 
VARIOMAG Monotherm Heatable 
Magnetic Stirrer 
VARIOMAG-USA, Daytona 
Beach, USA 
PCR 
Eppendorf Mastercycler ep 
gradient S 
Eppendorf AG, Hamburg, Germany 
PSQ 96MA instrument Biotage AB, Uppsala, Sweden 
pH meter 
Schott Intruments Lab 870 pH 
meter (N 6000 A electrode) 
SI Analytics GmbH, Mainz, 
Germany 
Photometer Aurius CE2041 Spectrophotometer 
CECIL Instruments Ltd., 
Cambridge, UK 
Pipetting 
Biohit m10 (0.5-10 µL), m200 (20-
200 µL), m1000 (100-1000 µL) 
pipette 
Biohit Deutschland GmbH, Rosbach 
v. d. Höhe, Germany 
Combitips plus; 0.5, 1, 5, 10, 25 
mL Eppendorf AG, Hamburg, Germany 
Multipette plus 
Pipette tips 20 µL, 200 µL, 1000 
µL Sarstedt, Nümbrecht, Germany 
Serological Pipette 10 mL, 25 mL 
Reaction tubes 
PCR Tubes 0.2 mL, PCR clean Eppendorf AG, Hamburg, Germany 
Microtube 1.5 mL 
Sarstedt, Nümbrecht, Germany 
Tube 12 mL, 105x16.8 mm, PS; 
Tube 15 ml, 120x17 mm, PP; Tube 
50 mL, 114x28 mm, PP 
OptiSeal Polyallomer Centrifuge 
Tubes 1 x 3 ¼ in. (26 x 77 mm), 
29.9 mL  
Beckman Coulter GmbH, Krefeld, 
Germany 
Sample preparation 
Oasis MAX (1 ccm/30 mg and 3 
ccm/60 mg) columns 
Waters Corporation, Milford, USA 
Varian Bond Elut PBA columns Varian Inc., Palo Alto, USA 
Ultrasonic cleaner VWR USC600T 
VWR International GmbH, 
Darmstadt, Germany 
UPLC columns 
Acquity UPLC BEH HILIC 
column (100 mm x 2.1 mm (i.d.); 
1.7 µm particle size) 
Acquity UPLC BEH C18 column 
(50 mm x 2.1 mm (i.d.); 
1.7 µm particle size) 
Acquity UPLC BEH Shield RP18 
column (100×2.1 mm (i.d.); 1.7 
μmol/L particle size) 
Waters Corporation, Milford, USA 
UPLC in-line filter 0.2 µm in-line filter Waters Corporation, Milford, USA 
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Equipment Description Company 
UPLC precolumns 
Acquity HILIC VanGuard pre-
column (5 mm x 2.1 mm (i.d.); 
1.7 µm particle size) 
Acquity BEH C18 VanGuard pre-
column (5 mm x 2.1 mm (i.d.); 
1.7 µm particle size) 
Acquity UPLC BEH Shield RP18 
VanGuard pre-column (5×2.1 mm 
(i.d.); 1.7 μmol/L particle size) 
Waters Corporation, Milford, USA 
UPLC system Waters Acquity UPLC Waters Corporation, Milford, USA 
Vials and 
glassware 
5-SV – EPA Screw Top Vials, 5 mL 
glass tubes 
Chromacol, Herts, UK 
11 mm Snap Cap with PTFE/Silicone 
septa 
SUN-Sri (Thermo Fischer), 
Rockwood, USA 
12 x 32 Maximum Recovery glass 
vials including Snap Caps with 
locked-in, Pre-slit PTFE/Sil Septa 
Waters Corporation, Milford, USA 
Snap/Crimp V-Vial 8002-SC-
D/V15µ 
Glastechnik Graefenroda GmbH, 
Gräfenroda, Germany 
Wheaton Sample Vial Clear, with 
Screw Thread, 19x65 mm, 12 mL, 
with Screw Caps 
neoLab Migge Laborbedarf-
Vertriebs GmbH, Heidelberg, 
Germany 
DURAN GL 45 glass bottles, 200 
mL, 500 mL, 1000 mL 
DURAN Group GmbH, 
Wertheim/Main, Germany 
Water purification Milli-Q Academic Millipore, Molsheim, France 
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Appendix C: Reference ranges for laboratory parameters 
 
Parameter Sample material Method of determination Reference range 
Creatinine Lithium-heparin plasma 
Jaffé determination  
(kinetic colorimetric assay) 
males: 0.7-1.2 mg/dL  
(61.9-106.1 µmol/L
a
) 
females: 0.5-0.9 mg/dL  
(44.2-79.6 µmol/L) 
GFR Lithium-heparin plasma MDRD equation 80-140 ml/min 
Urea Lithium-heparin plasma 
Kinetic test with urease 
and glutamate 
dehydrogenase 
16.6-48.5 mg/dL 
Uric Acid Lithium-heparin plasma 
Enzymatic colorimetric 
assay 
males: 3.4-7 mg/dL  
females:  2.4-5.7 mg/dL 
Glucose Lithium-heparin plasma 
UV test  
(hexokinase/G6P-DH) 
60-100 mg/dL  
ASAT Lithium-heparin plasma IFCC (37°C) 
males: 10-50 U/L 
females: 10-35 U/L 
ALAT  Lithium-heparin plasma IFCC (37°C) 
males: 10-50 U/L 
females: 10-35 U/L 
Gamma-GT Lithium-heparin plasma 
Enzymatic colorimetric 
assay 
males: < 60 U/L 
females: < 40  U/L 
ALP Lithium-heparin plasma Colorimetric assay 
males: 40-129 U/L 
females: 35-104 U/L 
Blood count EDTA whole blood 
SYSMEX  
SF 3000 or 
XE 5000 
males: 
Hb: 14.0-18.0 g/dL 
Hct: 41-53% 
females: 
Hb: 12.0-16.0 g/dL 
Hct: 36-46% 
CRP Lithium-heparin plasma 
Immunoturbidimetric 
determination 
< 5 mg/L 
Total PSA Serum 
Elecsys® test based on 
sandwich principle 
0-4 ng/mL 
a
 Conversion factor creatinine: 88.4 
Reference values were retrieved November 03, 2014 from: http://www.uniklinikum-
saarland.de/de/einrichtungen/kliniken_institute/zentrallabor/referenzwerte_verfahrensliste/.  
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